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Abstract 
ABSTRACT 
Severe limitations exist in the treatment of post-infraction congestive heart failure. 
Autologous bone marrow-derived stem cells have the potential to regenerate tissues 
damaged by ischaemia. Thus multiple types of stem cells are currently being 
investigated as a potential therapeutic option for myocardial repair at the cellular level. 
Underlying mechanisms of observed functional improvement -at the experimental as 
well as clinical setting- continue to remain unknown. Cells expressing early cardiac 
markers have been identified within a CD34 subpopulation of bone marrow-derived 
stem cells; isolation and expansion of these cells prior to cellular transplantation may 
provide an alternative to crude preparations and maximise clinical effect. We aimed to 
investigate the differentiation potential of this CD34+ subpopulation in vitro. In 
addition we aimed to assess functional improvement of myocardial ischaemia after 
transplantation of this subset of CD34+ cells into a rodent animal model of chronic 
myocardial ischaemia. 
G-CSF mobilised peripheral blood progenitor cell samples were obtained from 
leukapheresis in excess of clinical requirements. Following separation of the CD34+ 
via positive cell selection the candidate subpopulation of interest is isolated via 
adherence to tissue culture plastic. Cell analysis was carried out with PCR, microarray, 
immunocytochemistry, western blot and flow cytometry for endothelial and cardiac 
markers. Positive expression for specific cardiac as well as primitive and mature 
endothelial markers was detected. These findings were further verified via 
demonstration of protein expression. In vitro culture under pre-defined conditions was 
also indicative of directional differentiation potential. Expression of homing to injury 
receptors was also shown. Finally, animal work showed evidence of engraftment as 
well as functional improvement as assessed by MRI and echocardiography. We 
proceeded in designing a phase 1/11 clinical trial to determine the safety and 
tolerability of the optimum dose of autologous adult CD34+ stem cells when infused 
directly into the coronary circulation in ischaemic heart disease. This study is 
currently in the recruiting phase at the Hammersmith Hospital. 
In conclusion, the proposed candidate stem cell subpopulation may provide an 
expandable autologous multipotent population for myocardial cellular transplantation. 
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1. INTRODUCTION 
Introduction 
1.1 THE CLINICAL PROBLEM: CORONARY HEART DISEASE 
AND HEART FAILURE 
Heart failure is a clinical syndrome characterised by the inability of the heart to pump 
blood at an adequate rate to satisfy the demands of the body, or ability to do so only in 
the presence of elevated filling pressure (1). It is a condition which is extremely 
prevalent, affecting an estimated 5 million people in United States, and it underlies or 
contributes to the deaths of 286,700 people a year (2). Coronary heart disease is a 
major cause of heart failure, especially in males (3). An estimated 565,000 new 
myocardial infarctions and 300,000 recurrent infarctions occur each year (2). Current 
treatment consists of timely coronary reperfusion using pharmacological agents and 
percutaneous coronary intervention (PCI). This reduces mortality resulting from 
myocardial infarction (4), but adverse myocardial remodelling may still occur, in 
which changes in ventricular architecture result in impaired pump function and 
contribute to heart failure (5). 
At present the only radical treatment of end stage congestive heart failure (CHF) is 
cardiac transplantation. A shortage of donors imposes a severe limitation on this 
approach without mentioning the complications of post-operative immunosuppression. 
Various techniques have been described and developed to reshape the dilated left 
ventricle either by endocardial patch plasty or by passive constraint and shape-change 
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(6,7). Left ventricular assist devices do exist, mainly to facilitate bridging patients to 
cardiac transplantation. 
Coronary artery disease leading to ischaernia of the human myocardium is one of the 
chief causes of CHF. The natural progress of a myocardial infarction involves 
myocyte death and segmental scarring with replacement fibrosis. An important 
aftermath is the impact on the remaining functional myocardium. This most often 
results in remodelling, which ultimately progresses to impaired ventricular function 
(8). 
Therefore, several alternative novel approaches to treat end-stage heart failure are 
being considered. One such approach is cellular transplantation, where the impaired 
myocardium could be replaced by stem cells that would proliferate in the recipient 
heart. 
1.2 REGENERATIVE POTENTIAL OF NATIVE MYOCARDIAL 
TISSUE 
Traditionally it has been considered that human cardiornyocytes exit the cell cycle in 
early post-natal life. Thus adult myocardial cells are regarded as post-mitotic 
differentiated end cells with no ability for division and proliferation following an 
ischaemic insult. Recent experimental evidence in addition to clinical findings are 
questioning these assumptions. In the murine fetal heart the retinoblastoma protein 
has been implicated in the observed cell withdrawal from the cell cycle (9). It has 
been shown that inactivation of the retinoblastorna protein in terminally differentiated 
cells allows them to re-enter the cell cycle (10). Endo and Nadal-Ginard were able to 
show ten-ninally differentiated myotubes completing canonical mitosis and 
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cytokinesis illustrating the proof of principal that even terminally differentiated cells 
retain the ability to re-enter the cell cycle (11). 
Synthesis of cardiomyocyte DNA in the mammalian heart has been demonstrated 
without researchers being able to ascertain if this is part of a physiologic response. 
Activation of cardiornyocyte DNA synthesis may require certain in vivo micro 
environmental alterations (12). Kajstura et al reported that 14 myocytes per million 
were seen to be in mitosis by examining control human hearts by confocal 
microscopy. A nearly I 0-fold increase in these figures was observed in end-stage 
ischaemic heart disease and in idiopathic dilated cardiomyopathy (13). A slow but 
persistent myocyte turnover seems to exist providing a theoretical explanation for 
why certain pathologies linked with myocyte death, such as diabetic cardiomyopathy, 
do not progress to myocardial cellular extinction (14). 
Conventional teaching has been that cardiornyocyte hypertrophy is the only 
mechanism to compensate for loss of functional myocardium following an ischaemic 
insult. Cellular proliferation has been attributed exclusively to endothelial and 
fibroblast populations, with collateral circulation and scar formation respectively 
being the product of these proliferations. Recent studies, however, have shown that a 
small number of cardiornyocytes re-enter the cell cycle following such an insult (15). 
This proliferation is not sufficient to compensate for the up to I billion 
cardiomyocytes that are lost after myocardial infarction (16). 
The origin of primitive cells residing in the myocardium remains unclear. Whether 
they belong to a resident cardiac stem cell population or are recruited into the heart 
from the systemic circulation, ultimately being derived from the bone marrow, 
remains to be answered. 
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The finding of cardiac chimerism following peripheral blood and bone marrow 
transplantation in sex-mismatched patients has shed new light on this topic. Bayes- 
Genis et al reported the presence of cardiac chimerism with the use of a sensitive 
polymerase chain reaction assay for donor and recipient genotyping (17). Furthermore, 
homing of recipient progenitor cells in the myocardium has been shown in sex- 
mismatched cardiac transplantations (18,19). Based on their observations, Quaini et 
al hypothesize that the donor heart harbours a population of resident primitive cells as 
well as attracting a second population of progenitor cells from the recipient. Further 
support for this notion has been provided by the demonstration of post-natal human 
bone marrow cells expressing early cardiac markers (20); data from our group has 
also confirmed this observation (2 1). 
1.3 DEFINITIONS AND GENERAL CONCEPTS ABOUT STEM 
CELLS 
Stem cells are undifferentiated clonogenic cells mainly characterised by an inherent 
capacity for self-renewal as well as the ability to generate committed progenitors 
and/or mature cells via multi-lineage differentiation (22,23). Stem cells are present 
throughout life in all cellular developmental stages; however discrete differences 
regarding their differentiation potential allows for further classification into subgroups. 
As stem cell nomenclature may vary within current literature the following 
terminology is in agreement with the definitions provided by the International Society 
of Stem Cell Research (24). Totipotent stem cells are capable of dividing and 
producing an entire organism, including extraembryonic tissues. These may be 
derived from fertilized oocytes and cells of the developing zygote up to the 8-cell 
stage of the morula. The gene for the transcription factor Oct-4 that is expressed in 
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totipotent embryonic cells appears to be downregulated as soon as totipotent cells 
differentiate to form somatic and/or extraembryonic tissues (25). As absence of this 
transcription factor results in early embryonic lethality, it has been suggested that Oct- 
4 is necessary for the maintenance of the totipotent phenotype of embryonic cells. 
Pluripotent stem cells may give rise to cells from any of the three embryonic germ 
layers (ectoderm, mesoderm and endoderm). Multipotent cells have a more restricted 
lineage differentiating capacity providing multiple types of differentiated cells, but all 
within a particular tissue, organ, or physiological system. Further down the line are 
ofigopotent stem cells, which can produce more than one type of mature cells (such 
as the clonal common myeloid progenitor), and unipotent cells that can self-renew 
but give rise to only one mature cell type (such as spermatogenic stem cells). Finally 
the term "progenitor cells", refers to those cells that differentiate into mature cells 
without being able to self-renew. Generated by stem cells, these cells lie at an 
intermediate position prior to the formation of mature cells. 
1.3.1 Types of stem cells 
Beyond varying degrees of potency stem cells are also categorized according to their 
source, with embryonic and adult stem cells being the two major groups. 
1.3.1.1 Embryonic stem cells 
Human embryonic stem (ES) cells are isolated from the inner cell mass of 5 day-old 
blastocysts. The first human ES cell lines were derived from human blastocysts in 
1998 (26). ES cells are pluripotent and are capable of differentiating into all three 
germ layers: endoderm, ectoderm and mesoderm (27). The isolation of human ES 
cells signified an important milestone in stem cell research as it raised hopes of 
obtaining a potent regenerative reservoir of different cell lines for transplantation in 
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end-stage organ diseases and degenerative disorders. Neurons and skin have been 
formed from ES cells, indicating ectodermal differentiation (27,28). ES cells are able 
to differentiate to cardiac cells, bone, cartilage and endothelial cells indicating 
mesodermal differentiation (29,30). Furthermore, they are able to give rise to 
pancreatic cells, indicating endodermal differentiation (31). However, a major 
limiting factor for their usefulness in clinical therapy is their tumorigenicity when 
introduced in vivo. Injected ES cells formed teratomas when injected subcutaneously 
in NOD/SCID mice (27). Their potential use and even research on these cells has 
been further restricted by the extensive ongoing public debate regarding the ethics of 
using unwanted early embryos to obtain ES cells (32). In addition, many existing 
approved ES cell lines have been cultured on mouse feeder cell layers, which can 
supply many needed growth factors. This has exposed the human ES cells to potential 
risk of viral transfer between species and has limited their clinical potential (33). 
1.3.1.2 Adult stem cells 
The ethical and legal considerations imposed on studying ESCs have redirected 
scientific research efforts elsewhere, shifting the focus to primitive cells known as 
adult stem cells found in human tissues. 
Like ES cells, adult stem cells possess self-renewal capacity and multilineage 
differentiation potential (34). Adult stem cells are present at approximately 1%-2% of 
the total cell population within a specific tissue and are vital for the maintenance of 
local tissue homeostasis by continuously contributing to tissue regeneration and 
replacing cells lost during apoptosis or direct injury. Adult stem cells are usually 
quiescent and are held in an undifferentiated state within their niche until they receive 
a stimulus to differentiate (3 5). More recent developments have proved that adult 
stem cells reside in nearly every tissue, including the bone marrow, brain, digestive 
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system, skin, retina, muscles, pancreas, and liver (36). However, there is a 
controversy about whether cells isolated from a particular tissue originated in that 
tissue or are circulating BM-derived stem cells (37). 
The main role of adult stem cells is thought to be the replenishment of tissue in 
appropriate proportions and numbers in response to 'wear and tear' loss or direct 
organ damage. 
1.3.1.2.1 Bone marrow stem cells 
At least two distinct populations of stem cells reside within the adult bone marrow: 
haemopoietic stem cells (HSCs) and mesenchymal stem cells (MSCs). The former are 
the precursors of all blood myeloid and lymphoid lineages and the latter give rise to 
stromal cells of the bone marrow including distinct mesodermal lineages such as 
osteoblasts, chondrocytes and adipocytes. 
1.3.1.2.1.1 Haemopoietic stem cells 
The best characterised and most widely understood adult stem cells are HSC, which 
sustain the formation of the blood and immune systems throughout life and were first 
identified in 1961 (38). HSCs are adult stem cells and can be identified by their ability 
to differentiate into all blood cell types and reconstitute the haemopoietic system in a 
host that has been lethally myeloablated. It was previously thought that adult stem 
cells were lineage restricted, but recent studies demonstrated that BM-derived stem 
cells in addition to haematopoiesis also participate in regeneration of ischemic 
myocardium (39), damaged skeletal muscle (40) and neurogenesis (41). 
Reconstitution of the haernopoietic system of a myeloablated host is the sole assay 
available at present for identification of HSCs. Surface markers in humans, such as 
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CD34 or the more primitive CD133 (AC133) help in distinguishing subpopulations 
enriched in HSC. Other haemopoietic markers are CD45 and c-kit (CD 117). 
Other populations of cells that are enriched for HSCs despite the fact that they are 
isolated independently of classic antigenic markers are the side population (SP) cells. 
SP cells account for about 0.05% of the total BM cell population and are identified by 
their ability to extrude Hoechst dye via the ABCG2 transporter on the membrane (42). 
SP cells reside in various organs besides the bone marrow and there is conflicting data 
as to the origin of these cells with some evidence supporting the fact of actually being 
bone marrow derived HSCs rather than tissue-specific (43,44). Furthermore, SP cells 
isolated from different tissues share transcriptome signatures (45) and common 
"stemness functions" (46). 
Mesenchymal stem cells 
MSCs (also known as marrow stromal cells) are characterized by two distinguishing 
features, the ability to adhere to cell culture dishes as well as to differentiate into a 
variety of lineages under appropriate conditioning. They are rare in bone marrow, 
representing approximately I in 10,000 nucleated cells (47) and besides renewing 
marrow stroma and supporting haemopoiesis, are capable of differentiating into 
osteogenic, chondrogenic and adipogenic lineages. Surface proteins including CD105 
(SH2), CD73 (SH3, SH4), CD29, CD44, CD7 1, CD90 (Thy- 1), CD 106 (vascular cell 
adhesion molecule-1), CD120a, and CD124, have been reported to be expressed in 
multiPotent MSCs (48). In contrast to HSCs these cells appear uniformly negative for 
typical haernopoietic surface antigens such as CD45 and CD34. 
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1.3.2 Stem cell kinetics 
Order of magnitude calculations carried out by Gordon and Blackett clearly 
demonstrated that the number of stem cells necessary to provide mature blood cells 
throughout life surpass the number of stem cells formed during development (49). In 
agreement with Virchow's fundamental law of biology laid down by "Omnis Cellula 
E Cellula " (all cells come from other cells) (50,5 1), it may be extrapolated that stem 
cells are responsible both for self-renewal of the stem cell pool as well as the 
production of differentiated progeny. Stem cells owe this ability to maintain steady 
state populations whilst concurrently generating a multitude of differentiated progeny 
to complex and not completely understood mechanisms of cell division. 
In order to regulate stem cell numbers, stem cells undergo two types of division (Fig 
1.3.1). Asymmetric division results in two different daughter cells with one of them 
retaining stem cell properties, and the other inheriting a limited self-renewal potential. 
Multiple theoretical paradigms have been proposed trying to explain asymmetrical 
division with cell polarisation of some description always being involved. 
Asymmetric localization of cell polarity regulators, segregation of cell fate 
determinants to the cytoplasm of one daughter cell, or regulated orientation of the 
mitotic spindle retaining only one daughter in the stem-cell niche, are all proposed 
mechanisms preceding asymmetrical division (52). Identifying mutations that result in 
stem cell type asymmetric division in nonstem precursor cells, or mutations resulting 
in symmetrical division may provide further insight into molecular mechanisms (53). 
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Figure 1.3.1 Schematic illustration of stem cell kinetics. Asymmetric division (A) provides 
another stem cell (open cell) along with a nonstem cell (filled cell) securing thus steady state 
kinetics. This is in contrast to symmetric division (B) where either to daughter stem cells (clonal 
expansion) or two nonstem cells are generated (clonal extinction). Symmetric division may also 
preserve steady state kinetics if one considers the net result of both divisions shown in the bottom 
row (B+Q. 
Symmetric division leads to two identical daughter cells with the same 
developmental potential. This may give rise to two daughter cells with stem cell 
properties; alternatively the two daughter cells may be progenitor cells with limited 
self-renewal potential. Theoretically the former leads to clonal expansion, while the 
latter process leads to clonal extinction at the stem cell level (54). Symmetric stem 
cell division is clearly crucial during development or tissue repair/regeneration 
following injury. In reality the two mechanisms of stem cell division are probably 
utilised in a coordinated manner by stem cells (52). Thus it appears that beyond the 
potential to self-renew and provide differentiated progeny, stem cells are also flexible 
in their response depending on cell-cell and cell-microenvironment interactions (55). 
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Parameters regulating stem cell populations in the bone marrow (54) may also be 
applied in the clinical translational setting. Once cell transplantation takes place the 
transplanted stem cell pool may only rely on self-renewal to balance potential 
differentiation into cells of the cardiornyogenic lineage and cell death due to apoptosis, 
inflammatory response, etc (Fig 1.3.2). As cell death takes a serious toll in the early 
post-transplantation period the starting number of "genuine" stem cells transplanted 
becomes crucial. Pre-transplantation stem cell expansion ex vivo as well as repeated 
administration may be potential strategies for clinical application. 
Input 
Differentiation 
Stem cell death 
Figure 1.3.2 Factors regulating transplanted stem cell populations in the experimental/clinical 
setting. 
1.3.3 Stem cell plasticity 
Minimal criteria of stem cell plasticity include capability for self-renewal, ability of a 
single cell to differentiate into cells of the tissue of origin and at least one different 
cell type, and functional differentiation in vivo into cells of the tissue of origin and at 
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least one cell type other than the tissue of origin (56). Although stem cell plasticity 
has been attributed to a variety of mechanisms, switching of cell lineage and cell 
fusion remain the two principal ones. 
1.3.3.1 Lineage switching 
Conceptually cells may switch between different lineages in three different ways (57): 
0 Transdifferentiation, 
o Transdetermination, and 
o Dedifferentiation. 
Transdifferentiation takes place when one differentiated cell adopts the phenotype 
of another differentiated cell. The mechanism of transdifferentiation has been 
established with a lens regeneration model in the adult newt (58). Pigmented 
epithelial cells changed phenotype and adopted the fate of lens cells following 
lenscectomy in vivo. In addition, during normal mammalian development, skeletal 
myocytes are formed from transdifferentiated smooth muscle in the oesophagus (59). 
Transdetermination occurs when a stem cell committed to certain cell lineage 
switches in order to generate cells of another lineage. This phenomenon has primarily 
been studied in transfonnations between different imaginal discs in Drosophila. 
Whilst imaginal discs do not differentiate during larval life, they subsequently 
differentiate into the specific segmental appendages or parts of segments, for example 
antennae, wings and legs (60). Occasionally the structures formed are not appropriate 
to the original character of the disc, i. e. tissue from a leg disc may produce wing 
structures (6 1 ). 
Dedifferentiation refers to a stem cell reverting to a more primitive progenitor stem 
cell type in order to re-differentiate down another cell lineage. This process is seen 
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following limb amputation in newts (62). Dedifferentiation of stump tissues, such as 
skeletal muscle, is one of the mechanisms involved in the observed regeneration of a 
new limb. 
A widely held theory is that, whilst primitive cell differentiation involves mainly 
stochastic processes, deterministic processes become of critical importance as stem 
cells proceed into lineage restriction (63). In conclusion, although stem cell fate is Pre 
determined to a certain point, cells retain the ability to respond to environmental cues 
as needed. 
1.3.3.2 Cell fusion 
Stem cell plasticity may also be explained by fusion between two cells, in which the 
end-product may express genes of both fusion partners to various degrees (64). For 
example, the product of fusion between myoblasts and fibroblasts may lead to 
expression of muscle proteins in the latter (65). Reported fusion has only been seen in 
vitro under high selection pressures, such as tissue damage, and is a rare event 
occurring in only I in every 105 _ 106 cells (64,66). 
1.3.4 Haemopoietic progenitor cells 
Developments mainly in the field of radiation biology during the 1940s and 1950s 
were the triggering factor for haernatological research as bone marrow tissue appeared 
to be heavily affected by exposure to ionising radiation. It was estimated more than 
thirty years ago that approximately 200 x 10 9 erythrocytes and 50 x 109 granulocytes, 
as well as numerous platelets, lymphocytes, and monocytes enter the systemic 
circulation from the bone marrow on a daily basis (67). Beyond the mere magnitude 
of the haernopoietic blood cell pool what is even more capturing is the remarkable 
ability of this compartment to maintain homeostasis. Insults such as hypoxia, 
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haemorrhage, and infection initiate biological cascades shifting the production of 
lineage-specific circulating blood cells as required in the periphery (while maintaining 
intra compartmental stability). 
Many methods of haernopoietic progenitor cell isolation and purification have been 
described to date. Progenitor cells' physical, biological, and immunological properties 
have been successfully used to establish reproducible laboratory isolation techniques 
(68). Advances in the fields of flow cytometry and fluorescence-activated cell sorting 
(FACS) have assisted in identifying and selecting cells based on their 
immunophenotype. 
1.3.4.1 CD34 
CD34 is a 115 kDa transmembrane glycoprotein of the sialomucin family (69). It is 
expressed on the surface of hematopoietic progenitor cells (70) and human endothelial 
cells (71). CD34 is expressed in approximately 1.5% of bone marrow mononuclear 
cells. However, this fraction contains precursors for all lymphohernatopoietic lineages 
(72). 
The expression of CD34 on bone marrow progenitor cells has lead to the belief that it 
plays an important role in haemopoiesis. In particular, CD34+ CD38- cells are 
considered to be pluripotent haemopoietic progenitor cells. CD34 expression is not 
constant under all conditions and in vitro expression of CD34 by CD34- and CD34+ 
populations is tightly linked to cellular proliferation (73). Ex vivo studies have shown 
that CD34+ cells may originate from CD34- progenitors which do not as yet possess 
colony forming ability in vitro (74). 
The CD34 molecule contains several epitopes which has led to the production of more 
than thirty monoclonal antibodies; based on epitope enzymatic cleavage with various 
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glycoproteases (namely neuraminidase, chymopapain and glycoprotease) monoclonal 
antibodies may be sub classified in groups 1,11, and 111 (75). Although a linear 
relationship between class 11 and III CD34 epitopes on haemoPoietic progenitor cells 
has been documented (76), investigators have shown that class III epitopes are more 
broadly distributed on normal haernopoietic progenitor cells, whilst class I and 11 
epitopes may be down-regulated prior to class III epitopes during normal 
haernoPoietic progenitor cell differentiation (77). 
1.4 OVERVIEW OF STEM CELLS IN MYOCARDIAL 
REGENERATIVE STUDIES 
The myocardium is formed from units, consisting of myofibres oriented in a particular 
direction, with a vascular network, an electrical conduction system, gap junctions 
connecting myocytes allowing electromechanical coupling, a nervous system and an 
underlying fibrous skeleton (78). Ideally, if we aim to implant stem cells into 
infracted myocardium, they should replenish dying myocytes by giving rise to 
functional cardiornyocytes (myogenesis) and new blood vessels (angiogenesis). For 
this, cells have to acquire cardiac morphology and express cardiac specific markers 
and sarcomeric structures. More importantly, they must demonstrate robust functional 
and electromechanical coupling with the host myocytes within the recipient heart. 
Other desired characteristics are that they should be to be autologous, so as to avoid a 
need for immunosuppressive therapy, and be easily isolated in relatively large 
quantities. 
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Figure 1.4.1 Diagrammatic representation of all potential types of stem cells that may play a role 
in myocardial repair. 
As presented in figure 1.4.1 the armamentarium of potential donor cell types available 
to researchers and clinicians is not confined to adult stem cells. The introduction of 
the ma . ority of these cell groups in clinical trials is associated with serious drawbacks j 
(table 1.4.1). Although embryonic stem cells may seem as the ideal candidate, their 
clinical application is not foreseeable in the near future. Serious ethical considerations 
remain the main drawback; other issues complicating clinical application include 
insufficient availability, disadvantages of allograft transplantation, unpredictable 
electrical behaviour and the risk of turnour formation. 
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Cell type Advantages Disadvantages 
1-1 IFWLý11L LýUii%, ai ta3mz5 
Highly expandable Insufficient availability 
Possibly immuno-privileged Risk of tumor formation 
Cryopreservation for future use 
Immortal in vitro 
Umbilical cord stern Pluripotent Ethical issues 
cells Cryopreservation for future use Allograft (applies only to present) 
Easily available 
(Autologous transplantation in future) 
Fetal cardiornyocytes Established phenotype 
Cardiac progenitor cells Autologous transplantation 
Established phenotype 
Skeletal myoblasts Established phenotype 
Easily available 
Ischaernia resistant 
Fatigue resistant, slow-twitch fibers 
Excellent expansion in culture 
Autologous transplantation 
Cell line Established phenotype 
Highly expandable 
Cryopreservation for future use 
Immortal in vitro 
Ethical issues 
Allograft 
Insufficient availability 
Limited availability 
Questionable postnatal presence 
Expansion issues 
No evidence of gap junctions 
Potentially arrhythmogenic 
Need for ex vivo expansion 
Allograft 
Risk of tumor formation 
Table 1.4.1 Advantages and disadvantaged of other potential donor cell groups besides adult 
bone marrow-derived stem cells. 
1.4.1 Native cardiac stem cells 
Several cardiac progenitor cell (CPC) pools residing in postnatal hearts have been 
reported in different species including mice, rats, dogs and humans. The degree of 
overlap between different CPC subpopulations remains unclear. 
Stem cellfactor receptor (c-kit) is widely used as a cell surface marker of pluripotent 
stem cells. Clusters of c-kit+ /Lin- cells expressing Ki67 as well as the transcription 
factors GATA4, Nkx2.5, and MEF2C have been identified in the intersticia between 
terminally differentiated myocytes (79). These cells are pluripotent and self-renew in 
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vitro and can differentiate into cardiornyocytes, smooth muscle cells and endothelial 
cells (79). The authors acknowledged that it is impossible to determine whether these 
cells are true stem cells or multipotent cells that have progressed further along the 
differentiation pathway. The c-kif/Lin- fraction of stem cells within the myocardium 
at any given time consists of a mixture of resident and BM-derived cells that are 
chemoattracted to inflammatory stimuli (80). Age, underlying pathology and stage of 
disease are important parameters determining the above ratio. 
Stem cell antigen-I (Sca-1) is another murine cell surface marker used to identify 
primitive cells. In the adult murine heart Sca-l+ cells are identified as small interstitial 
cells adjacent to the basal lamina, typically co expressing platelet-endothelial cell 
adhesion molecules (CD31) in close proximity to endothelial Sca-l- CD31+ cells (81). 
Based on the lack of haernopoietic and (pre)mature endothelial marker expression the 
authors argued against a haernopoietic or enclothelial phenotype. Interestingly, 
telomerase activity suggestive of self renewal capacity was documented in cardiac 
Sca-l+ cells in similar levels to neonatal myocardium, whereas telomerase was not 
detected in cardiac Sca-l- cells. Although 0.03% of cardiac cells exert SP properties, 
approximately 93% of the SP fraction was Sca-l+ cells. SP cells have the ability to 
efflux a Hoechst dye by a MDR-like protein and this feature has been applied to 
isolate resident CPCs as will be discussed later. While cardiac Sca-l+ cells initially 
lack the expression of cardiac structural genes, they are capable of differentiating into 
cardiornyocytes when exposed to the DNA dernethylation agent 5-azacytidine (5-aza) 
in vitro. Pfister et al reported that among the SP cells the greatest potential for 
cardiornyogenic differentiation is restricted to CD31-/Sca-1+ cells (82). 
Cardiospheres which are myocardial stem cells isolated from adult hearts of humans 
and mice, and are capable of proliferating in vitro (83). In a culture medium 
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supplemented with epidermal growth factor (EGF), basic fibroblast growth factor 
(PFGF), cardiotrophin-I (CT-1), thrombin and under low serum conditions a cell 
population of the dissociated heart formed spheroids on poly-D-lysine-coated culture 
dishes. These cells expressed c-kit, CD34 and kinase insert domain receptor (KDR). 
In vitro, murine cardiosphere-derived cells beat spontaneously, while human cells 
require co-culture with rat cardiac myocytes to achieve this. Another category of 
cardiospheres are the SP-derived neuronal crest stem cells which reside mainly at the 
outflow tracts, express markers of undifferentiated neural precursor cells and 
differentiate into neurons, glia, smooth muscle cells and cardiornyocytes (84). 
Cardioblasts express the LIM homeodomain transcription factor Islet-1 (IsI-I) and are 
not present in the SP fraction (85). Transcription factor Isl-I is linked with a cell 
population that makes a substantial contribution to the embryonic heart, comprising 
most cells of the right ventricle, both atria, the outflow tract as well as specific regions 
of the left ventricle. They can be expanded and show distinct cardiomyogenic 
potential in vitro. Although these cells may be directly traced in the myocardium from 
the early embryonic stage, their presence appears to be confined to the first days 
postpartum in humans. Further work from the same group has lead to the discovery of 
the multipotent Isl I' cardiovascular progenitor cell (MICP) (86). 
1.4.2 Embryonic stem cells 
Proof for the ability of ES cells to differentiate into cardiomyocytes is provided by the 
spontaneous contraction observed in embryoid bodies (29). Besides spontaneous 
'beating', cells from these areas exhibit typical immunophenotypic, molecular, and 
e lectrophy sio logical properties of cardiornyocytes (29,87). Following 
intramyocardial transplantation into rodent models of myocardial infarction, 
engraftment with subsequent cardiac-lineage differentiation has been reported by 
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many groups. Sustained improvement in cardiac function was also noted (88,89). 
Recent data also suggest that ES cells are capable of homing to myocardial injury 
following peripheral delivery being chemoattracted to locally released cytokines (90). 
Although a high degree of in vitro electromechanical coupling has been documented 
for embryonic stem cells and cardiomyocytes (91), concerns regarding underlying 
arrhythmogenic potential (92) are still under debate. 
1.4.3 Umbilical cord stem cells 
Umbilical cord blood cells are easily obtainable and may be cryopreserved for 
autologous or even allogeneic matched transplantation. Experience collected from 
clinical BM transplantation has shown that partial tissue mismatches are well- 
tolerated; a smaller incidence of graft-versus-host disease is also associated with 
allogeneic cord blood transplantation compared to BM transplantation. One hour after 
ligation of the left anterior descending artery, rats were injected with human cord 
blood cells in the peri-infarct border (93). Long-term follow-up revealed substantial 
reduction in infarct size with improvement of left ventricular function parameters 
compared to untreated animals; interestingly animals were not given any 
immunosuppression in this study, confirming that cord blood cells may be 
immunoprivileged to a certain degree. When human cord blood cells were injected 
into the tail vein of control as well as NOD/SCID mice that were previously rendered 
ischaemic via LAD ligation, homing to the myocardium was only observed in the 
latter group (94). Although there was no evidence of differentiation into 
cardiornyocytes, transplanted cells promoted neoangiogenesis, and exerted a 
beneficial influence on left ventricular remodelling. 
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1.4.4 Skeletal myoblasts 
Introduction 
Skeletal myoblasts reside under the basal lamina of adult skeletal muscle and can be 
easily obtained by muscle biopsy. They may be expanded in culture, are ischaemia 
resistant and provide fatigue resistant, slow-twitch fibres. When compared to CD 133+ 
BM-derived haernopoietic progenitors transplanted in an animal model, similar results 
of functional improvement were recorded (95). The main concern of introducing 
skeletal myoblasts within myocardial tissue is the lack of electrical communication 
with native cardiomyocytes (96). There has been no demonstration of gap junction 
formation post-transplantation, which may potentially contribute to the generation of 
arrhythmias seen in patients receiving these cells. Genetic modification of myoblasts 
to express the gap junction protein connexin43 has been proposed as an 
antiarrhythmic measure (97);. Unfortunately, it seems that arrhythmias may be also 
attributed to other mechanisms beyond the lack of functional gap junction mediated 
intercellular communication (98). 
1.4.5 Bone marrow-derived stem cells 
Bone marrow and blood are attractive, readily accessible sources of stem cells. The 
multilineage differentiation and the multiorgan engraftment potential of bone marrow 
derived stem cells have been previously demonstrated (99). Other advantages of these 
cells are that they are easy to prepare, simple to administer and do not require 
additional immunosuppressive treatment in the autologous setting. Also, their use 
does not raise the ethical controversies associated with the use of embryonic stem 
cells. Multiple experimental as well as phase 1/11 clinical studies have been carried out 
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to date assessing various types of adult bone marrow-derived stem cell delivery 
(discussed in section 1.8). 
Prospective isolation of BM-derived stem cells is performed mainly via cell surface 
receptor recognition or even certain physical properties, such as adherence. As murine 
progenitor cells do not express the same surface markers, the principal means of 
identifying enriched populations is lineage depletion (Lin-) (100). Another murine cell 
surface marker used to identify primitive cells is stem cell antigen-I (Sca-1). In 
Orlic's landmark paper (10 1), transplanted Lin- c-kit+ cells were demonstrated to form 
new myocytes, endothelial cells and smooth muscle cells, leading thus to de novo 
myocardial regeneration; similar data has also been produced with human peripheral 
blood CD34 + cells (102). Nonetheless, controversy remains as to whether HSCs are 
capable of transdifferentiation into cardiomyocytes (103,104) or even confer any 
functional improvement whatsoever (105). 
Endothelial progenitor cells (EPCs) or angioblasts differentiate into endothelial cells 
and are defined by their ability to participate in neovasularization. Endothelial 
progenitor cells and HSCs are thought to share a common precursor, the 
haemangioblast (106). They exist in the bone marrow as well as the systemic 
circulation. Studies have shown the connection between angioblasts residing within 
the bone marrow and neovascularization (107,108). EPCs are recruited to sites of 
ischaernic injury and promote angiogenesis; Fazel and colleagues suggest that this is 
achieved via regulation of the myocardial levels of various angiogenic cytokines such 
as the angiopoietins I and 2, and vascular endothelial growth factor (VEGF) (80). 
Primitive bone marrow EPCs express CD133, CD34 and CD45 and can be 
indistinguishable from primitive HSCs. Mature EPCs express CD34, vascular 
endothelial growth factor receptor-2 (VEGFR2), Tie-2, VE-cadherin, CD3 1, von 
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Willebrand factor and are negative for CD45. Absolute numbers and functional 
activity of EPCs appear to be inversely correlated with risk factors for coronary artery 
disease (109,110). 
Many groups have demonstrated the proof of principal by trans-differentiating 
marrow stromal cells into cardiomyocytes in vitro. This has mainly been 
accomp is e by treating cells with chemicals promoting DNA demethylation, such 
as 5-aza-2'deoxycytidine (111-113), which induces transcription of critical 
transcription factors by demethylating CpG islands of promoter regions. All cells 
produced expressed cardiornyocyte specific genes and could be seen to spontaneously 
beat in the petri dish. Apart from innate plasticity, MSCs may exhibit 
immunomodulatory effects (114) that may allow for allogeneic in vivo transplantation 
with minimal risk of immune rejection (115). Possible co-delivery of MSCs with bone 
marrow-derived mononuclear cells in order to maximize clinical effect has also been 
proposed (116). 
An interesting adult bone marrow derived population of high plasticity reported by the 
Minnesota group are the multipotent adult progenitor cells (MAPCs) (117). Originally 
isolated from mesenchymal stem cell cultures, this subset of progenitor cells has been 
shown to differentiate in vitro into cells of the three germ layers. Worth mentioning is 
the claim that single MAPCs injected into an early blastocyst, contribute to most, if 
not all, somatic cell types. Whilst the phenotype of mMAPCs in fresh bone marrow 
remains unknown, the phenotype of cultured mN4APCs is CD34, CD44, CD45, c-Kit, 
and major histocompatibility complex (MHC) class I and 11 negative; mMAPCs were 
shown express low levels of Flk- 1, Sca- I and Thy- 1, and higher levels of CD 13 and 
stage-specific antigen 1. A recent study did not yield any promising results regarding 
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either global contractile function or evidence of differentiation into cardiomyocytes or 
engraftment with MAPCs in a rat model of myocardial transplantation (118). 
Yoon et al have also reported a subpopulation of stem cells within adult human BM, 
isolated at the single-cell level for myocardial regeneration (119). This population 
expresses minimal levels (less than 3%) of CD90, CD 115 and CD 117. The authors 
claim that these cells are capable of inducing both therapeutic neovascularization as 
well as enclogenous and exogenous cardiornyogenesis. 
1.4.6 Other stem cell sources 
Fetal cardiornyocyte transplantation has been successfully performed in various 
animal models. Most groups have shown formation of intercalated disks between 
grafted fetal cardiornyocytes and host myocardium. In an interesting study, 
Sakakibara et al noted that fetal cardiornyocyte transplantation was able to prevent, 
but not to reverse, cardiac remodelling in myocardial infarction in a rat model (120). 
Gao et al carried out human fetal cardiomyocyte transplantation (obtained from 
aborted human embryos) in a rat model of myocardial infarction with good functional 
results (121). As with ESCs ethical issues, lack of availability and the disadvantages 
of allograft transplantation apply to the fetal cell category. An exciting field of fetal 
tissue transplantation that may provide answers to many of these concerns is nuclear 
transplantation. Lanza et al not only demonstrated the feasibility of this technique, but 
also recorded myocardial regeneration significantly superior to that achieved with 
adult bone marrow cells (75). 
Due to an established phenotype and an unlimited availability cell lines have been 
thought to be a possible alternative for myocardial regeneration. Koh et al 
transplanted cells from an established myoblast cell-line to murine ventricles (122). 
The absence of a cardiornyocyte cell-line along with the innate characteristics of cell 
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lines (allograft transplantation, potential for tumour development) does not make this 
group of cells favourable to scientists. 
1.5 STEM CELL HOMING TO ISCHAEMIC MYOCARDIUM 
Complex mechanisms, unknown to a great degree, are responsible for homing and 
holding haemopoietic progenitor cells within the bone marrow. Among these, and of 
clinical relevance, is the CXCR4/SDF-I chemotactic axis. Stromal cell-derived 
factor-I (SDF-I/CXCL12) is a marrow-stromal and bone-derived chemokine with 
two isoforms, a and P. It is thought to form a decreasing gradient from the 
extravascular toward the intravascular compartment within the bone marrow. SDF- I 
plays an important role during fetal development in bringing about the relocation of 
fetal haernopoiesis to the BM from the liver (123,124). In the adult it promotes 
engraftment of transplanted HSCs within the recipient's bone marrow (125). The 
chernotactic effects of SDF-I are mediated by its receptor CXCR4 which is 
responsible for the observed chemoattraction of primitive bone marrow CD34+ CD3 8- 
populations in vitro (126). 
Mobilization of stem cells is a dynamic process involving chemokines, cellular 
surface receptors, metalloproteinases (MMPs), and adhesion molecules in addition to 
remodeling of the extracellular matrix. Ischaernia is known to cause migration of bone 
marrow-derived progenitors within ischaemic areas. SDF-I/CXCL12 and VEGF 
appear to be involved in this process (127,128). 
Ceradini et al have demonstrated that SDF-I gene expression is controlled by the 
transcription factor hypoxia-inducible factor-I (HIF-1) translating to increased 
expression in the presence of tissue hypoxia (129). Heissig et al have shown in a 
murine model that bone marrow mobilization takes place via a mechanism initially 
activating MMP-9 (130). 
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By blocking the binding of SDF-I to receptor CXCR4 in a rodent myocardial 
infarction model, homing of progenitor cells in injured myocardium was inhibited 
(131). The establishment of a positive gradient of SDF-I concentration between 
ischaemic tissue and BM is suggested to promote mobilization of progenitor cells and 
subsequent homing at sites of injury (132). This would be consistent with the cytokine 
induced BM mobilization with granulocyte colony- stimulating factor (G-CSF) being 
achieved via decreasing bone marrow levels of SDF- I (133). 
Locally delivered SDF-l can augment neovascularization in ischaernic hindlimb 
models (134). VEGF gene expression is also upregulated in myocardial infarction 
(135,136). HIF-I is an early transcription factor for VEGF during ischaemia-related 
tissue injury. This has been shown in human ventricular biopsies taken during surgical 
revascularization following myocardial infarction (13 7). 
Further to these two factors, ischaemia induces the production of a variety of other 
factors and mediators that may participate in stem cell homing (13 8). Even if they are 
not directly involved in generating a homing signal their significance lies in creating 
the appropriate microenvironment required for integration of the homed cells. 
1.6 MECHANISMS OF CARDIAC FUNCTION IMPROVEMENT 
Even if cell trafficking to ischaemia-related homing signals was fully understood, 
what takes place once the 'homed' cells reach or are directly introduced to their new 
microenvironment is an area of ongoing research. The functional improvement 
observed in animal and human studies may constitute manifestations of either direct 
mechanical reinforcement of the left ventricular wall, incorporation and integration of 
implanted stem cells into native myocardial fibers, improvement in neovascularization, 
or even be a result of paracrine factor production and delivery exerted by the 
implanted cells. 
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By introducing a volume of cell suspension into the myocardium, a local thickening 
occurs. Thus, taking advantage of the law of Laplace, less tension is exerted in the left 
ventricular wall avoiding further dilatation and haemodynamic deterioration. 
The histopathological evidence of engraftment reflects the plastic character of the 
introduced cells. Possible theoretical factors accounting for this attributed plasticity 
include: 
* the existence of myocardial- specific stem cells within the bone marrow or 
other non-myocardial tissue, 
* transdifferentiation of introduced cells into cardiac and/or endothelial cells, 
* cell fusion between the transplanted cells and host cardiornyocytes, 
0 injected cells (or certain subpopulations) may retain a pluripotent character 
enabling them to reconstruct de novo myocardial tissue, 
o restoration of CSC niches, and 
* combinations of the above. 
Transdifferentiation refers to stem cells adopting the characteristics of other tissue- 
specific cell types. Orlic et al indicated that HSCs after transplantation into infarcted 
mice differentiated into new myocytes, endothelial and smooth muscle cells (101). 
This claim for transdifferentiation has been challenged by many other groups and 
remains a controversial issue to date (103-105) . 
Fusion between transplanted and host cells is another proposed mechanism. 
Accordingly, cell fusion causes the transfer of cell contents, including genetic 
material from transplanted to host cells. Cell fusion is a tightly regulated process 
restricted to a few types of normal somatic cells in humans (139). Several reports 
showed that BM stem cells engrafted into the adult heart myocardium by fusing with 
preexisting cardiac myocytes (140-142). It has also been suggested by investigators 
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that what was supposed to be transdifferentiation was in fact cell fusion. Subsequent 
studies have excluded the contribution of cell fusion to cardiac regeneration and as it 
happens in such a low frequency, it is unlikely that cell fusion effects are significant 
enough to affect contractile function (143). 
Another mechanism by which stem cell therapy may have beneficial effects is via a 
paracrine effect. The concept is that transplanted cells release cytokines, growth 
factors and signalling proteins that induce positive effects on resident cell populations , 
thus stimulating proliferation and repair within host tissue. This positive effect on 
resident myocytes includes neoangiogenesis, proliferation of endogenous CPCs and 
prevention of apoptosis. It is highly likely that the resident stem cells unable to cope 
with extensive myocardial injury are supported by distant stem cell recruitment, 
which may in turn convey a 'boosting' effect to the resident stem cell niches. 
Neovascularization as a result of bone marrow-derived or circulating endothelial 
progenitor cells has been documented (107,144,145). Many reports have 
demonstrated that different subpopulations of bone marrow-derived cells have the 
ability to secrete angiogenic factors, such as VEGF, FGF, hepatocyte growth factor 
(HGF) and angioprotein-I (146,147). The formation of new blood vessels results in 
decreased apoptosis of myocytes in the border zone of the infarct limiting the 
remodelling process in this way. 
Besides promoting neovascularization via secretion of angiogenic factors, BM- 
derived cells also secrete an array of other cytokines and growth factors. These 
include interleukin I (IL-1), interleukin 6 (IL-6), tumor necrosis factor-a (TNF-a) and 
transforming growth factor-P (TGF- P), placental growth factor, SDF-I, MMPs, and 
granulocyte-macrophage colony-stimulating factor (GM-CSF). In a mouse model of 
hindlimb ischemia, cell-free MSC conditioned medium were shown to have beneficial 
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effects on blood flow and limb function (146). Collateral perfusion has been shown to 
be improved by angiogenic factors and cytokines produced by the transplanted cells 
(148). 
Finally, an interesting theory attempting to explain the observed improvement in 
cardiac outcome is the dying stem cell hypothesis (149). As a great proportion of 
delivered stem cells die from apoptosis, it is proposed that down-regulation of both 
innate and adaptive immunity take place as apoptotic cells act as inhibitors of 
inflammation. This is mainly mediated via the production of anti-inflammatory 
cytokines by macrophages as well as immature dendritic cells, eventually leading to 
reduced scar formation and improved cardiac outcome. 
1.7 ANIMAL EXPERIMENTAL WORK 
1.7.1 Representative small animal experiments 
In the quest for assessing the ability of the various cell categories under investigation 
for myocardial regeneration, the contribution of animal myocardial infarction models 
has been invaluable. Transmural myocardial scars can be induced in numerous ways 
in small animals, i. e. rodents. Direct ligation of the left anterior descending artery 
with suture application is the best described and most commonly used. Other methods 
include cryoinjury via cryoprobe and topical injection of a cardiotoxin (such as the 
snake cardiotoxin Naja mossambica mossambica) in the ventricular wall. 
Reproducibility in creating transmural scars of similar size in study animals is 
relatively easy in the latter methods with the serious drawback of not incorporating a 
4physiologic' process of ischaernic disease simulation. Critical technical points in the 
design of such an experimental protocol are the timing of intervention with regard to 
the initiating insult along with the preferred route of delivery. 
-45- 
Chapter I Introduction 
The initial encouraging data indicating that primitive BM-derived cells are able to 
'repair' injured heart muscle came from a small number of studies. In one of the first 
published reports, it was seen that the transplantation of autologous BM cells (BMCs) 
stimulated angiogenesis in the recipient ischaernic myocardium. BMCs labelled with 
bromodeoxyuridine (BrdU) were transplanted into myocardial scar tissue created by 
cryoinjury three weeks earlier. Increased capillary density was seen in the cell 
transplant groups compared to the control group eight weeks post transplantation. 
Interestingly, BrdU positive cells were seen in the capillary wall of the newly formed 
vessels. Functional improvement was observed only in the MSC subgroup without 
cells that had been treated with 5-aza (150). 
The most important paper of this era was published two years later by Orlic and co- 
workers in 2001 (101). By means of a mouse ligature-induced myocardial infarction 
model, the transplantation of a pre-defined BM subpopulation in the acute ischaemia 
phase was assessed. Autologous lineage negative (Lin-) BMCs isolated from male 
transgenic mice expressing enhanced green fluorescent protein (GFP) were injected 
directly into the myocardium of female mice 3-5 hours after coronary ligation. When 
hearts were removed 9 days post transplantation, proliferating myocytes and vascular 
structures occupied 68% of the infarcted segment of the left ventricle. The authors 
concluded that Lin- c-kit+ BMCs have the capability of regenerating acutely 
significant amounts of contracting myocardium. 
Jackson and colleagues developed an interesting protocol to investigate the 
regenerative capacity of the SP cells isolated from BM (15 1). Lethally irradiated mice 
transplanted with SP cells were subsequently rendered ischaernic by transient 
coronary occlusion and reperfusion. Mice were sacrificed at two to four weeks after 
injury. Examination of the hearts once more suggested that the BMCs were able to 
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transdifferentiate and engraft into myocardium and endothelial cells. In another model 
of myocardial ischaernia, systemic infusion of human BM-derived EPCs was able to 
intercept the remodelling process of the left ventricle (152). The observed 
neovascularisation prevented apoptosis of hypertrophied myocytes reducing collagen 
deposition and subsequent scar formation. Post-transplantation ventricular function 
improved as well. 
Following analytical processing of their previous work, Orlic et al attempted to take 
advantage of the observed homing of stem cells to injured myocardium (153). They 
hypothesised that cytokine mobilization of the animals own BM should increase the 
trafficking of desirable cells the sites of injury. A 68% decrease in mortality with 
significant haernodynarnic improvement was documented when stem cell factor (SCF) 
and G-CSF mobilization was undertaken in ligature-induced ischaemic mice. 
Due to technical difficulties intracoronary infusion in a rodent model cannot be 
performed in a similar fashion as in large animal models or humans. In order to 
reproduce intracoronary delivery, two weeks after coronary artery ligation Wang et al 
infused MSC suspensions in briefly occluded ascending aortas (154). Injected cells 
were identified after three weeks as cardiomyocytes or fibroblasts. Once more it was 
concluded that cells migrated through the coronary circulation to sites of injury and 
under the effect of the local microenvironment transdifferentiated into the required 
phenotypes. 
These studies constitute a representative sample of small animal studies involving 
adult BM-derived stem cell populations. A vast number of projects have been 
published since these reports investigating a variety of cell types in conjunction with 
various cytokines or even gene therapy. 
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1.7.2 Representative large animal experiments 
Large animal constructs have been used extensively to elucidate cellular and 
extracellular mechanisms in ischaemic heart disease. Non-human primates can 
unquestionably provide scientists with a model that most closely resembles humans. 
The remarkable similarity between the porcine and human coronary anatomy is the 
main reason for the popularity of this model. Ovine models should also be mentioned. 
The canine model is not commonly used mainly due to the presence of a significant 
collateral circulation that makes the creation of an infarction unreliable between 
subjects. An additional advantage of large animal models is the ability to perforin 
minimally invasive procedures (such as intracoronary coil embolization or even 
angiography) with instrumentation used in humans. Finally, periprocedural 
assessment may be performed with conventional imaging techniques thus avoiding 
the need for developing or even adapting equipment to the anatomic and physiologic 
standards of small animals. 
Creation of myocardial infarction in larger animals can be generated with either open 
or closed chest techniques. Ameroid constrictor application around the proximal 
circumflex coronary artery, transient snaring of the distal left anterior descending 
coronary artery, or even micro coil embolization into any of the main branches of the 
left coronary artery results in reproducible myocardial infarction. 
Guided by ventricular electromechanical mapping, Fuchs and co workers delivered 
autologous BM-derived cells using a transendocardial injection catheter in pigs 
previously rendered ischaemic (155). An approximately 50% increase in regional wall 
thickening leading to improved myocardial function was measured by 
echocardiography in the cell transplanted group. No significant changes were seen in 
the control group. Of interest is the fact that the only observed improvement in 
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myocardial perfusion was localized entirely in injected ischaernic areas. No positive 
effect on regional myocardial blood flow was seen either in control animals or in non- 
ischaernic injected areas in the cell transplant group. Histopathological examination 
revealed a 100% increase in total endothelial cell area in the ischaernic collateral- 
dependent zone compared with the non-ischaernic territory of the cell treated group. 
In another study BrdU labeled marrow stromal cells were directly injected into a 
porcine ischaernic myocardium four weeks after occlusion of the left anterior 
descending artery with coils and Gelfoam sponge (156). Four weeks after 
implantation BrdU labelled cells that also stained for troponin I were seen in tissue 
slices from transplanted areas. Some endothelial cells from the same areas also 
stained positively for BrdU. Even though no junctions were apparent between these 
cells and host cardiornyocytes, once more a significant improvement both in 
myocardial blood flow and left ventricular performance was shown by scintigraphy in 
the cell transplant group compared to the control animals. Shake et al also 
demonstrated engraftment, using double staining for membrane and muscle-specific 
proteins, along with functional improvement (157). This was once again performed 
with transplantation of MSCs in pigs with left anterior descending coronary artery 
ligature-induced ischaernia. 
The toxicity and therapeutic potency of autologous BM cell transplantation has been 
also assessed in a canine chronic coronary occlusion model by Hamano et al (158). 
Thirty days after left anterior descending coronary artery ligation autologous BMCs 
were introduced directly into infarcted, marginal as well as healthy myocardium. The 
control group received injections of phosphate-buffered saline in respective sites. 
Cardiac function along with local wall motion was evaluated by echocardiography 
thirty days after imPlantation. Angiogenesis was measured by microvessel counting 
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under light microscopy. A significant increase in local wall thickening and density of 
microvessels was documented only in the marginal area of the BMC treated group. 
No further differences were seen between the two groups. Once again no systemic or 
local toxicity was observed. 
Pak et al observed overexpression of cardiac tenascin, increased cardiac nerve 
sprouting and amplified magnitude of atrial sympathetic hyperinnervation two months 
post-transplantation (159). 
In a nonhuman primate model, male and female baboons were treated with 
haemoPoietic growth factors following ligation of the lateral branches of the 
circumflex coronary artery (160). Norol et al showed regeneration of vascular 
structures in treated animals, but no evidence of cardiac cell differentiation. Although 
in a few animals regional myocardial blood flow for the infarcted area increased, no 
overall improvement was seen in myocardial function between the two groups. 
A controversial study in a canine model carried out by Vulliet et al reported 
micro infarctions in subjects following intracoronary infusion of MSCs (161). Early 
passage cells were infused into the circumflex coronary artery of healthy dogs. Hearts 
were examined after 7 days and the presence of microinfarctions in areas supplied by 
the circumflex artery was documented. 
A great interest has also been shown in similar models to develop reliable techniques 
that will facilitate implantation and continuous tracking of stem cells into myocardial 
tissue (162-164). A percutaneous transvenous approach through the coronary venous 
system has also been described and demonstrated in a porcine model (165). 
1.8 CLINICAL TRIAL DATA 
Encouraging data from the continuously produced in vitro as well as in vivo 
experimental work has prompted many groups to initiate clinical studies/trials to 
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assess any beneficial effects of adult stem cells in myocardial ischaemia. The 
selection of cell type, timing as well as route of delivery is predefined by factors such 
as phase of disease (acute myocardial infarction or established myocardial ischaemia) 
and patient's clinical status (end-stage heart failure patients cannot be enrolled in a 
trial where cell delivery is combined with open-chest surgery). All trial protocols 
should be designed in accordance with the Declaration of Helsinki for medical 
research involving human subjects (166). 
1.8.1 Initial pilot studies 
These can be broadly grouped into those which studied effects of cell therapy in 
patients who had had a recent acute myocardial infarction (167-170), and those which 
investigated patients with chronic ischaernic heart disease (e. g. myocardial infarction 
at least 3 months previously) (171-173). One of the earliest pilot studies involved 5 
patients being administered autologous BMCs during simultaneous coronary artery 
bypass grafting (CABG) (174). One strict inclusion criterion resulting from ethical 
considerations in this pilot trial was that these patients had to have at least one area of 
ischaernic myocardiurn which was not amenable to standard interventional or surgical 
revascularisation. Mononuclear cells were isolated from a BM aspirate, and were 
transepicardially injected into the ungraftable area of myocardium during the period 
after the main CABG procedure while the heart was in an arrested state under 
cardiopulmonary bypass. Post-operative cardiac scintigraphy showed some 
improvement in myocardial perfusion in 3 out of the 5 patients and there were no 
significant adverse effects of therapy. 
The three pilot studies investigating patients with chronic angina or severe 
ischaemic heart failure used similar cell harvesting techniques, isolating the BM 
mononuclear cells of interest by density gradient (171-173). These investigators all 
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used electromechanical mapping of the left ventricle using a percutaneous mapping 
catheter to delineate viable myocardium and areas of hibernating myocardium. Tse et 
al implanted autologous mononuclear BMCs into the hearts of 8 patients with stable 
angina refractory to medical therapy. This was performed using direct intramyocardial 
injection via an injection needle catheter guided by prior mapping with an 
electromechanical mapping catheter. There were no procedural complications or 
serious adverse events. Outcome measures included frequency of angina episodes, use 
of antianginal drugs, and perfusion and left ventricular ejection fraction (LVEF) as 
measured by magnetic resonance imaging (MRI) (173). While benefits were seen in 
all three areas at 3 month follow-up, the very small sample size meant that no 
concrete conclusions could be drawn on efficacy or safety. Two other trials using 
similar methodology found intramyocardial injection to be a relatively safe and 
practicable mode of treatment (171,172). 
Numerous pilot studies have taken place to determine whether stem cell therapy in 
the acute setting after a myocardial infarction is safe, feasible and effective. Strauer 
and colleagues treated 10 patients with autologous mononuclear BMCs via an 
intracoronary route, which involved the use of a balloon catheter to transiently 
obstruct coronary flow in the target vessel while cells were infused at high pressure 
distal to the inflated balloon (170). This procedure was deemed to be safe according 
to results at 3 months follow-up. However, evidence of the efficacy of cell therapy 
demonstrated by functional cardiac studies such as dobutamine stress 
echocardiography and radionuclide ventriculography cannot be taken at face value in 
such a small, unrandomised group of patients. Femandez-Aviles et al performed a 
similar trial in which they non-randomly allocated 13 patients to intracoronary cell 
therapy, and 7 patients to a control arm which received the same acute medical 
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treatment (168). They used MRI to measure left ventricular volumes and ejection 
fraction, and left ventricular and coronary angiography was also performed. These 
main investigations were used to compare post-transplantation LVEF and end-systolic 
volume with values obtained at baseline. No adverse effects were detected by clinical 
examination, post-procedure creatine kinase (CK-MB) and troponin T levels, Holter 
electrocardiogram monitoring, cardiac MRI and left ventricular and coronary 
angiography up to 6 months of follow-up. LVEF and end-systolic volume 
significantly improved over these 6 months from pre-treatment levels. 
A trial by Stamm et al, involving 12 patients, examined the effects of cell therapy 
using an CD133+ population of stem cells isolated from the BM (169). They 
performed intramyocardial injections at concomitant CABG surgery into areas of 
myocardium which were unsuitable for conventional revascularisation procedures. 
This was performed between 10 days and 3 months after admission for acute 
myocardial infarction. Investigators reported no major complications along with 
improved myocardial perfusion after cell therapy, seen on single-photon-emission 
computed tomography (SPECT). 
The biggest preliminary study on the effects and safety of BM progenitor cell therapy 
to treat acute myocardial infarction was the Transplantation of Progenitor Cells and 
Regeneration Enhancement in Acute Myocardial Infarction (TOPCARE-AMI) study 
(167). The first part of this trial involved an interim analysis of 20 patients, 9 of whom 
were randomised to transcoronary treatment with BM progenitor cells (BMPCs), 
while the remaining II patients received transcoronary blood-derived progenitor cells. 
These 20 patients were matched to a non-randomised reference group (n=l 1) with 
matched ejection fraction, and infarct site and size. All patients had already been 
treated successfully with coronary stenting and glycoprotein (Gp)-Ilb/111a blockade. 
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BMPCs were isolated using a density gradient, while circulating progenitor cells were 
expanded ex vivo in culture for 3 days. An average of 4.3 days after infarction, the 
patients received an intracoronary infusion of progenitor cells, by injecting cells via 
an intermittently inflated balloon catheter. After 4 months these patients were 
followed up with cardiac catheterisation and left ventriculography. Promising results 
were seen at this time, with a significant approximate increase in LVEF of around 8% 
in both BM cell and circulating progenitor cell recipients from baseline to 4 month 
follow-up, which was also significant when compared to the non-randomised 
reference group of patients. There was also improvement in regional wall motion in 
the infarct zone from baseline to follow-up. No differences were seen between those 
who received circulating or BM-derived progenitor cells (175). Serial contrast- 
enhanced MRI in 28 patients from the study population verified these results over a4 
month period, demonstrating a reduction in infarct size, an increased LVEF of about 
5%, and a decrease in end-systolic volume from around 69mL to 60mL (176). 
Expansion of the trial after the 4 month interim period to include 59 patients randomly 
allocated to receive circulating progenitor cells (n=30) or BM-derived progenitor cells 
(n=29) found a similarly significant rise in LVEF at one year follow-up in the study 
population (from around 50% to around 58%) and a significant decrease in end- 
systolic volumes as measured by left ventricular angiography (177). LVEF and infarct 
size were also measured by contrast-enhanced MRI, providing correlating results in 
tenns of an increase in LVEF of around 9.3%, together with evidence of a reduction 
in infarct size. The only significant adverse event directly related to cell therapy was a 
procedure-related, embolic occlusion of a distal coronary vessel after balloon 
dilatation. 
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Encouraging phase I clinical trial data also exist incorporating transepicardial, trans- 
coronary venous, and transendocardial approaches utilising skeletal myoblasts as the 
cell of choice (77,178-182). All studies demonstrated procedural safety whilst post 
transplantation assessment suggested associated clinical improvement in research 
participants. The main concern remained that of arrhythmogenicity with episodes of 
ventricular tachycardia being noted in at least half of these studies (179-18 1). Worth 
noting is the fact that Dib et al included patients receiving skeletal myoblasts along 
with left ventricular assist devices as a bridge to transplantation (180). Following 
subsequent cardiac transplantation, hi stopatho logical examination demonstrated 
engraftment" of transplanted cells within the recipient's myocardium. 
1.8.2 Randomised controlled studies 
The results of the non-randomised studies above were promising in terms of their 
safety profile and clear feasibility of cell therapy as a treatment modality, but the 
functional and symptomatic improvements seen in patients could have been 
attributable to placebo effect, due to the small sizes of patient groups involved and the 
lack of randomised control groups. Randomised controlled trials began with Wollert 
et aL publishing the results of their study (183). Sixty patients who had suffered from 
an acute ST-segment elevation myocardial infarction and had had successful PCI with 
coronary stenting were randomly allocated to either a control group (n=30), which 
received optimal medical treatment, or a cell therapy group (n=30) that received 
autologous BMCs by intracoronary infusion 4.8±1.3 days after PCI. Baseline cardiac 
MRI was performed, and BM was aspirated from the cell therapy group and processed 
by density gradient sedimentation. Around 24.6 x 108 nucleated cells were 
transplanted into each patient by multiple short infusions via an over-the-wire balloon 
catheter. This catheter was transiently inflated during the 2.5-4 minute long infusions 
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to stop instant washout of the cells by coronary blood flow. No sham BM aspiration 
or intracoronary infusion was performed with the control group, but all MRI images 
were assessed by investigators blinded to whether patients were in the control or 
treatment arm. The main result reported was that LVEF, the primary endpoint at 6 
month follow-up, increased significantly by 6.7% in the cell therapy group compared 
to a non-significant increase of 0.7% in the control group. 
A follow-up study of these patients by cardiac MRI at 18 months found that the 
significant LVEF improvement in the BM cell therapy group previously seen at 6 
months had disappeared (184). Patients treated with BMCs had on average a 5.9% 
improvement in LVEF at 18 months, compared to a 3.1% increase in LVEF in 
controls. These were the first results suggesting that any benefit from BM cell therapy 
was only transient, and were disappointing given the atmosphere of optimism 
generated by earlier pilot studies and the encouraging long-term picture on cardiac 
function painted by the final I year results of the TOPCARE-AMI trial (177). 
In another study from China 69 patients having been treated for acute myocardial 
infarction were once again randomised to receive either autologous BM MSCs or 
saline as the control arm (185). A considerable improvement was seen at three-month 
follow-up both in left ventricular haemodynamics as well as in myocardial perfusion. 
Later in 2006, the research group behind TOPCARE-AMI reported the results of 
their randomised controlled crossover study (186). This study focused on patients 
with "healed myocardial infarction, " i. e. those who had had myocardial infarction at 
least 3 months previously. After a pilot study on 17 individuals, 75 patients were 
initially allocated to either no cell infusion (n=23), circulating progenitor cells (n=21) 
or BMPCs (n=28). After 3 months, patients given intracoronary cell infusions were 
crossed over to the alternative cell type, while the original control patients were 
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randomised to either a circulating (n=10) or a BM (n=1 1) progenitor cell infusion. At 
3 month follow-up, it was found that BM cell infusion resulted in a significantly 
larger increase in LVEF (2.9%) compared to circulating progenitor cell 
transplantation (-0.4%) or no cell infusion at all (-1.2%), independent of whichever 
way patients were crossed over. While significant, the increases in LVEF seen in BM 
cell therapy were still small, although the authors point out that similarly modest 
improvements in LVEF were seen in large trials evaluating the current best medical 
reperfusion treatment for improving left ventricular function after myocardial 
infarction (187,188). 
Another randomised controlled trial involving 100 patients with acute ST-elevation 
myocardial infarction randomly allocated individuals to either a control group (n=50) 
who received medical treatment according to national guidelines (189), together with 
cardiac rehabilitation and lifestyle advice, or a group of 50 patients who underwent 
intracoronary injection of autologous BM mononuclear cells around 6 days after PCI 
(190). Left ventricular function was measured with SPECT and echocardiography at 
baseline, then with MRI 2-3 weeks post-infarction. All investigations were repeated at 
6 month follow-up. Lunde and colleagues found no significant effect of cell therapy in 
terms of LVEF increase, end-diastolic volume decrease or infarct size, regardless of 
whichever imaging modality was used to measure these endpoints. 
The accumulating evidence for the safety of the procedures involved in stem cell 
therapy, coupled with lack of any placebo-controlled trials, eventually led to two 
double-blinded randomised controlled trials (191,192). Another need for placebo- 
controlled trials is that they can allow to decipher whether the benefit in outcome seen 
in BM cell therapy was due to the transient inflations of balloon catheters during 
intracoronary stem cell delivery, resulting in some form of ischaernic preconditioning. 
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The trial by Schachinger and colleagues had notably larger sample sizes than 
preceding trials, with a total patient population of 204 being randomised into either a 
treatment group receiving an intracoronary infusion of BMPCs (n=101), or a control 
group which received intracoronary placebo medium (n=103) (191). Patients were 
included in the study if they had suffered an acute myocardial infarction which had 
been successfully reperfused by PCI with stent implantation, and if they had an 
estimated ejection fraction of 45% or less. BM aspiration was performed on both 
treatment and control groups 3-6 days after PCI. Left ventricular angiography was the 
sole imaging modality used to measure LVEF, left ventricular volumes, and to assess 
regional wall motion. Global LVEF increased from 46.9% at baseline to 49.9% at 4 
months in the placebo group, compared to a rise from 48.3% to 53.8% over the same 
time period in the BM cell treatment group. The improvement from baseline was 
significantly greater in the treatment group (p=0.01) Predefined subgroup analysis 
revealed that patients with lower baseline LVEF derived the most benefit from BM 
cell therapy. 
Janssens and colleagues' randomised, double-blinded, placebo-controlled study 
was a smaller scale trial involving 34 patients in the placebo arm and 33 in a BM 
progenitor cell therapy arm (192). The patient population consisted of individuals who 
had had an acute ST-elevation myocardial infarction with successful reperfusion 
treatment with PCI and stenting, together with significant residual left ventricular 
dysfunction. All patients underwent BM aspiration I day after PCI. Assessment by 
MRI at 4 months found no significant improvement in global LVEF, the primary 
endpoint. LVEF increased from 46.9% to 49.1% over 4 months in controls, while 
there was an increase from 48.5% to 51.8% in the treatment group. While examining 
the lack of significant improvement in cardiac function associated with intracoronary 
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BM cell delivery, the authors suggested that microvascular obstruction in the infarct 
territory following an infarction could hinder stem cell delivery. This raises the 
possibility that taking measures to reduce the extent of this pharmacologically could 
improve the usefulness of BM cell therapy (193). The average baseline LVEF in the 
patient population was also quite high (55-56% as determined by angiography), as 
pointed out by Penn (194). If Schachinger et al. were correct in saying that patients 
with a lower baseline LVEF of below 48.9% benefit the most from BM cell therapy 
(191), the patients in the study by Janssens and colleagues might not have been 
impaired enough with regard to cardiac function to benefit from cell therapy. 
1.9 OBJECTIVE OF THE STUDY 
The principal aims of this work were: 
1. The isolation of adherent CD34+ adult bone marrow-derived stem cells and the 
definition of optimal conditions for their expansion and endothelial/cardiac 
differentiation in vitro. 
2. Performing cellular transplantation studies using a rodent animal model of chronic 
myocardial ischaemia. The main aim is to assess functional improvement of 
myocardial ischaernia after transplantation of this subset of CD34+ cells 
3. Design of a phase 1/11 clinical trial to assess the clinical safety and feasibility of 
stem cell transplantation into the coronary circulation of patients with established 
ischaemic heart disease. The maximum tolerated dose of adult stem cells will be 
determined. The trial will also seek to determine clinical improvement or deterioration 
by measurement of several clinical parameters. 
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2. MATERIALS AND METHODS 
2.1 SAMPLE SOURCES 
Granulocyte colony-stimulating factor (G-CSF)-mobilized peripheral blood 
progenitor cells were obtained from leukaphereses processed by the Stem Cell 
Laboratory, Hammersmith Hospital, in excess of clinical requirements. Informed 
consent and local research ethics committee approval were granted in all cases. 
Human umbilical vein endothelial cells (HUVECs) were isolated from umbilical 
cords (kindly donated by Dr Ewa Paleolog at the Kennedy Institute of Rheurnatology). 
2.2 CD34+ CELL ISOLATION 
Following dilution of harvested peripheral blood samples at 1: 4 in Hanks buffered 
saline solution (HBSS; Gibco), the mononuclear cell fraction was separated by 
centrifugation over a density gradient (Lymphoprep, Axis-Shield) at 1800 rpm for 30 
minutes. Once collected, counted, and washed in HBSS the mononuclear cells were 
labelled for CD34 + cell isolation using the MiniMacs CD34+ positive isolation kit 
(Miltenyi Biotec) as per the manufacturer's protocol. In brief, each 108 mononuclear 
cells was incubated in 350gl MACS buffer (phosphate-buffered saline (PBS) buffer 
supplemented with 0.5% bovine serum albumin and 5 mM EDTA), 100ýil FcR 
blocking agent, 5041 CD34+ magnetic bead at 4'C for 15 minutes. The collected 
labelled cells were rewashed in MACS buffer at 1800 rpm for 3 minutes, and 
resuspended in 500ýtl of MACS buffer per 108 labelled cells. This final suspension 
was put through a magnetic column (Miltenyi Biotec), and the CD34+ cells were 
retrieved. Unlabelled cells which passed through were collected, and the column was 
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washed three times with 3mL of MACS buffer. The column was then removed from 
the magnetic field and 5mL of MACS buffer was used to flush out the fraction of 
magnetica y labelled cells into a collection tube. 
2.3 CELL CULTURE 
Following isolation CD34+ cells were resuspended in a-Minimal Essential Medium 
(a-MEM, Gibco, UK) supplemented with 15% foetal bovine serum (FBS) and 
incubated for 2 hours at 37'C and 5%CO2.5 x 105 cells were plated per each 35MM2 
Petri dish. After 2 hours, the non adherent cell fraction was removed from the 
underlying adherent cells and the adherent cells were washed 3 times with PBS. 
Adherent CD34+ cells were grown for 7 to 14 days in a-MEM supplemented with 
30% FBS and cytokines GM-MIX (SCF 20ng/ml, GM-SCF Ing/ml, IL-3 5ng/ml, G- 
SCF I OOng/ml). Additional cytokines were added for differentiation studies. For 
certain experiments, non-adherent cells were cultured in parallel in the same medium. 
The cells were incubated at 37'C and 5%CO2. 
2.4 CELL MORPHOLOGY 
All cell cultures were examined on a daily basis to check for contamination, and to 
assess for any morphological changes. Cell morphology was recorded using a light 
microscope (Leitz, Germany) which was connected to a Nikon Coolpix 5400 digital 
camera (Nikon, Japan). 
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2.5 NESTED POLYMERASE CHAIN REACTION 
2.5.1 RNA Isolation 
Once cells reached optimal time points they were harvested (this included adherent 
populations that were scraped off Petri dishes) and stored at -80'C until RNA was 
isolated using the RNeasy Mini kit according to the manufacturer's instructions 
(QlAGEN, UK). In order to avoid contamination with genomic DNA, RNA was 
treated with DNAse I during isolation. In brief, cells were disrupted with 600ýtl of 
RLT buffer. 600ýtl of 70% ethanol was added to the resultant cell lysate, which was 
subsequently transferred to a RNeasy mini column. The column was centrifuged for 
15 s at 13000 rpm several times with the different buffers supplied by manufacturer. 
The elution stage was carried out with RNAase-free DEPC-treated H20. The 
supernatant was discarded and the RNA pellet air-dried and dissolved in 50ýtl of 
RNAase-free DEPC-treated H20. RNA absorbance was read with the NanoDropg 
ND-1000 UV-Vis Spectrophotometer provided by the MRC Microarray Centre and 
stored at -801C. 
2.5.2 Reverse Transcriptase (RT)-PCR 
The One-Step RT-PCRTm kit (QIAGEN, UK) was used, following the manufacturer's 
instructions. RT-PCR amplification was performed in a typical RT-PCR amplification 
mix consisting of the following: 
I ýtl of DNA free RNA 
2ýtl of OneStep RT-PCR enzyme mix 
3.75gl of Q solution 
7.5gl of 5x PCR buffer 
1.5ýtl of 25mM dNTP mix 
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16.25ýd RNase free dH20 
I ýd of 20pmol forward primer 
I ýtl of 20pmol backward primer 
Materials and Methods 
Typically, 35 cycles of RT-PCR were carried out, each cycle including I hour at 50'C, 
I min at 94'C, I min at 56'C, and I min at 72'C followed by I cycle of 10min at 72'C. 
The RT-PCR products were then used for nested PCR. For culture medium controls, 
a-MEM culture medium supplemented with 30% FBS was used. No template RNA 
was added to the negative control tubes. PCR products were confirmed by 
sequencing at the MRC sequencing laboratory at Hammersmith Hospital. 
2.5.3 Nested PCR 
Amplification with nested primers was performed in a typical PCR amplification mix 
consisting of the following: 
I ýtl of DNA free RNA 
0.5gl of Taq DNA polymerase 
5 ýtl of 10 x PCR buffer 
0.5 [d of I OOmM dNTP mix 
12ýtl of 50mMMgCI2 
31.5gl RNase free dH20 
I ýtl of 20pmol forward primer 
I [tl of 20pmol backward primer 
Typically, 35 cycles of PCR were carried out. Each cycle comprised Imin at 94'C, 
Imin at 56'C, and Imin at 72'C followed by I cycle of 10min at 72'C. The final 
products were mixed with loading buffer and size fractionated by gel electrophoresis. 
Primer sequences for both RT-PCR and nested-PCR may be found in appendix 1. 
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2.5.4 Gel electrophoresis 
Agarose gels (3%) were prepared by mixing 9g of agarose powder with 300ml of Ix 
TAE. The agarose was dissolved at boiling point in a microwave oven. After cooling 
to 55'C, 4ýtl of 10mg/ml ethidium bromide was added per 100ml and mixed 
thoroughly. Gels of 300ml were poured into a sealed gel former with an appropriate 
comb. Once mixed with an appropriate volume of loading buffer, samples to be 
electrophoresed were loaded along with the appropriate size marker I 00bp DNA 
ladder. The electrophoresis ran at 180V for approximately lhr from the cathode 
(negative) to the anode (positive). DNA fragments were visualised under long wave 
ultraviolet (UV) light on a trans iI luminator and photographs were captured using an 
UV camera connected to the computer. 
2.6 IMMUNOFLUORESCENCE 
On days 5,7,15 or 21 after initial isolation of the subpopulation of CD34+ cells, non- 
adherent cells were aspirated from culture dishes and adhered on to slides for I hour 
at room temperature or cytospun. at 35rpm for 8 minutes using a Cytospin machine 
(Shandon, UK) and air dried. They were then fixed by pipetting I 00[tL of ice-cold 
methanol on to each slide. Adherent cells were left in situ in the culture dishes either 
to continue in cell culture, or to be fixed using 500ýtL of ice-cold methanol per dish. 
Fixed cells were washed twice with PBS at 5 min per wash, at room temperature. 
Blocking solution was made using 10% normal rabbit serum and 1% bovine serum 
albumin (BSA) (PAA Laboratories GrnbH, Linz, Austria) in PBS. Cells were 
incubated for 30 min in this blocking solution, at room temperature, in order to 
prevent artefacts from non-specific binding of antibodies. The cells were then washed 
once in PBS and incubated for lh in an appropriate dilution of the chosen primary 
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antibody against human antigen in blocking solution (see Table 1), at room 
temperature. To control for non-specific secondary antibody binding some slides were 
stained with appropriate isotype (IgG) control or with secondary antibody only. 
The cells were washed 3 times with blocking solution, for 5 min per wash. Cells 
which were being stained for vWF and VEGFR2 were next incubated for I hour at 
room temperature in the dark with secondary antibodies. These secondary antibodies 
were rabbit anti-mouse immunoglobulins conjugated with fluorescein isothiocyanate 
(FITC) (DakoCytomation, UK), diluted 1: 200 in blocking solution. Afterwards, the 
cells were washed twice in blocking solution, and once in PBS, for 5 min per wash. 
Vectashield Hard-SetTM mounting medium with DAPI (Vector Laboratories, 
Burlingame, US) was used to mount the slides or dishes. The cells were then 
examined and photographed under a fluorescent microscope (Olympus, UK), and 
cells were counted in at least three random fields of view to assess the approximate 
percentage of cells with positive expression of the marker of interest. 
2.7 FLOW CYTOMETRY 
To analyze the expression of cell surface markers, 2xI 05 cells cultured in different 
conditions in a-minimal essential medium (a-MEM) supplemented with 15% fetal 
bovine serum (FBS). After different time-points the cells were harvested and stained 
with the appropriate antibodies (details and dilutions at table 2.7.1) for 30 minutes at 
40C. An aliquot of each sample was reacted the same way with directly conjugated 
isotype-matched control. Samples were washed in calcium/magnesium-free PBS 
(GibcoBRL) and re-suspended in PBS for final analysis. Analysis was performed 
immediately after the staining procedure. 
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Cells stained for intracellular proteins (for example vWF) were fixed by adding 
100ýtL (per FACS tube) of Reagent A (Fixation Medium) from the Fix and Perm'D cell 
permeabilization kit (Caltag Laboratories, Austria), and were incubated thus for 15 
min at room temperature. The appropriate amount of primary antibody (see Table 
2.7.1) was added to 100ýiL of Reagent B (Permeabilization Medium). A negative 
control was run concurrently, using normal mouse IgGI as a primary antibody, 
together with 100ýtL of Reagent B. All cells were incubated with primary antibody for 
20 min. Cells were then washed by adding 3mL PBS and centrifuging for 5 min at 
1800rpm, with subsequent removal of the supernatant. 
Analysis of the labeled cells was performed with a FACScalibur flow cytometer 
(Becton Dickinson, San Jose, CA, USA). At least 10,000 cells were collected for each 
test sample to ensure a sufficient number of positive stained cells. 
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Antibody Diluti Type Source 
on 
Normal 1: 100 Mouse Dako- 
immunoglobulin Cytomation, 
(IgG)l Denmark 
IgG-PE 1: 100 Mouse, SeroTec 
phycoerythrin 
(PE)-conjugated 
vWF 1: 50 Mouse, Abcarn 
monoclonal 
VEGFR2/KDR 1: 100 Mouse, Abcam 
monoclonal 
CD31/PECAM-1 1: 100 Mouse, Becton 
Dickinson 
PE-conjugated, 
monoclonal 
CD133 1: 11 Mouse, Becton 
Dickinson 
PE-conjugated, 
monoclonal 
CD102 /ICAM-2 1: 10 Mouse, SeroTec 
FITC-conjugated, 
monoclonal 
CXCR-4 1: 11 Mouse, Becton 
Dickinson 
PE-conjugated, 
monoclonal 
CD144/ 1: 10 Mouse, R&D Systems 
VE-Cadherin PE-conjugated, 
monoclonal 
Table 2.7.1 Primary antibody dilutions for immunofluorescence and flow cytometry. 
-67- 
Chapter 2 
2.8 WESTERN BLOT 
2.8.1 Preparation of cell lysate 
Materials and Methods 
Primary cells were removed from the medium and washed twice in PBS, the 
supernatant was removed and the pellet was resuspended in residual PBS. Cell were 
lysed in 200ýtl lysis buffer [50 mM Tris-HCI pH 7.5,1 mM EDTA, I mM EGTA, 1% 
(v/v) Triton X-100,10 mM b-glycerophosphate, 50 mM NaF, I mM sodium 
orthovanadate, 5 mM sodium pyrophosphate, 100 nM okadaic acid, 0.27 M sucrose, I 
mM DTT, Ix PIC (protease inhibitor cocktail of 1001U/ml aprotinin, 3mM 
phenylmethanesulfonylfluoride, 5mM benzamidine) (all Sigma, Poole, UK)] per 107 
cells on ice. After a 10 minute incubation on ice the cells are lysed using a needle and 
syringe and added to an equal volume of loading buffer (2.3% sodium dodecyl 
sulphate (SDS), I OmM DL-dithiothreitol (DTT), 0.01% bromophenol blue (all Sigma, 
Paisley, UK), 10% glycerol and 62.5mM Tris g pH6.8) and boiled for 5 minutes at 
100'C for quantification of lysate proteins by western blotting. Lysates were stored at 
-80'C for western blot analysis. 
2.8.2 Western Blot 
Samples and coloured molecular weight markers (BioRad, Hemel Hempstead, UK) 
were run in parallel on SDS-PAGE minigels, prepared as shown in table 2.8.1, at 100 
volts. Moreover,, cell lysates that were known to express the protein of interest were 
used as positive controls (shown in the table 2.8.2). Then they are transferred to 
0.45[tm polyvinyl idenedifluoride membranes (ImmobilonTM, Sigma, Poole, UK) 
using a semi-dry transfer system (Biorad, Hemel Hempstead, UK) for 50 minutes at 
18 volts. Membranes were blocked for I hour at room temperature in 1% milk 
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(Marvel, Dublin, Eire) made up with TBS containing 0.05% Tween (BioRad). Stained 
with anti- GATA4, MEF-2C, Nkx-2.5 (Santa Cruz), Nkx-2.5 (R&D Systems), Oct-4 
and Nanog (abcam) in 1% milk/TBS-Tween and incubated overnight at 4'C. The 
dilutions and the details of the antibodies are shown at the table 2.8.2. After four 
washes in TBS-Tween, relevant HRP-conjugated secondary antibodies were diluted 
1/1000 in milk/TBS-Tween and incubated for 30 minutes at room temperature. 
Membranes were washed four times in TBS-Tween and visualised by ECL 
chemiluminescence (Amersham Biosciences, Little Chalfont, Bucks, UK) on Kodak 
Biomax MR film (Sigma, Poole, UK). 
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Resolving 6.5% 8% 10% 12% 15% Stacking 
(RG) (SG) (Tris 
1M) 
pH 6.8 
37.5: 1 2.2ml 2.6ml 3.3ml 4ml 5ml 830gl 
Acrylamide/ 
Bis 
(30%) 
Water 6.1ml 5.7ml 5ml 4.3ml 3.3ml 3.4ml 
Tris (1.5M) 2.5ml 2.5ml 2.5ml 2.5ml 2.5ml 630[d 
pH 8.8 (pH 6.8) 
SDS 10% 100ý11 100[d 10091 1 00ýd 100gl 50ýd 
(Reducing 
agent) 
Ammonium I OOgI 100ýd IOORI 100[11 100gl 50[d 
Persulfate 
(APS) 
Temed 6[d 6gl 6ýd 6ýd 6gl 51il 
Total I OMI I OMI 10[d 10ý11 I Oýd 5ml 
Volume 
Table 2.8.1 Composition of polyacrylamide gels. 
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Primary antibodies 
Antibody Positive control Type Dilut Source 
ion 
GATA-4 (G- SW480 (Human mouse 1: 100 Santa Cruz 
4) colorectal monoclon Biotechnology 
adenocarcinoma) al 
lysate 
MEF-2C SK-N-SH (Human goat 1: 400 Santa Cruz 
(E-17) neuroblastoma) lysate polyclonal Biotechnology 
Nkx-2.5 Human Heart Tissue rabbit 1: 500- Santa Cruz 
(H-114) lysate polyclonal 1: 100 
Biotechnology 
Nkx-2.5 Human Heart Tissue goat 1: 100 R&D Systems 
lysate polyclonal 0- 
1: 200 
Oct4 MEL- I (Human rabbit 1: 100 abcarn 
embryonic stem cell) polyclonal 
0- 
lysate 1: 500 
Nanog MEL- I (Human rabbit 1: 200 abcarn 
embryonic stem cell) polyclonal 0- 
lysate 1: 300 
Secondary HRP antibodies 
HRP rabbit anti-goat polyclona 
I 
1: 1000 Dako Cytornation 
HR. P rabbit anti- polyclona 1: 1000 Dako Cytornation 
mouse 
HRP swine anti-rabbit polyclona 
I 
1: 1000 Dako Cytornation 
Table 2.8.2 Antibodies used for Western Blotting. In the table are shown the details of each 
antibody and the dilutions that were used as well as the positive control that was used for each 
antibody (second column). 
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2.9 cDNA MICROARRAYS 
For the synthesis of double-stranded cDNA from 15 [ig total RNA the cDNA 
synthesis system kit (Roche) has been used. Biotinylated cRNA was synthesized with 
Perkin-Elmer's nucleotide analogs using the Ambion's MEGAScript T7 kit. After 
fragmenting of the cRNA for target preparation using the standard Affymetrix 
protocol 15 ýtg fragmented cRNA was hybridized for 16 h at 45 OC. Following 
hybridization arrays were washed and stained with streptavidin-phycoerythrin in the 
Affymetrix Fluidics Station 400 and further scanned using the Hewlett-Packard 
GeneArray Scanner G2500A. The image data were analyzed with GCOS 1.4 using 
Affymetrix default analysis settings and global scaling as normalization method. (Dr 
Herbert Schulz,, Berlin) 
Each time three independent RNA preparations from two different adherent CD34+ 
cell population points were processed and hybridized on the Human Genome 133 
Version 2 Array (Affymetrix) which includes 54675 probe sets. After RMA 
normalization descriptive statistics and a parametric pair-wise comparisons using the 
Student t-test (unpaired, assuming unequal variances) have been performed (195). The 
false discovery rate of the test-set has been calculated using the Benjamini Hochberg 
procedure (196). 
2.10 ANIMALS 
All animal studies were carried out in accordance with the Animals (Scientific 
Procedures) Act 1986 (A(SP)A 86) and local institutional guidelines. All rats were 
purchased from the same supplier (Harlan, UK; n=50), fed a standard diet with free 
access to water and housed under the same conditions. During the surgical procedure, 
male Sprague-Dawley rats (250-300g at time of procedure) were anaesthetized with 
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1.5-2% isoflurane oxygen mixture, intubated and ventilated using a small animal 
ventilation apparatus (VetTech Solutions Ltd, UK). Subcutaneous buprenorphine (0.1 
mg/kg) was given as analgesia, with intra-peritoneal saline injection and post-op 
warming to aid recovery. 
2.10.1 Operative procedures 
Following left thoracotomy, myocardial infarction was achieved by ligation of the left 
coronary artery using a 4-0 silk suture (Ethicon, UK) tied around the left anterior 
descending coronary artery approximately 1-2 mm from its origin. The ischemic area 
was identified visually as a result of "blanching" of the tissue upon ligation. In cases 
where the latter was not observed, a second ligature was applied. The muscle layer 
and skin incision were closed with 3/0 silk sutures. 
IR, ethoracotomy for stem cell implantation was carried out in a similar fashion as 
further described in section 6.2. 
2.10.2 Immune suppression 
Control and stem cell transplanted animals were given Cyclosporin A (CsA) 
(Sandimmum) via the intraperitoneal route at an approximate dose of 10 mg/ k9-l/d-1. 
2.11 CARDIOVASCULAR 
IMAGING 
MAGNETIC RESONANCE (CMR) 
Post implantation stem cell localisation and heart function were assessed in 
anaesthetised rats using high-resolution MR images acquired on a 9AT horizontal- 
bore animal scanner (Varian, Palo Alto, CA, USA) using a surface coil (diameter 38 
mm). A stack of contiguous I mm short-axis ECG-gated gradient echo cine-MR 
images were acquired to cover the entire left ventricle using the following parameters: 
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TR=10ms, TE=1.8ms, FOV=4Ox4Omm, matrix 128xl28, flip angle 20', slice 
thickness I mm, 16 averages, 20-25 cardiac phases. 
2.11.1 Cell Labelling 
Cells were labelled with Tat pepticle derivatized ultrasmall superparamagnetic iron 
oxide (USPIO) nanoparticles coated with dextran (IODEX-TAT-FITC; 15-20 nm) 
(kindly provided by Dr K Bhakoo) by incubation for 15 hours with 50gg/I 06 cells of 
the iron oxide nanoparticles per mL of culture medium. The cells were then 
resuspended in PBS IX for implantation. 
2.12 TRANSTHORACIC ECHOCARDIOGRAPHY 
All scans were performed with a commercially available Sequoia C256 
echocardiography system (Siemens, Mountain View, CA, USA) equipped with 7.5 
MHz phased-array transducer. 
2.13 HISTOLOGY AND IMMUNOHISTOCHEMISTRY 
Under terminal anaesthesia hearts were rapidly excised and cardiac chambers were 
thoroughly rinsed with PBS to remove any residual blood and thrombus. Tissue was 
then fixed in 10% formalin for 24 hours and immediately afterwards embedded in 
paraffin. 
2.13.1 Tissue sectioning 
Tissue sections (4 ýtm) were cut using a rotary microtome (AS 325, SHANDON, UK). 
Sections immediately after cutting were floated on 20% alcohol and then on distilled 
H20 at 37'C for 5 min. Sections were then picked up with a charged slide and dried at 
39'C overnight. The blade was wiped with 70% ethanol to avoid cross-contamination. 
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2.13.2 Haernatoxylin and Eosin Staining (H&E) 
H&E staining was used for routine morphological assessment of fixed tissues due to 
its ability to demonstrate clearly a large number of different tissue structures. Briefly, 
4 pm sections were taken though 3 changes of xylene, hydrated through 2 changes of 
absolute alcohol and I change of 70% alcohol and brought to running tap water for I 
min. Slides were stained with Harris' Haematoxylin for 30 sec, and washed in 
running tap water for 3 min. Slides were differentiated in 1% acid alcohol (1% HCL 
in 70% alcohol) for 5 sec and again washed in running tap water for 3 min. 
Sections were stained with 1% eosin for I min and washed in running tap water for 3 
min. Finally, sections were dehydrated though graded alcohols, cleared in xylene and 
mounted with DPX mounting media. 
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2.13.3 Standard avidin-biotin complex (ABC) immunostaining 
method 
The following figure demonstrates the ABC immunostaining method. 
0 ABC 
40 peroxidase 
Biotinylated Avidin 
peroxidase Streptavidin 
Antigen in tissue 
Figure 2.13.1 The ABC immunostaining method. (Figure kindly provided by Dr D Lykidis) 
In all experiments, slides were dewaxed in 3 changes of xylene, rehydrated through 
graded alcohols and brought to tap water. Slides were immersed for 15 min in 0.6% 
H202 in distilled water washed for 5 min in PBS and then transferred to Sequenza 
racks (Thermo Shandon). Appropriate normal serum (from the species providing the 
second antibody) diluted 1: 20 in volume was applied for 10 min followed by a wash 
in PBS/Tween for 5min. 100 ýtl of the primary antibody in PBS diluent was applied at 
4'C overnight. Sections were washed in PBS/Tween for 5 min and incubated for Ih 
with appropriately diluted biotinylated secondary antibody. A negative control was 
included for every experiment where, instead of the primary antibody, PBS diluent 
was added to the slides. Sections were rinsed in PBS/Tween for 5 min and incubated 
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for 30 min with peroxidase-labelled ABC reagent. Slides were rinsed in PBS/Tween 
for 5min. Diaminobenzidine/H202 (DAB) was prepared, slides were developed for 10 
min and then checked under a microscope. Slides were washed with PBS and then 
brought to tap water. Sections were counterstained with haernatoxylin for I Osec, 
dehydrated in graded alcohols, cleared with xylene and mounted in DPX (permanent 
mountant) medium. 
Antibody Source Manufacturer Dilution 
Factor 
Primary 
Antibodies 
Anti-VEGF Mouse/Monoclonal DakoCytomation 1: 200 
Anti-CD31 Mouse/Monoclonal Abcam 1: 100 
Secondary 
Antibodies 
FITC-labelled 
Donkey polyclonal Novocastra 1: 200 Donkey anti- 
mouse Ig 
Table 2.13.1 Sources and dilutions of antibodies for IHC. 
2.13.4 TUNEL staining 
The DeadEnd. Colorimetric TUNEL System (Promega) end-labels the fragmented 
DNA of apoptotic cells using a modified TUNEL assay. Biotinylated nucleotide 
is 
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incorporated at the Y-OH DNA ends using the Terminal Deoxynucleotidyl 
Transferase, Recombinant, (rTdT) enzyme. Horseradish peroxidase-labeled 
streptavidin (Streptavidin HRP) is then bound to these biotinylated nucleotides, which 
are detected using the peroxidase substrate, hydrogen peroxide, and the stable 
chromogen, diaminobenzidine (DAB). Using this procedure, apoptotic nuclei are 
stained dark brown. 
Briefly, the procedure for analysis of apoptosis in tissue sections followed according 
to the manufacturer was: 
1. Paraffin-embedded tissue sections were deparaffinized (attached to microscope 
slides) by immersing the slides in fresh xylene in a Coplin jar for 5 minutes at room 
temperature twice. 
2. Slides were washed by immersion in 100% ethanol for 5 minutes at room 
temperature in a Coplin jar. 
3. The 100% ethanol wash was repeated for 3 minutes. Samples were then rehydrated 
by sequentially immersing the slides through graded ethanol washes (95%, 85%, 70% 
and 50%) for 3 minutes each at room temperature. 
4. Slides were washed by immersion in 0.85% NaCl for 5 minutes at room 
temperature. 
5. Slides were further washed by immersion in PBS for 5 minutes at room 
temperature. 
6. Tissue sections were fixed by immersing the slides in 4% paraformaldehyde 
solution at room temperature. 
7. Slides were immersed in PBS for 5 minutes at room temperature twice. 
8. Any liquid was removed from the tissue and slides were placed on a flat surface. 
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100ýil of the 20ýLg/rnl Proteinase K solution was added to each slide to cover the 
tissue section and slides were incubated for 20 minutes at room temperature. 
9. Slides were washed by immersion the in PBS for 5 minutes at room temperature in 
a Coplin jar. 
10. Tissue sections were refixed the after washing by immersing the slides in 4% 
paraformaldehyde solution for 5 minutes at room temperature. 
11. Slides were washed by immersion in PBS for 5 minutes at room temperature twice. 
12. Excess liquid was removed by tapping the slides. Cells were covered with 100[il 
of Equilibration Buffer and allowed to equilibrate at room temperature for 10 minutes. 
14. Tissue paper was used to blot around the equilibrated areas with and IOORI of 
rTdT reaction mix was added to the sections on a slide, which were allowed to dry. 
15. Sections were covered with Plastic coverslips to ensure even distribution of the 
reagent. Slides were incubated at 370C for 60 minutes inside a humidified chamber to 
allow the end-labeling reaction to occur. 
16. Plastic coverslips were removed and reactions were terminated by immersing the 
slides in 2X SSC in a Coplin jar for 15 minutes at room temperature. 
17. Slides were washed by immersion in fresh PBS for 5 minutes at room temperature 
twice to remove unincorporated biotinylated nucleotides. 
18. Endogenous peroxidises were blocked by immersing the slides in 0.3% hydrogen 
peroxide in PBS for 3.5 minutes at room temperature. 
19. Slides were washed by immersion in PBS for 5 minutes at room temperature twice. 
20. Add 100pl of Streptavidin FIRP solution 1: 500 in PBS was added to each slide 
and incubated for 30 minutes at room temperature. 
21. Slides were washed by immersion in PBS for 5 minutes at room temperature twice. 
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22.100ýtl of DAB solution was added to each slide and developed until there was a 
light brown background (approximately 10 minutes). 
23. Slides were rinsed several times in deionized water. 
24. Slides were mounted with a DPX (permanent mountant) medium. 
2.13.5 Masson's Trichrome 
By sequentially applying acid dyes in ascending order of size differential staining is 
achieved due to varying pore sizes in connective tissue components. Paraffin- 
embedded tissue sections were deparaffinized and then dehydrated by sequentially 
immersing the slides through graded ethanol washes. After an initial stain with 
Weigert's iron haematoxylin for 5 minutes slides were washed with H20 prior to 
differentiation with 1% acid alcohol. Following another wash with H20 slides were 
stained blue in Scott's and stained in 1% of phosphomolybdic acid solution for 15 
minutes. Sections were counterstained in 1% light green in 1% acetic acid, and then 
were mounted with a DPX (permanent mountant) medium. Nuclei appear blue-black, 
muscle red, and collagen green. 
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Chapter 3 
3 CHARACTERISATION OF PLASTIC ADHERENT 
CD34+ SUBPOPULATION 
3.1 INTRODUCTION 
Stem cells residing within haernopoietic tissue have been extensively used in 
experimental as well as clinical haernatological reconstitution for many years (197). 
Autologous haernopoietic stem cell transplantation (HSCT) following administration 
of high-dose therapy has become the commonest type of transplantation therapy, and 
is used with curative intent for an array of diseases including acute myeloid leukemia, 
non-Hodgkin lymphorna, Hodgkin disease, and multiple myeloma (198). Recent data 
are actually indicative of a rising trend in relation to ones lifetime probability of 
undergoing autologous or allogeneic HSCT (199). 
HSCs, as already discussed in 1.4.2, may give rise to all blood cell lineages and are in 
their vast majority CD34+ and CD133+. It is this latter attribute that makes HSCs 
attractive to clinical work as it permits prospective isolation in known numbers. One 
of our early hypotheses was that a CD34' subpopulation was responsible for the inert 
regenerative potential of HSCs (21). It was further demonstrated that the candidate 
subpopulation could be separated from the CD34+ pool due to their capacity to adhere 
to culture dish plastic. 
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3.2 DISTINCTIVE FEATURES BETWEEN ADHERENT CD34' 
CELLS AND NON ADHERENT CD34+ CELLS 
The selection protocol for plastic adherent CD34+ resembles to a certain extent the 
procedure used for MSC isolation from mononuclear fractions. In contrast to MSC 
proliferation kinetics where mesenchyrnal cells rapidly outgrow every other cell type, 
plastic adherence is the second step in our positive selection process. Purified CD34+ 
cells that have been preselected and depleted of MSCs are the starting population 
ensuring their homogeneity with regard to CD34 expression and plastic adherence of 
the selected cells. 
0 
0 
AdhswtCO34*csb Hoo -A-dftý ,... wOa>wcsos 
Figure 3.2.1 Morphology of freshly isolated adherent and nonadherent CD34+ cells. (Figure 
kindly provided by Professor M Gordon) 
Adherent CD34+ cells were found to be morphologically small and lymphocyte-like 
with a high nuclear/cytoplasmic ratio; on the other hand non adherent CD34 
+ ce s 
exhibit a larger blast cell-like morphology (Fig 3.2.1). From a phenotypic point of 
view, adherent CD34+ cells were 99% pure and expressed uniformly low levels of 
CD38, CD33, and HLA-DR (21). The expression of these antigens is markedly more 
variable in the respective non adherent cell samples. 
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3.3 NESTED POLYMERASE CHAIN REACTION FOR STEM 
CELL MARKER GENES 
Samples were assessed for the expression of typical stem cell marker genes including 
CD34, a monomeric cell surface antigen that is selectively expressed on haernopoietic 
progenitor cells (70); oct-4, a mammalian transcription factor expressed by early 
embryo cells and germ cells which is necessary for the pluripotency of stem cells 
(200); nanog, a homeobox transcription factor, that plays a crucial role in the 
secondary embryonic cell fate specification following formation of the blastocyst 
(201); and Rex-I which encodes an acidic zinc finger protein and is expressed at high 
levels in ESC and teratocarcinorna cells (202). CD133 antigen is selectively expressed 
on a sub-population of CD34+ haernopoietic stem and progenitor cells derived from 
human foetal liver and bone marrow, and blood (203). Freshly isolated adherent 
CD34+ cells, as well as cells cultured for 7 days expressed all aforementioned stem 
cell marker genes (Fig 3.3.1). 
Haematopoietic progenitor cell antigen 
precursor (CD34) - 402 bp 
Octomer binding transcription factor 4 
(Oct4) -184bp 
Zinc finger protein 42 (Rex-1) - 540 bp 
Glyceraldehyde 3-phosphate 
dehydrogenase (GAPDH) - 300 bp 
Figure 3.3.1 Fig LExpression of stem cell marker genes by nested RT-PCR for adherent CD34+ 
cells. 
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3.4 NESTED POLYMERASE CHAIN REACTION FOR 
CARDIAC MARKER GENES 
We evaluated the expression of the Nkx2.5, GATA-4, MEF2C, phospholamban 
(PLN), cardiac troponin 1, and other end-differentiated cardiac protein gene transcripts 
(Appendix 1) in adherent and non adherent CD34+ cells. Freshly isolated adherent 
CD34+ cells,, as well as cells cultured for 7 days (Fig 3.4.1) expressed Nkx2.5, 
GATA-4, MEF2C, MEF2D, and PLN gene transcripts. Cardiac troponin I and other 
end-differentiated cardiac protein gene transcripts represent products of terminal 
cardiac muscle differentiation, however, adherent CD34+ cells did not express either. 
No visible band was produced by the negative controls. 
DAY I CELLS (. )CONTROLS CONTROLS MUNUM DAY 7 CELLS P)CONIMA "CwrmmA 
CONTROL ccpnm 
GI%TA, 4 401bo 
Nba & "no 
um2c 
CD&M imp 
MkL-l Wo 
vow 12 Ipbo 
WPPA 45W com M-P 
PLN nabo 
GAPOH 500bp 
L 
Gam mo 
Figure 3.4.1 Expression of cardiac and endothelial marker genes by nested RT-PCR for adherent 
CD34+ cells. Positive expression was documented for primitive endothelial markers such as TAL- 
I and CD133. Cells were also positive for mature endothelial markers including PECAM, VEGF- 
R2, ICAM-2, CDH5 and von Willebrand factor amongst others. 
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3.5 NESTED POLYMERASE CHAIN REACTION FOR 
ENDOTHELIAL MARKER GENES 
We evaluated the expression of an array of gene transcripts including early as well as 
late markers of endothelial differentiation. Early markers incorporated T-cell acute 
lymphocytic leukernia-I (TAL-1) and CD133 (also found in the literature as AC133). 
Late markers were von Willebrand factor (vWF), platelet/endothelial cell adhesion 
molecule-I (PECAM-1, also known as CD31), intercellular adhesion molecule-2 
(ICAM-2), vascular endothelial growth factor (VEGF), vascular endothelial growth 
factor receptor-2 (VEGFR-2, also known as KDR), the endothelial receptor tyrosine 
kinase Tie-2, and the angiopoietins land 2. Freshly isolated adherent CD34+ cells, as 
well as cells cultured for 7 days (Fig 3.4.1) expressed all aforementioned marker 
genes. No visible band was produced by the negative controls. 
3.6 NESTED POLYMERASE CHAIN REACTION FOR THE 
CD34' NONADHERENT FRACTION 
The non adherent CD34+ fraction was also evaluated with nested RT-PCR for 
expression of stem cell, cardiac and endothelial markers following the same protocols 
as above. Interestingly collected data confirm the distinct nature of these two 
subpopulations expressing the CD34 surface marker. No cardiac cell markers were 
found on freshly isolated nonadherent CD34+ cells, as well as cells cultured for 7 days. 
Sporadic expression of vWF, ANGPT I and 2, and PECAM-1 on days 0 and 7 
represent genes required by cells of haernopoietic origin as well as endothelial cells. 
Interestingly, stem cell marker genes were expressed at both time points consistently 
(Fig 3.6-1). 
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Culture 
+ ve - ve medium 
Day 0 Day 7 control control control 
Von Willebrand Factor 
(VWF) 470 bp 
Actinin 
(Alpha2) 275 bp 
Angiopoietin 1 
(ANGPT 1) 540 bp 
Anglopoletin 2 
(ANGPT 2) 677 bp 
Platelet adhesion molecule 
(PECAM) 204 bp 
Kinase insert domain receptor 
(KDR) 167 bp 
Nebulin 
(NEB) 254 bp 
Vascular endothelial factor 
(VEGF) 273 bp 
TEK receptor tyrosine kinase 
(TIE-2) 450 bp 
T-Cell ALL 
(TAL-1) 185 bp 
Intercellular adhesion mol. 2 
(ICAM2) 326 bp 
Chemokine motif receptor 4 
(CXCR4) 386 bp 
Figure 3.6.1 Expression of endothelial marker genes by nested RT-PCR for nonadherent CD34+ 
cells. 
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3.7 WESTERN BLOT ANALYSIS OF EARLY CARDIAC 
TRANSCRIPTION FACTORS 
The expression of transcription factors identified by nested PCR was assessed by 
Western Blot in cultured cells after 7 days culture. These included GATA-4 and 
MEF-2C as demonstrated in fig 3.7.1. positive control were positive lysates 
recommended by individual antibody suppliers. We were unable to produce a similar 
result for Nkx2.5 despite using multiple different commercially available antibodies. 
234c 
a flow MUM 
it 
am gmwo 
GATA-4 MEF-2C 
Figure 3.7.1 Western blot analysis of the transcription factors GATA-4 and MEF-2C in day 7 
cells. Each column numbered 1-4 represents a different patient. End columns (C) represent 
positive control lysates. 
3.8 FACS FOR ENDOTHELIAL MARKERS 
FACS analysis for endothelial cell surface receptors was carried out on day 10 
cultured cells. We were not able to perform this assay on day 0 cells as insufficient 
numbers of cells were available to us at that particular time point. Expression 
confirmed our nested-PCR findings at the protein level and cells stained highly 
positive for the majority of markers as seen in fig 3.8.1. 
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Figure 3.8.1 Flow cytometry analysis of cultured cells on day 10 after plating. 
Cell culture 
medium was supplemented with VEGF and 
P FGF. These data showed the expression of CD133, 
CD34, PECAM, ICAM-2, vWF and KDR. 
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3.9 CXCR4 EXPRESSION- CHEMOTAXIS ASSAY 
Stem cell homing to injury, as already discussed in subchapter 1.5, involves several 
chernotactic pathways, with the CXCR4/SDF- I axis being held to be one of the main 
mechanisms in current literature (204). We assessed CXCR4 expression in day 0 and 
day 7 cells at both the gene and protein levels as may be seen in figure 3.9.1. Further 
to the characterization of expression levels we assessed the functionality of CXCR4 in 
our cell population by performing chemokinesis assays with SDF-I. 
DAY 0 DA Y7 (+VE) (- VE) MEDIUM 
CONTROL CONTROL C()NTROL 
iom 
Soo 
sm 
4UD 
200 
Figure 3.9.1 Expression of CXCR4 after 7 days of culture (top). Flow cytometry analysis (bottom 
left) along with immunocytochemical analysis (bottom right). 
Chemokinesis medium at a volume of 0.5 ml containing SDF-l at concentrations of 
50ng/ml or I OOng/ml, or control medium was added to the lower chamber of a6 ýtm- 
pore polycarbonate transwell (Coming, Amboise, France); 5x] 05 cells from 7 day-old 
cultures were suspended in 0.2ml of control medium, added to the upper chamber and 
allowed to migrate at 37'C. Migrating cells were harvested from the lower chamber 
and were counted at two different time points, at 8 and 24 hours post seeding 
respectively. There was a significant effect of migration towards the SDF-I gradient 
compared to the control dishes as initially hypothesized. This effect was 
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concentration-dependant as may be seen in figure 3.9.1 regarding the earlier time 
point of 8 hours. Similar equilibriums were achieved at 24 hours irrespective of SDF- 
I concentration. 
6. OOE+05 
5. OOE+05 
c 
4. OOE+05 
3. OOE+05 
2. OOE+05 
1. OOE+05 
O. OOE+00 
8hrs 24hrs 
Control medium 
* SIDIF 50ng/ml 
* S-DF 100 ng/mI 
Figure 3.9.2 Kinetics of adherent CD34+ cell migration. Cell migration was monitored during 24 
hours at 8 and 24 hours after setting initial positive gradients with SDF-I 50ng/mL and 
IOOng/mL. Cell numbers in the lower chambers were counted and the average and range is 
shown. 
3.10 EXPANSION STUDIES FOR ADHERENT CD34' STEM 
CELLS 
3.10.1 Standard growth curve 
Adherent CD34 cells were plated under described conditions and cell counts for both 
adherent and floating fractions were obtained on days 7,11, and 14. As approximately 
1% of CD34 cells are adherent, starting numbers for day 0 were considered 5xl 03 for 
every culture dish. As seen from figure 3.10.1 a 2.5log increase was achieved by day 
10. At this point cultures cells entered the plateau of the growth curve with cell 
numbers remaining constant to day 14. 
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cell growth-GMMIX 
1 OOE+07 
total cells 
floating cells 
adherent cells 
1. OOE+06 
0 
1. OOE+05 
1. OOE+04 
1. OOE+03 I 
0 10 
days 
15 
Figure 3.10.1 Cell growth curve for adherent CD34+ cells in culture supplemented with GMMIX. 
3.10.2 Effect of 5-aza on growth curve 
As 5-aza was planned to be used in the differentiation experiments the impact on 
treatment on the cells' growth was assessed as induction of replicative senescence has 
been reported (205). At a concentration of 5ýLmol/L 5-aza did not exert a limiting 
effect on cell growth, opposed to 10ýtmol/L as seen in fugure 3.10.2. 
1. OOE+07 I 
1. OOE+06 
1. OOE+05 
Q) 
U 
1. OOE+04 
1. OOE+03 
07 14 
days 
Figure 3.10.2 Effect of various concentrations of 5-aza on cell growth. 
GMMIX 
5-aza 5 pmol/ L 
5-aza 10 pmol/ L 
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3.11 DISCUSSION 
The existence of cardiac progenitor cell populations within the body is probably one 
of the most important 'discoveries' in the field of myocardial regeneration. Based on 
their anatomical location two distinct populations have been described. The first 
resides within the postnatal myocardium and can be identified by the expression of 
the transcription factor islet-I (85). Further to this a few groups have identified and 
described cells expressing early cardiac markers residing within adult human bone 
marrow (20). The fact that adherent CD34+ cells express stem cell, early cardiac and 
endothelial genes, amongst others (21), is probably proof of them belonging to a 
stem/progenitor cell population with the potential to generate cells belonging to a 
range of tissue types. 
During the development of the embryonic heart it has been shown that primitive cells 
take on myocardial cell phenotypes as a consequence of complex signaling that 
includes both stimulatory (BMP-2) as well as inhibitory (Wnt proteins) pathways 
(206). Acquisition of cardiomyocyte fate is heralded by the expression of a number of 
specific transcription factors, which include GATA-4, Nkx2.5, and MEF2C, in a 
consistent temporal and spatial sequence (78). It is well documented, for example, 
that GATA-4 is a well characterized cardiac muscle-restricted transcription factor 
whose properties suggest an important regulatory role in mammalian cardiogenesis 
(207). 
On the other hand extracardiac mesoderm that does not normally produce heart tissue, 
may do so if transplanted into a specific cardiac extracellular medium or treated with 
specific extracellular regulators (78). These facts signify even greater importance of a 
plethora of molecular pathways implicated in stem cell differentiation into functional 
myocardial cells once transplanted in vivo. Soluble chemokines, cell surface receptors, 
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extracellular matrix substrata as well as intercellular gap junctions, are all potential 
cofactors. 
Belema-Bedada et al have shown that even after inducing the expression of marker 
genes characteristic of cardiac and skeletal muscle, the bone marrow-derived stem 
cells they worked with did not acquire several features of functional cardiomyocytes 
(208). Although it is suggested that it may be the mere fact of these cells not being as 
44plastic" as their ancestors, it is also hypothesised that the explanation lies with the 
absence of activating molecules within the cells or the presence of inhibitory factors. 
From the endothelial perspective adherent CD34+ cells appear to encapsulate the 
features of an endothelial progenitor population. The expression of early 
endothelial/stern cell markers (TAL-1, CD133) in addition to mature surface receptors 
of terminal differentiation is evidence of the potential of adherent CD34+ cells to 
induce angiogenesis (209). 
Bone marrow mononuclear cells have already been demonstrated to induce functional 
angiogenesis in patients suffering from critical lower limb ischernia (210). As the role 
of EPCs in the formation of collateral circulation in myocardial ischaemia is 
recognised (211), adherent CD34+ cells may have a role in the clinical setting. 
Interestingly expression of the gap junction protein connexin 43 was also identified. 
Cxn43 is the major gap junction protein of in the heart, playing a crucial role in 
synchronized contraction and embryonic development. A latent network of Cxn43 
gap junctions exists in normal quiescent marrow that is amplified under the need for 
stem cell division (212). Furthermore functional Cxn43-type gap junctions have been 
shown to exist between stromal cells and immature HPCs (213). Approximately 80% 
of CD34+ progenitors appear to communicate with the haemopoietic stroma via gap 
junction proteins (214). Finally endothelium has been shown to play a pivotal role in 
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cardiac repair, promoting cardiac myocyte survival and spatial reorganization (215). 
This characteristic of adherent CD34+ cells may prove important in myocardial repair. 
A CXCR4+/CD34+/AC133+/CD45- subpopulation of bone marrow-derived 
mononuclear cells has been described by Kucia et al as a non haemopoietic 
population of cells that express markers for cardiac differentiation residing within the 
bone marrow in postnatal life (20). Following myocardial infarction these cells are 
mobilized into the peripheral blood and chemoattracted to the injured heart in an 
SDF- I -CXCR4-, HGF-c-Met-, and LIF-LIF-R-dependent manner. The high level of 
expression of CXCR4 observed in adherent CD34+ cells in combination with 
confirmed chemokinesis provide additional evidence for their potential for clinical use. 
It must also be added that adherent CD34+ cells have been shown to express the 
tyrosine kinase membrane receptor for hepatocyte growth factor c-Met (2 1). 
Translational research in terms of both experimental as well as clinical requirements 
necessitates sufficient starting cell numbers prior to delivery into subjects. Post 
transplantation stem cell survival is obviously dependent on the number of stem cells 
delivered. Furthermore a dose-dependent potential for vasculogenesis and 
cardiornyogenesis for human CD34+ cell transplantation has been documented (216). 
Described attempts at increasing cell numbers did not produce statistically significant 
higher cell yields so new approaches are under evaluation as discussed in chapter 8. 
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4 DIFFERENTIATION STUDIES 
4.1 INTRODUCTION 
4.1.1 Progenitor cell differentiation into endothelial cells 
Endothelial progenitor cells or angioblasts and HSCs are thought to share a common 
precursor, the haernangioblast (106). This progenitor cell is present in the embryo and 
is responsible for blood vessel formation (217). EPCs that circulate in the blood have 
been shown to be recruited in newly forming vessels and give rise to vascular 
endothelial cells in the process (218). In angiogenic defective, tumour resistant Id- 
mutant mice, transplantation of wild-type BM or vascular endothelial growth factor 
(VEGF)-mobilized stem cells was demonstrated to restore tumour angiogenesis and 
growth (219). Furthermore, BM-derived CD34+ HSCs circulating in the peripheral 
blood are also capable of producing endothelial cells (220,221). 
Cytokine-mediated differentiation of EPCs into mature endothelial cells in vitro has 
been documented with vascular endothelial growth factor (VEGF), basic fibroblast 
growth factor (PFGF), and insulin-like growth factor-I (IGF-1) (221). Examples of 
other cytokines used to promote endothelial differentiation include stem cell growth 
factor (SCGF) and fibroblast growth factor 2 (FGF-2) (108,222). 
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4.1.2 Progenitor cell differentiation into cardiac cells 
The majority of data accumulated to date regarding cardiomyogenic differentiation 
of stem cells originates from in vivo studies with plasticity of transplanted cells being 
attributed mainly to the mechanisms of milieu-dependent differentiation or cell to cell 
fusion. The development of in vitro protocols to direct stem cell differentiation 
towards the cardiomyocyte lineage does not only assist in deciphering molecular 
signal pathways of differentiation, but also augments in creation of safer and more 
efficient stem cell transplantation models. A plethora of molecular pathways is 
implicated in stem cell differentiation into functional myocardial cells once 
transplanted in vivo. Soluble chemokines, cell surface receptors, extracellular matrix 
substrata as well as intercellular gap junctions, are all potential cofactors. Cellular 
proliferation, differentiation and three-dimensional structural organisation outline the 
process of cardiogenesis in embryonic life. Within the core of this process is the 
activation of certain transcription factors (examples include FOG-2, members of the 
GATA family, Nkx2.5, etc) via morphogenetic proteins (e. g. members of the bone 
morphogenetic protein family). The range of molecules and pathways involved in 
cardiogenesis is actively widening to incorporate more transcriptional activators such 
as serum response factor (223) and morphogenesis- controlling pathways such as the 
wnt pathway (224,225). A plethora of growth factors has been shown to initiate this 
process via a variety of pathways (Table 4.1.1). 
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Growth factor Main Signalling pathway 
Transforming Growth Factor-P Superfamily 
(BNIP, TGF P, Activin) (226-229) 
Smad/p38/ TAK I /ERK /JNK/MAPK 
Fibroblast Growth Factor (230) 
Insulin-like growth factor-I (23 1) 
Platelet-derived growth factor (232,233) 
Leukaernia inhibitory factor/Cardiotrophin-1(234) 
PLCy/Ras/MAPK 
ERK/JAK-STAT/Pl3K 
JAK/Pl3K/ MAPK 
JAK-STAT/ NlAPK 
Erythropoietin(235) JAK-STAT/Akt 
Table 4.1.1 Principal growth factor-mediated signalling pathways. Akt indicates protein kinase B; 
ERK, Extracellular Signal-Regulated Kinase; JAK, Janus kinase; JNK, c-Jun N-terminal kinase; 
MAPK, Mitogen Activated Protein Kinase; PUK, Phosphatidyllnositol 3-Kinase; PLCY, 
PhosphoLipase C-y; STAT, Signal Transducer and Activator of Transcription; TAK1, Tyrosine 
Kinase 1. 
Besides cytokines, DNA demethylating agents have attracted the interest of many 
groups; as DNA methylation is associated with a repressed chromatin state and 
subsequent gene silencing (236), it is thought that hypornethylation may play a role in 
epigenetic reprogramming during somatic cell cloning and stem cell function (237). 
Early reports have shown a connection between DNA hypornethylation and in vitro 
myoblast differentiation (238). Compounds promoting DNA demethylation, such as 
5-azacytidine or 5-aza-2'deoxycytidine, have endorsed trans-differentiation of 
embryonic (239,240), cord blood (241), as well as marrow stromal cells into 
cardiornyocytes in vitro (111-113). Upregulation of expression of cardiornyocyte 
specific genes/proteins was noticed, along with 'beating' on the petri dishes in a few 
cases. More surprisingly cardiomyocyte-like cells have been reported to be obtained 
from adipose tissue-derived stem cells with such pre-treatment (242). 
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4.2 ENDOTHELIAL DIFFERENTIATION 
4.2.1 Experimental design 
The adherent subpopulation of CD34+ was isolated as described in section 2.3. 
Adherent CD34+ cells were cultured in a-MEM supplemented with 30% FBS (a-30) 
and GM-MIX cytokines (SCF 20ng/mL, GM-SCF Ing/mL, IL-3 5ng/mL, G-SCF 
100ng/mL). On day 4, cells used for endothelial experiments were scraped off their 
dishes and were entered into one of the three culture protocols below to investigate 
their differentiation potential: 
1. As a control, cells were plated on culture dishes and were cultured in a-30 plus 
GM-MIX. 
2. Cells were plated on culture dishes and were cultured in a-30, GM-MIX and a 
mixture of 50ng/mL VEGF (PeproTech, Rocky Hill, USA) and lOng/mL PFGF 
(PeproTech, Rocky Hill, USA). 
3. Cells were cultured as above, but on dishes pre-coated with fibronectin (Sigma, 
Poole, UK). 
4.2.2 Morphology of adherent CD34' subpopulation 
All culture conditions were monitored on a daily basis for morphological changes. At 
day 3 the cells had a round lymphocyte-like appearance (Fig 4.2.1 A), and by day 14 
cells in the groups treated with VEGF and PFGF had elongated to form spindle- 
shaped cells and had organised themselves into long tracks of cells arranged end-to- 
end (Fig 4.2.1 C and 4.2.1 D). Control cells at this time also showed a small number 
of spindle-shaped cells, without track formation (Fig. 4.2.1 B). By day 21, tracks of 
cells cultured in the presence of VEGF and PFGF appeared wider and more cellular 
(Fig 4.2.1 F and 4.2.1 G), while control cells had fon-ned remarkably straight tracks 
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one to two cells in width (Fig. 4.2.1 E). This result indicates that VEGF and PFGF, 
with or without fibronectin, enhanced the organisation and of track fon-nation in the 
cultures. 
Day 3 
Control 
Stimulated 
with 
VEGF+bFGF 
Stimulated 
with 
VEGF+bFGF 
on fibronetin 
Figure 4.2.1 Cell morphology photographs. All cells appear uniformly round in shape on day 3 
(A). Later, on d14, control cells that were grown in a-30 and GM-MIX mostly remained round in 
shape with only a minority becoming elongated and spindle shaped (B). In comparison, cells 
which had been stimulated with VEGF and PFGF formed long, straight tracks or networks of 
elongated cells, regardless of whether they were cultured in the absence (C) or presence (D) of 
ribronectin. Cells within these tracks appear to be in contact with each other in numerous places. 
By day 21, some formation of thin tracks had taken place amongst control cells (E), while tracks 
appeared more cellular amongst those cells which had been stimulated with VEGF and PFGF (F, 
G), the presence of fibronectin again making little difference in final morphology. 
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4.2.3 Immunofluorescence 
Differentiation studies 
To investigate whether the cultured subpopulation of CD34+ cells possessed an 
endothelial cell phenotype, and to assess the effects of supplementing the culture 
medium VEGF and PFGF with and without fibronectin, expression of vWF, VEGFR2 
and CD31 was determined using immunofluorescence for the cells adhered to the 
culture dishes (Figures 4.2.2-4.2.4). 
All cells were negative for vWF on day 5. Cells exposed to VEGF and PFGF with 
fibronectin had the highest expression of vWF both at day 15 and day 21, compared to 
VEGF and PFGF without fibronectin and control conditions. VEGFR2 expression on 
day 7 was minimal, and its prevalence was similar in all three culture conditions. 
Majority of cells expressed CD31 by day 17, both in the presence and absence of 
VEGF and PFGF stimulation. 
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with 
VEGF+bFGF 
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with 
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Figure 4.2.2 Immunofluorescence for vWF of adherent cells. After 5 days in culture, cells did not 
express detectable levels of vWF (A and B). After 15 days in culture, control cells (a-30 and GM- 
MIX) expressed low levels of vWF (C), while many cells stimulated with VEGF+bFGF were 
vWF-positive and were connected by strands of cytoplasm (D). Cells grown on fibronectin 
stimulated with VEGF+bFGF appeared to be even more positive for vWF and to form tracks of 
vWF-positive spindle-shaped cells (E), persisting to day 21 (H). By this time point, control cells (F) 
and VEGF+bFGF-stimulated cells (G) had both formed thin tracks of vWF-positive cells. vWF 
protein is stained with green (FITC) and nucleus with blue (DAPI). 
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Figure 4.2.3 Immunofluorescence for VEGFR2 of adherent cells. After 7 days in culture, cells 
expressed minimal to undetectable levels of VEGFR2 staining under all three conditions (A, B, 
and Q. At day 21, apparent track formation, primarily involving elongated spindle-shaped 
VEGFR2-positive cells, was seen in all three culture conditions (D, E and F). VEGFR2 protein is 
stained with green (FITC) and nucleus with blue (DAPI). 
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Day 14 
Figure 4.2.4 Immunofluorescence for CD31 of adherent cells. The majority of cells were CD31- 
positive on day 7 (A and B) and day 14 (C and D), both under control conditions and when cells 
were stimulated with VEGF and bFGF. Positively stained cells appeared to have a faint hue or 
halo of red colour. CD31 protein is stained with red (PE) and nucleus with blue (DAPI). 
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4.2.4 Flow cytometry 
Differentiation studies 
To substantiate immunofluorescence results, flow cytometry was performed on day 
14 of culture of the subpopulation of CD34+ cells, and included cells which were both 
adherent and non-adherent to the culture dishes at the time of sampling. The results of 
vWF, VEGFR2 and CD31 staining are shown in Figures 4.2.5-4.2.7. 
Virtually all cells expressed vWF regardless of whether they were grown under 
control conditions (Fig 4.2.5 B) or in the presence of VEGF and PFGF (Fig 4.2.5 Q 
(isotype negative controls are shown on the left side of each figure). Likewise, 
VEGFR2 was expressed by the majority of cells, both in the absence (Fig 4.2.6 B) and 
presence (Fig 4.2.6 Q of VEGF and PFGF. Percentage VEGFR2 expression (64 to 
71%) was slightly less than vWF expression. The extent of CD31 (PECAM) 
expression was virtually identical between cells exposed to control conditions (Fig 
4.2.7 A) and those stimulated with VEGF and PFGF (Fig 4.2.7 B). 
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Control cells WVF 
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Figure 4.2.5 vWF expression in cells after 14 days in culture, as assessed by flow cytometry. 
Isotype immunoglobulin (IgG) negative controls, shown on the left, were run in parallel with cells 
stained using mouse anti-vWF antibody and FITC-conjugated rabbit anti-mouse 
immunoglobulin, shown on the right. HUVECs (human umbilical vein endothelial cells) were 
used as a positive control (A). Cells from the subpopulation of CD34+ cells were either grown in 
a-30+ GM-MIX culture medium (B), or stimulated on day 4 by the supplementation of this 
culture medium with VEGF and bFGF (C). Gating was performed during analysis to eliminate 
dead cells and debris. The rectangular "112" boxes delineate the gating area for vWF expression 
and the percentage of vWF-positive cells is included in italics. (X axis = forward scatter; Y axis 
fluorescence intensity) 
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Figure 4.2.6 VEGFR2 expression on d14 of culture assessed by FACS. Isotype immunoglobulin 
(IgG) negative controls, shown on the left, were run in parallel with cells stained using mouse 
anti-VEGFR2 antibody and FITC-conjugated rabbit anti-mouse immunoglobulin, shown on the 
right. HUVECs (human umbilical vein endothelial cells) were employed as a positive control (A). 
Cells from the subpopulation of CD34+ cells were either grown in U-30 + GM-MIX culture 
medium (B), or stimulated on day 4 by the supplementation of this culture medium with VEGF 
and bFGF (C). Gating was performed during analysis to eliminate dead cells and debris. The 
rectangular "R2" boxes delineate the gating area for VEGFR2 expression and the percentage of 
VEGFR2-positive cells is included in italics. (X axis = forward scatter; Y axis = fluorescence 
intensity) 
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Figure 4.2.7 CD31 expression on d14 of culture assessed by FACS. Isotype immunoglobulin (IgG) 
negative controls, shown on the left, were run in parallel with cells stained using conjugated 
mouse anti-CD31-PE antibody, shown on the right. Cells from the subpopulation of CD34+ cells 
were either grown in a-30 + GM-MIX culture medium (A), or stimulated on day 4 by the 
supplementation of this culture medium with VEGF and bFGF (B). Gating was performed 
during analysis to eliminate dead cells and debris. The rectangular "R2" boxes delineate the 
gating area for CD31 expression and the percentage of CD31-positive cells is included in italics. 
(X axis = forward scatter; Y axis = fluorescence intensity) 
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4.3 CARDIAC DIFFERENTIATION 
Differentiation studies 
Multiple protocols to induce adherent CD34+ cells into cardiomyocytes were 
undertaken. Cultured cells were evaluated on a daily basis for morphological changes. 
Screening for differentiation was performed by nested PCR for end-proteins of 
cardiac differentiation. As we did not detect any such protein at the molecular level 
we did not proceed further with immunofluorescence, FACS, or western blotting. 
4.3.1 Growth factors 
Adherent CD34+ cells were cultured in a-MEM supplemented with 30% FBS (a-30) 
and GM-MIX cytokines (SCF 20ng/mL, GM-SCF Ing/mL, IL-3 5ng/mL, G-SCF 
I OOng/mL). On day 4, cells used for cardiac differentiation experiments were scraped 
off their dishes and were entered into one of the three culture protocols below to 
investigate their differentiation potential: 
1. As a control, cells were plated on culture dishes and were cultured in a-30 plus 
GM-MIX. 
2. Cells were plated on culture dishes and were cultured in a-30, GM-MIX and a 
mixture of lOng/mL BMP-2 (Sigma, Poole, UK) and 5ng/mL TGF-p (Sigma, Poole, 
UK). 
3. Cells were plated on culture dishes and were cultured in a-30, GM-MIX and 
I Ong/mL Cardiotrophin- I (CT- 1) (R &D Systems). 
4. Cells were plated on culture dishes and were cultured in a-30, GM-MIX and 
I Ong/mL platelet-derived growth factor (PDGF) (Sigma, Poole, UK). 
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Figure 4.3.1 Cell morphology photographs during cardiac differentiation protocols with various 
cytokines. Cells retained morphology similar to control culture dishes at day V (B-E) and d14 of 
culture (F-1). A small degree of elongation and spindle shape cells were seen in agreement with 
previous observations. No myotube-like structures were seen at any point. 
4.3.2 5-azacytidine 
Following isolation of adherent CD34+ cells and in parallel with routine cell cultures, 
cells were treated with 5-azacytidine (Sigma, Poole, UK) at a concentration of 5 or 
10ýtrnol/L. After incubation for 24 hours, cells were washed twice with PBS and the 
medium was changed to complete medium without 5-azacytidine. The experiment 
was terminated 2 weeks after the drug treatment. Once again no morphological 
changes were observed suggesting cells taking on a cardiomyocyte- like appearance. 
Nested PCR was also negative for end-proteins of cardiac differentiation. 
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day3 day7 day14 
Control 
Treated with 
5-aza 5umol/L 
Treated with 
5-aza 10umol/L 
Figure 4.3.2 Cell morphology photographs during cardiac differentiation protocol with various 
concentrations of 5-aza. Cells retained morphology similar to control culture dishes at day V (D- 
F) and d14 of culture (G-1). As with previous cytokine protocols, a small degree of elongation and 
spindle shape cells were seen in agreement with previous observations. No myotube-like 
structures were seen at any point. 
4.4 DISCUSSION 
Isolation of EPCs form BM or peripheral blood may be performed either via 
adherence culture of mononuclear cells or positive pre-selection based on 
immunophenotype with CD34, CD133 and CD31 being the commonest surface 
markers targeted for (243). Other researchers consider CD34, CD133 and KDR the 
combination of surface markers to identify peripheral blood EPCs (217). It is obvious 
that CD34 alone is not sufficient to select EPCs as it is expressed in HSCs as well as 
mature endothelial cells (209). As cells progress down the cascade hemangioblast- 
angioblast-early EPC-late EPC towards mature endothelial cells they change 
immunophenotype (243). Early EPCs are characterised by the expression of CD133 
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and lack of E-selectin, and vascular endothelial (VE)-cadherin compared to late EPCs. 
The distinction between late EPCs and mature endothelial cells is probably even more 
challenging. 
Studies have shown the connection between angioblasts residing within the bone 
marrow and neovascularisation (107,108). It has been claimed that within the CD34+ 
cell population, the CD34+KDR+ fraction is responsible for the seen improvement in 
cardiac haernodynamics and hence represents the candidate active CD34+ 
subpopulation (244). EPCs are recruited to sites of ischaernic injury and promote 
angiogenesis; Fazel and colleagues suggest that this is achieved via regulation of the 
myocardial levels of various angiogenic cytokines such as the angiopoietins I and 2, 
and vascular endothelial growth factor (VEGF) (80). Kocher et al showed that human 
EPCs infused into athymic nude rats subjected to experimental myocardial infarction 
coronary artery ligation induced new blood vessel formation in the infarct-bed and 
proliferation of pre-existing vasculature (152). This resulted in reduced cardiomyocyte 
apoptosis in the infarct border, reduced adverse cardiac remodelling and improved 
myocardial function. Similar results were reported for cardiac function and 
remodelling by Kawamoto et al (245). 
The endothelial differentiation experiments demonstrated that this novel 
subpopulation of CD34+ cells may provide a population enriched in EPCs following 
appropriate cytokine stimulation in vitro. The morphological appearances of the track- 
like cell formation in con . unction with their immunofluorescence patterns are highly j 
suggestive of this. 
In regards to cardiomyogenic differentiation we failed to obtain any evidence of 
differentiation with this particular series of experiments. 
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5 MICROARRAY EXPERIMENTS 
5.1 INTRODUCTION 
In the wider attempt to exploit stem cell plasticity a variety of synthetic chemicals 
have been found to induce cardiac differentiation cues (246). DNA demethylating 
agents have attracted the interest of many groups because DNA methylation is 
associated with a repressed chromatin state and subsequent gene silencing (236), it is 
thought that hypornethylation may play a role in epigenetic reprogramming during 
somatic cell cloning and stem cell function (237). Early reports have shown a 
connection between DNA hypornethylation and in vitro myoblast differentiation 
(238). Compounds promoting DNA demethylation, such as 5-azacytidine or 5-aza- 
2'deoxycytidine, have induced trans-differentiation of embryonic (239,240), cord 
blood (24 1), as well as marrow stromal cells into cardiomyocytes in vitro (I I 1- 113). 
Upregulation of expression of cardiomyocyte specific genes/proteins was noticed, 
along with 'beating' on the petri dishes in a few cases. More surprisingly 
cardiomyocyte- like cells have been reported to be obtained from adipose tissue- 
derived stem cells with such pre-treatment (242). 
Differentiation studies with various concentrations of 5-azacytidine proved unfruitful 
in terrns of detecting any changes in cell morphology or in the expression of 
terminally differentiated cardiomyocyte proteins with adherent CD34+ cells at the 
molecular level. In addition, results of preliminary expansion experiments indicated 
that 5-azacytidine at a concentration of 5ýtmol/L in the cell culture medium did not 
affect overall cell growth. In order to screen for possible undetected cardiac 
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differentiation in treated cells as well as the impact of treatment on the pure stem cell 
properties of adherent CD34+ cells we carried out cDNA microarray analysis (132). 
Gene expression profiling has been conducted to investigate and possibly identify 
novel aspects of gene regulation in cardiac differentiation of hESCs (247). Similarly, 
cDNA microarrays were used to map the detailed time course of changes in global 
gene expression during differentiation of P19CL6 cells, following dimethyl sulfoxide 
(DMSO) treatment, into spontaneously beating cardiac myocytes (248). 
5.2 cDNA MICROARRAYS EXPERIMENTAL DESIGN 
Following isolation of adherent CD34+ cells and in parallel with control untreated cell 
cultures, cells were treated for 24 hours with 5-aza at a concentration of 5[tmol/L. 
Cells were collected at V from cultures that were untreated and treated with 5-aza. 
This procedure was repeated for three separate patient samples. RNA was extracted 
from collected samples using the QIAGEN's RNeasy Total RNA Isolation kit (Qiagen 
GmBH, Hilden, Germany). The preparation quality was assessed by agarose- 
formaldehyde gel electrophoresis. 
The aim of carrying out a microarray analysis of day 7 adherent CD34+ cells versus 
day 7 adherent CD34 + cells treated with 5-aza was to determine whether any evidence 
of activation of pathways involved in cardiomyocyte differentiation could be 
identified at the molecular level. Also it was of interest to identify the fate of 
previously detected stem cell markers after treatment. Finally, although chemical 
agents have been shown to contribute to stem cell differentiation towards cardiac 
lineage phenotypes, their effect on the entire genome has not been addressed in 
respective papers. 
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5.3 DIFFERENTIAL GENE EXPRESSION BASED ON 5-AZA 
TREATMENT 
Descriptive statistics and parametric pair-wise comparisons using the Student t-test 
(unpaired, assuming unequal variances) were performed. The false discovery rate of 
the test-set was calculated using the Benjamini Hochberg procedure. Transcripts 
differentially expressed >1.5 fold with an associated p-value<0.05 were considered as 
significantly differentially expressed. 563 transcripts were found to be upregulated in 
non-treated day 7 adherent CD34+, whilst day 7 adherent CD34+ cells treated with 5- 
aza demonstrated upregulation of 102 genes (appendix 2). By uploading the 
respective Affymetrix probe set IDs onto the Database for Annotation, Visualization 
and Integrated Discovery (DAVID) bioinformatics database, functional analysis based 
on the Gene Ontology Consortium classification system was obtained as shown in 
tables 5.3.1 and 5.3.2. 
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Table 5.3.1 The 563 gene transcripts downregulated in treated plastic adherent CD34+ cells with 
5-aza compared to untreated cells were functionally catergorized according to Gene Ontology 
classification. 
Gene Ontology Functional Category 
# of 
gen 
es 
% of 
genes 
P- 
value 
cellular process 310 62.5 0.0056 
cellular physiological process 264 53.2 0.0200 
metabolism 210 42.3 0.0340 
primary metabolism 197 39.7 0.0063 
cellular metabolism 196 39.5 0.0440 
macromolecule metabolism 124 25 0.0330 
cell communication 99 20 0.0083 
signal transduction 97 19.6 0.0014 
response to stimulus 74 14.9 0.0460 
biopolymer modification 55 11.1 0.0089 
response to biotic stimulus 53 10.7 0.0000 
protein modification 52 10.5 0.0180 
intracellular signaling cascade 51 10.3 0.0000 
defense response 51 10.3 0.0001 
response to stress 47 9.5 0.0000 
immune response 47 9.5 0.0001 
response to pest, pathogen or parasite 33 6.7 0.0000 
response to other organism 33 6.7 0.0000 
phosphorus metabolism 33 6.7 0.0150 
phosphate metabolism 33 6.7 0.0150 
lipid metabolism 28 5.6 0.0010 
phosphorylation 28 5.6 0.0200 
response to external stimulus 27 5.4 0.0001 
protein amino acid phosphorylation 26 5.2 0.0051 
response to wounding 24 4.8 0.0000 
carbohydrate metabolism 23 4.6 0.0039 
cellular lipid metabolism 22 4.4 0.0040 
intracellular transport 22 4.4 0.0340 
establishment of cellular localization 22 4.4 0.0380 
cellular localization 22 4.4 0.0400 
positive regulation of biological process 22 4.4 0.0490 
transcription from RNA polymerase 11 promoter 20 4 0.0150 
cellular carbohydrate metabolism 17 3.4 0.0071 
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vesicle-mediated transport 16 3.2 0.0190 
regulation of enzyme activity 15 3 0.0016 
protein kinase cascade 15 3 0.0049 
inflammatory response 13 2.6 0.0032 
endocytosis 11 2.2 0.0020 
positive regulation of enzyme activity 10 2 0.0008 
immune cell activation 9 1.8 0.0034 
cell activation 9 1.8 0.0036 
membrane lipid metabolism 9 1.8 0.0100 
positive regulation of protein kinase activity 8 1.6 0.0003 
positive regulation of transferase activity 8 1.6 0.0004 
humoral defense mechanism (sensu Vertebrata) 8 1.6 0.0170 
regulation of kinase activity 8 1.6 0.0330 
regulation of protein kinase activity 8 1.6 0.0330 
regulation of transferase activity 8 1.6 0.0340 
lymphocyte activation 7 1.4 0.0180 
wound healing 7 1.4 0.0270 
response to virus 6 1.2 0.0350 
antimicrobial humoral response (sensu Vertebrata) 6 1.2 0.0450 
receptor mediated endocytosis 5 1 0.0074 
antigen presentation, endogenous antigen 5 1 0.0074 
antigen processing, endogenous antigen via MHC 
class 1 5 1 0.0099 
cellular polysaccharide metabolism 5 1 0.0290 
detection of stimulus 5 1 0.0380 
polysaccharide metabolism 5 1 0.0450 
detection of biotic stimulus 4 0.8 0.0110 
endosome transport 4 0.8 0.0160 
response to pathogen 4 0.8 0.0290 
B cell activation 4 0.8 0.0430 
Notch signaling pathway 4 0.8 0.0430 
developmental growth 3 0.6 0.0160 
mitotic spindle organization and biogenesis 3 0.6 0.0380 
superoxide metabolism 3 0.6 0.0430 
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Table 5.3.2 The 102 gene transcripts upregulated in 5-aza treated plastic adherent CD34+ cells 
compared to non treated cells were functionally catergorized according to Gene Ontology 
classification. 
Gene Ontology Functional Category 
# of 
gen 
es 
% of 
genes 
P_ 
value 
primary metabolism 43 42.2 0.0180 
macromolecule metabolism 33 32.4 0.0020 
biopolymer metabolism 20 19.6 0.0330 
cell cycle 14 13.7 0.0000 
DNA metabolism 10 9.8 0.0023 
organelle organization and biogenesis 10 9.8 0.0100 
mitotic cell cycle 9 8.8 0.0000 
regulation of progression through cell cycle 9 8.8 0.0009 
regulation of cell cycle 9 8.8 0.0009 
mitosis 7 6.9 0.0000 
M phase of mitotic cell cycle 7 6.9 0.0000 
M phase 7 6.9 0.0002 
DNA replication 7 6.9 0.0002 
establishment of cellular localization 7 6.9 0.0480 
cellular localization 7 6.9 0.0500 
DNA-dependent DNA replication 6 5.9 0.0000 
amine metabolism 6 5.9 0.0220 
nitrogen compound metabolism 6 5.9 0.0280 
cell division 5 4.9 0.0072 
amino acid and derivative metabolism 5 4.9 0.0400 
microtubule-based movement 4 3.9 0.0120 
aromatic compound metabolism 4 3.9 0.0140 
cytoskeleton -dependent intracellular transport 4 3.9 0.0160 
microtubule-based process 4 3.9 0.0370 
translation 4 3.9 0.0470 
establishment of chromosome localization 3 2.9 0.0002 
chromosome localization 3 2.9 0.0002 
establishment of organelle localization 3 2.9 0.0006 
organelle localization 3 2.9 0.0010 
DNA replication initiation 3 2.9 0.0063 
chromosome segregation 3 2.9 0.0110 
regulation of mitosis 3 2.9 0.0150 
interphase of mitotic cell cycle 3 2.9 0.0270 
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interphase 3 2.9 0.0290 
heterocycle metabolism 3 2.9 0.0320 
regulation of translation 3 2.9 0.0490 
chromosome movement towards spindle pole 2 2 0.0085 
kinetochore organization and biogenesis 2 2 0.0085 
kinetochore assembly 2 2 0.0085 
mitotic chromosome movement towards spindle pole 2 2 0.0085 
metaphase plate congression 2 2 0.0170 
purine base biosynthesis 2 2 0.0170 
mitotic spindle checkpoint 2 2 0.0210 
spindle checkpoint 2 2 0.0210 
purine base metabolism 2 2 0.0250 
nucleobase biosynthesis 2 2 0.0380 
DNA replication and chromosome cycle 2 2 0.0420 
nucleobase metabolism 2 2 0.0500 
5.4 CARDIAC TRANSCRIPTION FACTOR EXPRESSION 
To assess the possible effect of 5-aza treatment on promoting a cardiornyocyte 
phenotype a full panel of twenty one cardiac transcription factors was investigated in 
detail for differential expression between treated and untreated cell populations (table 
5.4.1). This revealed only one transcript of the MADS box transcription enhancer 
factor 2, polypeptide A (myocyte enhancer factor 2A, MEF2A) to be upregulated in 
the untreated day 7 adherent CD34+ cells (2.3fold, p= 0.013). The data were also 
indicative of increased expression in the untreated population of transcripts of both 
MADS box transcription enhancer factor 2, polypeptide B (myocyte enhancer factor 
2B, MEF2B) and MADS box transcription enhancer factor 2, polypeptide C (myocyte 
enhancer factor 2C, MEF2C) but they did not reach statistical significance. 
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Symbol Entrez ID Description 
ATF-2 NM001880.2 activating transcription factor 2 
BOPI NM015201.3 block of proliferation I 
FOXHI NM003923.1 forkhead box HI 
GATA4 NM002052.2 GATA binding protein 4 
GATA5 NM002052.2 GATA binding protein 5 
GATA6 NM005257.3 GATA binding protein 6 
HANDI NM004821.1 heart and neural crest derivatives expressed I 
HAND2 NM021973.1 heart and neural crest derivatives expressed 2 
ISLI NM-002202.1 ISLI transcription factor, LMhomeodomain, (islet-1) 
MEF2A NM005587.1 
MADS box transcription enhancer factor 2, polypeptide A 
(myocyte enhancer factor 2A) 
MEF213 NM005919.1 
MADS box transcription enhancer factor 2, polypeptide B 
(myocyte enhancer factor 213) 
MEF2C NM002397.2 
MADS box transcription enhancer factor 2, polypeptide C 
(myocyte enhancer factor 2C) 
MIEF2D NM005920.2 
MADS box transcription enhancer factor 2, polypeptide D 
(myocyte enhancer factor 21)) 
MESPI NM-0 18670.1 mesoderm posterior I 
NKX2- 
5 NM-004387.2 NK2 transcription factor related, locus 5 (Drosophila) 
PITX2 NM-000325.4 
paired-like homeodomain transcription factor 2, transcript 
variant 3 
SNLA_D2 NM-005901.2 SMAD, mothers against DPP homolog 2 (Drosophila) 
TBXI NM 005992.1 T-box 1, transcript variant B 
TBX2 NM-005994.3 T-box 2 
TBX20 XM294236.1 T-box 20 
TBX5 NM_181486.1 T-box 5, transcript variant 4 
Table 5.4.1 A list of transcription factors involved in cardiac development (247). All genes were 
assessed for differential expression amongst non-treated and treated with 5-aza adherent CD34' 
cell populations. 
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5.5 CARDIAC-RELATED GENE EXPRESSION 
All differentially expressed transcripts from treated and untreated cell populations 
(only p<0.05) were cross-referenced against a list of cardiac-related genes (247). The 
5-aza treated cell samples did not provide any matches in this search. Notably the 
non-treated cells provided a few matches including the transcript for CXCR4 as may 
be seen in table 5.5.1. No structural proteins were detected to be upregulated in either 
group. 
Symbol Entrez ID Description 
CXCR4 NM-001008540.1 Chemokine (C-X-C motif) receptor 4 
JAGI NM000214.1 Jagged I (Alagille syndrome) 
PIK3CD NM005026.2 Phosphoinositide-3-kinase, catalytic, delta polypeptide 
SERPIN136 NM004568.4 
Serine (or cysteine) proteinase inhibitor, clade B, 
member 6 
SPTANI CD514930.1 Spectrin, alpha, non-erythrocytic I (alpha-fodrin) 
Table 5.5.1 Cardiac-related transcripts found to be differentially expressed (p<0.05) in non- 
treated with 5-aza adherent CD34+ cell populations. The significance of CXCR4 for stem cell 
mobilisation and homing has been previously discussed. 
5.6 STEM CELL GENE EXPRESSION 
No statistically significant difference was documented for transcript regulation of 
genes denoting "sternness". Expression of pluripotency genes oct3/4, nanog, SOX-2, 
DU 
REX- I, nestin, and GATA-4 was found in both groups reconfirming previous nested 
PCR work. 
5.7 TGF SUPERFAMILY RECEPTORS 
The transfonning growth factor-P (TGFP) superfamily consists of a large and 
divergent group of polypeptide morphogens including, besides the TGFPs themselves, 
members such as the activins and the bone morphogenetic proteins (BMPs) (249). 
Cytokines and their respective receptors have been shown to be involved in a variety 
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of processes within cardiogenesis. Transcripts for receptors BMPR2, TGFRI, TGFR2, 
and activin A receptor were found to be expressed by both populations. 
5.8 UPREGULATION OF "UNWANTED" TRANSCRIPTS 
FOLLOWING 5-AZA TREATMENT 
Upregulated transcripts for the 5-aza treated adherent CD34+ cell group included a 
group of genes involved in a variety of malignancies. Although statistical significance 
was not reached for the majority of these transcripts a clear trend was evident. 
Findings are surnmarised in table 5.8.1. 
Symbol Entrez ID Description 
MYC NM002467 v-myc myelocytomatosis viral oncogene homolog 
BCLI IA NM-0 18014 B-cell CLL/lymphoma IIA (zinc finger protein) 
CEACAMI NM-00 1024912 
Carcinoembryonic antigen-related cell adhesion molecule 
1 
CD24 NM013230 CD24 molecule 
CDTI NM030928 Chromatin licensing and DNA replication factor I 
Table 5.8.1 Upregulated transcripts in the 5-aza treated group included a small array of genes 
with reported involvement in hematological malignancies mainly. 
5.9 DISCUSSION 
The transcriptome of non-treated and treated with 5-aza adherent CD34+ cell 
populations revealed significant differences as well as similarities. By examining the 
Gene Ontology terms it is evident that treated cells have a higher number of 
downregulated genes especially involved in cell communication, signal transduction, 
response to stimulus, response to biotic stimulus, intracellular signalling cascade, and 
response to wounding. It is apparent that stem cells destined to repair/regenerate 
cardiac tissue should be able to interact with the local microenvironment and respond 
accordingly. Although both groups appeared to maintain their pluripotency no 
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evidence of cardiac differentiation was seen. From the cardiac perspective no 
additional benefit may be seen from 5-aza treatment in this cell population under the 
given conditions. 
Valuable information was gained regarding cell surface receptor expression 
regarding the TGFP superfamily. Bone morphogenetic protein-2 (BMP2) plays a 
pivotal role in mammalian cardiac development as shown by Zhang and Bradley 
(250). Abnormal cardiac development was shown to ensue the generation of a 
homozygous null mutation of BMP2 in a murine embryonic model. Schultheiss et al 
were able to demonstrate full cardiac differentiation in non-cardiogenic tissue by 
administration of soluble BMP2 or BMP4 to explant cultures (25 1). Data have been 
produced for the discreet roles of BMP2 and BMP4 in the developing mouse heart. It 
appears that BMP2 is linked to the formation of the atrioventricular junction and 
valves, with BMP4 involved in the development of the outflow tract myocardium and 
of the endocardial cushion (252). Furthermore the addition of Noggin, a known BMP 
antagonist, resulted in inhibition of cardiac differentiation of the precardiac mesoderm 
(25 1). Even though BMPs play a crucial role in both processes of mesodermal 
induction (253) and cardiomyocyte differentiation (250), there seems to be a transient 
but essential inhibitory phase of BMP signalling between them (254). 
TGFP2 deficient mice demonstrate in addition to a high perinatal mortality a 
wide range of congenital cardiovascular anomalies comparable to malformations seen 
in humans (255). Even though all three recognised TGFp isoforms (01, P2, P3) are 
expressed within the developing murine heart (256), each isoform appears to exert 
specific functions the other two cannot compensate for (257). Combined application 
in vitro of TGFP and BMP2 to undifferentiated murine embryonic stem cells lead to 
upregulation of both mesodermal and cardiac specific transcription factors; likewise, 
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in vivo transplantation lead to cardiac differentiation only in animals with an intact 
TGFP/BMP2 signaling pathway (258). Kumar and Sun compared the effects of the 
three isoforms on cardiornyocyte differentiation from embryonic stem cells (259). A 
significant increase in embryoid body proliferation as well as spontaneous beating 
was noticed only in the TGFPZ subgroup. Finally, in a murine myocardial infarction 
model, transplantation of TGFP pretreated bone marrow-derived CD 117+ cells 
revealed superior functional improvement compared to untreated cell transplantation 
(260). Most importantly, newly formed myocardial tissue was seen on histology only 
in the TGF pretreated group. 
Finally, a member of the TGFp superfamily that has been studied less 
extensively are the activins. Exhibiting similar activities to TGFP, activin has been 
shown to promote cardiac myogenesis in avian embryonic cells not otherwise of 
cardiac fate (261). The authors submit evidence of activin/TGFP signaling lying 
upstream of BMP signaling in the cardiac myogensis pathway; the hypothesis is 
raised of TGFP acting via upregulation of activin expression. More interestingly 
activin A-stimulated human amniotic mesenchymal cells were shown to express a 
variety of cardiornyocyte-specific genes including Nkx2.5, ANP, and a-MHC (262). 
None of the marker genes mentioned above appeared to be expressed in the samples 
without stimulation. 
The potential role of the TGFP superfamily has already been highlighted in 
Chapter 4. The expression of transcripts for multiple receptors for members of this 
superfamily further underlies their importance for the regulation of adherent CD34' 
cells. Exogenous delivery via supplementation of the culture medium to induce 
phenotypic commitment via signal cascades may prove effective, even though the 
differentiation studies described earlier did not achieve this. 
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Finally, although 5-aza has received U. S. Food and Drug Administration 
(FDA) approval for the treatment of all subtypes of myelodysplastic syndrome (263), 
it must be remembered that it remains highly mutagenic (264). Along with our 
findings of upregulation of genes involved in various malignancies, treatment of cells 
with 5-aza was not implemented in experimental animal or clinical protocols. 
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Animal experimentation 
ANIMAL EXPERIMENTATION 
6.1 INTRODUCTION 
It is recognised that animal models are less than perfect for studying human disease as 
animals are normally not amenable by nature to similar pathologies. In addition they 
do not suffer from other co morbidities as human patients do. Despite these 
shortcomings animal models have proven indispensable in the study of myocardial 
ischaemia and ventricular remodelling. Technical feasibility along with lack of large 
animal facilities and financial cost are the main reasons small animal models are 
preferred by the majority of groups. To mimic the natural history of myocardial 
ischaernia in humans all models -acute and chronic- incorporate induction of 
myocardial injury via an invasive approach. Transmural myocardial scars can be 
induced in numerous ways in small animals. Direct ligation of the left anterior 
descending artery with suture application is the best described and most commonly 
used (265). Other methods include cryoinjury via cryoprobe (266) and topical 
injection of cardiotoxin (such as the snake cardiotoxin NaJa mossambica mossambica) 
in the ventricular wall (267) . Reproducibility 
in creating transmural scars of similar 
size in study animals is relatively easier in the latter methods with the serious 
drawback of not incorporating a 'physiologic' process of ischaemic disease simulation. 
A representative sample of small animal work has already been described in section 
1.7.1. 
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6.2 PILOT ANIMAL EXPERIMENTAL WORK 
Initial animal experimentation was conducted to establish optimal conditions for 
myocardial infarct creation and subsequent stem cell delivery in the left ventricular 
wall of animals. As this part of the study was primarily carried out to ascertain 
technical feasibility as well as identify technical difficulties, coronary artery ligation 
and stem cell delivery were carried out at the same time. Thirty minutes after 
coronary artery ligation a visible area of "blanching" was evident corresponding to 
the area of ischaernia within the left ventricular wall (Fig 6.2.1). PBS (n=2) or 5xI 06 
day 7 adherent CD34+ cells (n=2) were injected in the periphery of the lesion. Stem 
cells were labelled with tat peptide derivatized ultrasmall superparamagnetic iron 
oxide nanoparticles coated with dextran for CMR tracking. Total injected volume 
was 100ýtl and it was given in 3-4 injections with a micro syringe (Hamilton, 
Nevada,, USA). All animals were given immunosuppression in the form of 
Cyclosporin A (CsA) on a daily basis. 
Area of myocardial 
intarction Coron2rY 2rtery Mation 
m call Injection 
sttes 
Figure 6.2.1 Picture showing site of left anterior descending artery ligation with subsequent 
"blanching" in area of myocardial ischaemia. 
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6.2.1 Functional assessment 
Animal experimentation 
Functional assessment was carried out with CMR postprocedurally on the first day 
and after six weeks (Dr C Chapon). Analysis was carried out according to relevant 
literature (268). Multislice short-axis cine MRI series were analysed using the 
ImageJ program (National Institutes of Health, Bethesda, MD, 
http: //rsb. info. nih-gov/ij/). The window and level settings of a representative 
midventricular image were optimized for best image contrast between the 
myocardium and the ventricle and then set for all images. End-diastolic images (Fig 
6.2.2) were chosen as the first phase after triggering off the R-wave, while images 
with the smallest cavity area were selected as end-systolic images. 
Figure 6.2.2 CMR images during end diastole from a stem cell treated (A) and control (B) animal 
respectively. An increased end diastolic diameter (white arrow) is seen in the control subject 
indicating deterioration in left ventricular function. 
Epicardial and endocardial LV surfaces (including papillary muscles) were traced 
manually. Volumetric transformation was performed by multiplying the area within 
the endocardial tracing by the slice thickness. The end-diastolic volume (EDV) and 
end-systolic volume (ESV) were calculated by summing the volumes of all short-axis 
slices. The LVM was determined by multiplying the end-diastolic myocardial volume 
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by the specific gravity of myocardium (1.05 g/CM3). As rats' body weight progressed 
in the interval between the two scans all measurements were adjusted accordingly as 
seen in table 6.2.1. 
PBS Group (n=2) Stem Cell Group (n=2) 
Day 16 weeks Day 16 weeks 
Rat weight 238.5±1.5 375±17 228±7 321±21 
(g) 
EDV* 1.13±0.08 1.65±0.4 1.36±0.02 1.07±0.2 
(cm/g) 
ESV* 0.39±0.24 0.86±0.39 0.32±0.07 0.48±0.18 
(cm/g) 
EF 0.67±0.19 0.51±0.12 0.76±0.05 0.56±0.08 
LV mass* 1.95±0.03 2.05±0.60 2.46±0.03 1.69±0.04 
Table 6.2.1 CMR functional assessment at day I and six weeks after treatment. EDV, ESV, and 
LV mass all have been normalised to body weight (*). Values represent means and ranges (n =2 
rats per group). 
The stem cell treated group demonstrated an overall reduction in EDV* (1.36±0.03 
to 1.07±. 29) and LV mass* (2.46±0.04 tol. 69±0.06), indicating a potential benefit 
on preservation of left ventricular function. ESV* was also less impaired in stem 
cell treated animals (0.32±0.10 to 0.48±0.25) compared to PBS treated rats 
(0.39±0.34 to 0.86±0.55). 
These findings were considered adequate to proceed to a larger scale design with 
pre transplantation subject randomization into study groups. 
6.3 ANIMAL EXPERIMENTAL PROTOCOL 
To assess the reparative/regenerative potential of adherent CD34+ stem cells a 
chronic myocardial ischaemia rat model was selected 
in order to perform 
intramyocardial transplantation (Fig 6.3.1). After inducing myocardial infarction a 
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period of four weeks was allowed to resemble the clinical scenario of established 
myocardial ischaernic disease. Animals were assessed via echocardiography and 
randomised to treatment groups according to overall left ventricular function. 
Randomized animals were injected with one of the following: (1) 5x 106 CD34+ 
cells; (2) 5x 106 adherent CD34+ cells; (3) 107 adherent CD34+ cells (double 
Myocardial Stem cell 
Infarction transplantation 
Histology 
4 weeks 
2 weeks 6 weeks__ 
Echo Echo Echo 
t 
Immunosuppression 
Figure 6.3.1 Experimental design of animal study. Stem cell or PBS injection was carried out 
four weeks following myocardial infarction via coronary artery ligation. Assessment was 
performed via echocardiography at three different time points. A baseline scan was obtained 
immediately prior to rethoracotomy, and two further scans were done at 2 and 6 weeks following 
implantation. 
dose); or (4) PBS only. In order to evaluate left ventricular function, transthoracic 
echocardiography was performed on rats at three different time points. A baseline 
echocardiogram was obtained at 4 weeks after myocardial infarction. This coincided 
practically with the same day as stem cell implantation or saline injection in placebo 
animals. Scans were subsequently repeated at two and six weeks post 
transplantation to assess for early as well as late stem cell rescue. We also carried 
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out echocardiographic evaluation following the same methodology on a cohort of 
normal rats (n=5). 
6.3.1 Functional assessment 
Echocardiography was chosen as the sole modality of assessing cardiac 
performance for the principal study. Time and costing were the main parameters 
influencing this choice. All echocardiograms were performed under the same 
conditions according to local policy guidelines. Rats were initially anaesthetized 
with 4-5% isoflurane (Abbott Laboratories Ltd, UK) in an induction chamber and 
after appropriate thoracic wall shaving, subjects were placed in a shallow left lateral 
decubitus position while 1-2% isoflurane was continuously supplied via a facial 
mask allowing for spontaneous breathing throughout. All scans were performed 
with a commercially available Sequoia C256 echocardiography system (Siemens, 
Mountain View, CA, USA) equipped with 7.5 MHz phased-array transducer. In 
order to avoid hypothermia warm echocardiographic gel was applied to the chest 
wall and animals were lied on a heat pad whilst scanning was performed. As 
described by Leor et al longitudinal images of the heart were obtained at the outset, 
followed by M-mode tracings obtained at the level below the tip of the mitral valve 
leaflets at the level of the papillary muscles (269). Representative two-dimensional 
images, M-mode tracings and Doppler curves were recorded for later off-line 
analysis (Fig 6.3.2-6.3.5). After the studies were completed, the mask was removed, 
and rats were allowed to recover over 20-30 min prior to returning to individual 
holding cages. All measurements were averaged for 3 consecutive cardiac cycles 
and were obtained and analysed by an experienced echocardiographer (Dr J Yeh) 
who was blinded to the animals' allocation to treatment groups. Once again, as 
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animals' body weight progressed in the interval between the two scans all 
measurements were adjusted accordingly. 
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Figure 6.3.2 Parasternal long axis view. In diastole, the long axis illustrates the aortic root and 
basal segments of the left ventricle. This view allows for measurements of the aortic diameter, 
end-diastolic diameter (distance between two cursors), and end-systolic diameter (during systole). 
These measurements in turn are used to calculate fractional shortening and ejection fraction. All 
measurements were taken in triplicates. 
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Figure 6.3.3 Left ventricular M-mode tracing at the level of maximum observed left ventricular 
wall thinning. Limitation of representing a single plane through the heart and may misinterpret 
overall function. M-mode allows for measurements of the end-diastolic diameter, end-systolic 
diameter, and heart rate. These measurements in turn are used to calculate fractional shortening 
and ejection fraction. All measurements were taken in triplicates as seen from insets. 
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Figure 6.3.4 Left ventricular inflow velocity curve with pulsed Doppler demonstrating rapid 
early diastolic filling (E) along with the atrial contribution (A) during late diastole. 
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Figure 6.3.5 Left ventricular outflow velocity curve with pulsed Doppler. The area under the 
curve (outlined in upper row) may be used to calculate stroke volume by multiplying with the 
aortic cross-sectional area. 
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Animal weight and heart rates were equal between groups at all time points. Left 
ventricular dimensions (end-diastolic and end-systolic diameter) were reduced in all 
stem cell treated groups especially between the baseline and 6 week post stem cell 
transplantation (PSCT) assessments on M-mode tracing. Specifically, EDD (M-mode) 
was significantly decreased between baseline and 6 weeks PSCT in group 4 [t (6) =- 
2.39, p=0.05], group 5 [t (7) = -4-18, p=0.004], and group6 [t (1) = -42.33, p= 
0.01]. Also, ESD (M-mode) was significantly decreased between baseline and 6 
weeks PSCT in group 5 [t (7) = -2.74, p=0.02]. Cardiac output (CO) increased in 
group 2,4, and 6; the difference reached significance between baseline and 6 weeks 
PSCT in group 6 alone [t (1) = -15.65, p=0.04]. Myocardial performance index 
marginally improved between baseline and 6 weeks PSCT in groups 4,5, and 6; 
however, no significance was noted (p>0.05). Fractional shortening (M-mode) 
increased between baseline and 6 weeks PSCT in groups 3,5, and 6, although the 
differences were not significant (p>0.05). The degree of infarct damage reduced in all 
groups. Comparisons of continuous data between groups were performed with 
independent sample t-tests in order to detect between group differences at baseline 
and after treatment. Group means were compared between baseline and post- 
intervention scans using two tailed paired t-tests. Statistical significance levels of p< 
0.05 were used throughout. 
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Figure 6.3.6 Assessment of cardiac function. A. End diastolic diameter assessed with M-mode 
corrected for weight (EDD_MM; in cm/g), B. End systolic diameter assessed with M-mode 
corrected for weight (ESD_MM; in cm/g), C. Fractional shortening assessed with M-mode, D. 
Cardiac output, E. Left ventricular myocardial performance index (LVMPI), F. Degree of infarct 
damage. All measurements were taken at three different time points. Groups are: 1) Cohort of 
healthy rats (n=5), 2) Placebo rats injected with PBS (n=5), 3) Rats injected with 5x 106 0 CD34+ 
cells (n=6), 4) Rats injected with 5x 106 0 adherent CD34+ cells (n=8), 5) Rats injected with 5x 
107 V adherent CD34+ cells (n=8), 6) Rats injected with 5x 106 0 adherent CD34+ cells (n=3). *P 
< 0.05 
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6.3.2 Immunohistochemistry 
Animal experimentation 
6.3.2.1 Evaluation of myocardial fibrosis and apoptotic index 
To confirm the presence of fibrosis within the left ventricle transverse tissue 
sections were stained with Masson's Trichrome (Fig 6.3.7 A). There was no gross 
difference in extent of fibrosis between any of the groups. 
To assess apoptosis at the cellular level TUNEL (TdT-mediated dUTP Nick-End 
Labelling) staining was performed (Fig 6.3.7 B). Positive staining was minimal 
throughout including infarct scar, peri-infarct border, and surrounding myocardium. 
The time lapse of ten weeks from injury to retrieval of tissue from animals may 
explain this finding. 
Figure 6.3.7 A. Scar area of a treated animal 6 weeks after injection of adherent CD34+ cells. B. 
TUNEL staining of the peri-infaret border 6 weeks after injection of CD34+ cells. 
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6.3.2.2 Staining for human endothelial markers 
To detect for transplanted stem cell-related neoangiogenesis transverse tissue 
sections were labelled with VEGF and CD31 monoclonal antibodies. Minimal 
staining was observed only in animals from stem cell treated groups (Fig 6.3.8), 
indicating their potential role in neovascularisation. 
I" 
'1 
S 
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Figure 6.3.8 A. Staining with anti-VEGF (A) and anti-CD31 (B) of the peri-infarct border 6 
weeks after injection of adherent CD34+ cells. 
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6.3.2.3 Dystrophic bone formation 
An unexpected finding during the histopathological examination of all sections was 
the presence of chondroid and bone formation in the stem cell treated groups (4/17). 
On one occasion dystrophic bone formation was seen in the subendocardial zone 
(Fig 6.3.9). 
Figure 6.3.9 Dystrophic bone formation 6 weeks after injection of adherent CD34+ cells. 
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6.4 STEM CELL TRACKING 
Transplanted cells were not visualised on CMR during the pilot study. This was 
attributed to suboptimal labelling as insufficient quantities of the tat peptide 
derivatized ultrasmall superparamagnetic iron oxide nanoparticles were available at 
the time. During the randomised animal experiment 5x 106 adherent CD34+ cells 
were labelled with Resovistg (Schering AG, Berlin, active ingredient: 
Ferucarbotran). Detectable levels of uptake once stem cells were CMR imaged were 
achieved and this was confirmed on histopathology as seen in figure 6.4.1. 
'C 
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Figure 6.4.1 A. Demonstration of stem cell intramyocardial injection in the peri infarct border. B. 
Tracking of cells labelled with superparamagnetic iron oxide (ResovistO, Schering, Germany) 
seen on T2-weighted MR sequence at 9AT. C. Hematoxylin-eosin staining for morphology. D. 
Positive staining of myocardial tissue with Perl's Prussian blue for iron. 
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The main aim of this study was to determine whether human BM-derived adherent 
CD34+ stem cells were capable of improving cardiac function in a rat model of 
chronic myocardial ischemia. We studied adherent CD34' cells extracted from culture 
at two different time points (d3 and V). In addition, adherent CD34+ stem cells were 
delivered at two different doses. A control group consisted of animals receiving PBS 
injections, whilst a group of animals receiving an equal number of V CD34+ cells 
(starting population) was also included. Following myocardial infarction and prior to 
stem cell transplantation animals were assessed with baseline echocardiography in 
order to evaluate left ventricular function and allocate animals into treatment groups 
based on severity of created injury. 
Myocardial infarction is followed by decreased LV contractility and subsequently 
reduced stroke volume leading eventually to left ventricular dilatation (heralded by an 
increase of EDV and ESV) and disorganization of left ventricular architecture and 
failure (270). A model of chronic myocardial ischaemia was selected for these series 
of experiments for two main reasons; to permit maximal natural recovery of 
myocardium following ischaernic insult, and increase survival of transplanted cells as 
the acute inflammatory phase following creation of myocardial infarction would have 
resolved once a period of four weeks was allowed. Human cells have been delivered 
in rodent models of myocardial ischaemia (95,27 1). In both sited studies, for example, 
animals were athymic nude rats. We selected to work with adult rats receiving daily 
cyclosporine (272). All animals including the control group receiving PBS injections 
alone were administered daily immunosupression in order to eliminate any drug- 
related bias. 
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The basis of selection for the route of delivery was reproducibility and potential to 
meet endpoints of this particular study design. Alternative delivery routes include the 
intracoronary and intravenous routes. The former is not feasible in the rat model for 
pure technical reasons. On the other hand, although intravenous delivery is easily 
reproducible and well established (245,273,274), it would probably not be able to 
answer our queries especially with regards to dose dependency, as no modality may 
reliably measure actual cell uptake by the myocardium at present. In relation to the 
dose escalation part of the design this was thought to be the most robust method of 
delivering cells in predefined numbers. The trade-off with this approach was 
elimination of the processes of mobilization and homing altogether. 
A well recognized mechanism of cardiac function improvement is via release of 
paracrine factors from the transplanted cells. When human cells are transplanted into 
animals secreted cytokines may not produce the desired effect secondary to a variety 
of reasons. The bioactivity of human sequence proteins may be neutralised in a few 
weeks secondary to the development of antigenic stimulation (275). In addition 
certain cytokines may exhibit divergent function between species (275). The minor 
degree of functional improvement seen in this experiment may be attributed to the 
above. 
Endochondral ossification in aged Sprague Dawley rat hearts has been previously 
reported (276). A natural occurring process may have been expedited by myocardial 
infarction and repetitive surgery. On the other hand, the finding of dystrophic bone 
formation within the myocardium of animals demonstrates the broad differentiation 
potential of the transplanted multipotent stem cells. It also shows that stem cells 
interact with the local milieu in vivo with the end-effect not always being 
predetermined. Intramyocardial calcification has been reported following the 
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intramyocardial injection of crude BMCs in the peri-infarct region in rats (277). It is 
possible that the intramyocardial route predisposes to such developments as stem cells 
are introduced to areas of fibrosis that would otherwise not be emitting homing 
signals via soluble cytokine mediators. 
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7 CLINICAL TRIAL DESIGN 
7.1 INTRODUCTION 
Clinical trial design 
A number of clinical trials have suggested that HSCs can contribute to and/or 
stimulate the regeneration ischaemic myocardial tissue. The precise physiological 
conditions required for the migration and contribution of HSCs to tissue regeneration 
is not fully understood, but one important factor appears to be signals that are 
generated by the damaged tissue in the target organ (e. g. expression of SDF-I). 
Despite this growing body of evidence, whether the contribution made by the HSCs is 
in fact mediated by their trans-differentiation, their fusion with cells in the damaged 
tissue, or indeed stimulation of differentiation/regeneration by the stem cells of the 
target organ, remains unclear. There is therefore a pressing need for further clinical 
trials, both to assess the contribution of HSCs to tissue regeneration, and to 
distinguish between the different mechanisms by which the apparent clinical benefit is 
achieved. 
Initial experimental studies by a number of groups have indicated that HSCs may 
contribute to the functional regeneration of freshly infarcted myocardium by 
increasing neovascularisation of ischemic areas. A number of clinical trials have now 
shown the feasibility and safety of direct intracoronary infusion of HSCs as described 
in section 1.8. These studies have provided limited evidence in relation to enhanced 
recovery of myocardial function after acute cardiac infarction in patients receiving 
BM-derived haernopoietic progenitor cells. In fact, a number of publications on the 
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subject have highlighted the pressing need for proof-of-concept studies documenting 
a potentially beneficial effect of progenitor cell therapy on cardiac function (278). 
A Phase I clinical trial at the Hammersmith Hospital in 2004 studied the efficacy, 
tolerability and possible side effects of injecting autologous CD34+ stem cells into the 
liver of five patients with liver disease (21). This phase I study demonstrated good 
tolerability and the safety. We designed a phase 1/11 study where it was intended to 
administer incrementally increasing concentrations of stem cells in order to reach the 
optimum dose, assess the safety of dose escalation and then to assess the safety and 
efficacy of this treatment approach at the optimum CD34+ stem cell dose. 
7.2 STUDY OBJECTIVES 
The aim of this trial is to determine the safety and tolerability of the optimum dose of 
autologous adult CD34+ stem cells when infused directly into the coronary circulation 
in ischaemic heart disease. The trial will also seek to determine clinical improvement 
or deterioration by measurement of clinical parameters such as left ventricular 
dimensions. 
7.3 STUDY ENDPOINTS 
7.3.1 Primary endpoints 
To assess the safety of ascending doses of autologous adult stem cells when 
introduced into the coronary arterial circulation and to determine absence of adverse 
events at the optimum dose of CD34+ stem cells. 
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7.3.2 Secondary endpoints 
To assess improvement in cardiac function as measured by imaging modalities and 
determine whether there are any symptomatic improvements as reported by the 
patients. 
7.3.3 Safety endpoints 
The study will be stopped if serious and unexpected adverse events occur that are 
believed to be treatment-related. 
7.3.3.1 Clinical 
Safety will be evaluated in terms of adverse events graded according to CTC toxicity 
criteria and laboratory test results. All adverse events will also be graded for 
relationship to treatment and as expected and unexpected. They will be reported to 
the stem cell group, the appropriate Ethics Committee and regulatory bodies as 
required as well as an independent safety monitoring committee. 
7.3.3.2 Laboratory 
If laboratory results are significantly different from those of previous samples, further 
investigations may be required. Patients may be withdrawn from the study if 
significant deterioration occurs. 
7.4 PATIENT POPULATION 
A maximum of 40 patients will be recruited. 
7.4.1 Inclusion criteria 
Male or female patients aged from 40 years and above 
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A documented localised area of myocardial dysfunction within the left ventricular 
wall 
The infarct area should be supplied by a non-occluded coronary arterial network 
All patients must have a recent coronary angiogram (within the last 6 months) 
Clinical signs and symptoms of ischaernia or heart failure 
Subjects must either be no longer capable of reproduction or use a reliable and 
appropriate contraceptive method during the study 
Normal blood count 
Normal coagulation screen 
Life expectancy of at least 12 months 
Ability to give informed consent 
7.4.2 Exclusion criteria 
Patients below the age of 40 
Patients with a history of hypersensitivity to G-CSF 
Subjects requiring revascularisation on an urgent basis 
Target coronary artery stenosis >50% 
Patients undergoing surgery for concomitant cardiac procedures 
Severe co-morbidity associated with a reduction in life expectancy to less than I year 
Lack of ability to obtain vascular access for percutaneous procedures 
Left ventricular aneurysm 
Patients with underlying rhythm disturbances 
Pregnant or lactating women 
Unexplained abnormal baseline laboratory results 
-148- 
Chapter 7 Clinical trial design 
Males and females who are capable of reproduction and will not take acceptable 
measures to prevent reproduction during the study 
Subjects who test positive for HTLV, HIV, hepatitis B or hepatitis C, have a chronic 
inflammatory disease, autoimmune disease or are on chronic immunosuppressive 
medications 
History of alcohol or drug abuse within 3 months of screening 
Subjects with evidence (clinical, laboratory, or imaging) of cancer recurrence within 
the past 5 years (other than non-melanoma skin cancer or in situ cervical carcinoma) 
Currently enrolled in another investigational device or drug trial that has not 
completed the required follow-up period 
Patients unable to give informed consent 
7.5 STUDY DESIGN 
7.5.1 Overview 
The study design is that of a prospective dose escalation study following the 
administration of autologous adult human stem cells in patients with established 
myocardial ischaernia. The chronic nature of patients under consideration translates 
into recruitment taking place from patients already attending the Hammersmith 
outpatient Cardiology clinics. During the first part of the study (non-randomised) 
patients will be allocated to three dose groups, each containing two patients. The first 
six patients to enter the study will be allocated to these three groups in order of 
recruitment. These groups of two patients will receive ascending doses of autologous 
adult human stem cells starting at a dose of IX 107 cells. The cells will be infused into 
the coronary arterial circulation of research participants. A 4-week interval will be 
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allowed between patients during this first phase of the study to assess possible side- 
effects. 
The first patients (01 and 02) will receive IX 107 cells. If no adverse events are 
observed in either patient in the four-week period after stem cell administration, 
patient numbers 03 and 04 will receive IX 108 cells. This will continue through 
patients 05 and 06 receiving 2x 108 cells. If any patient in any cohort suffers adverse 
events considered to be treatment-related, the next group of patients will receive cells 
at a number one step down from that received by the patient suffering the adverse 
events. 
Once this part of the study is completed the second randomised phase of the trial will 
commence. Two groups of eighteen patients will be recruited. The first group will not 
receive treatment, but will continue with best care in the clinic as previously. The 
second group will receive stem cell treatment at the maximum tolerated dose 
determined by the first phase of the study. 
Patients will once again be recruited from the pool of patients already being followed 
at the Hammersmith Hospital who have a documented localised area of myocardial 
dysfunction. Double blind randomisation will take place using established 
randomisation software (Randomizer for Clinical Trials 1.6.0). Each patient recruited 
into the trial will undergo 5 days treatment with a subcutaneous injection of G-CSF at 
a concentration of 5 to 10 ýtg/kg prior to being admitted to hospital for leukapheresis 
for collection of leucocytes. Patients will not be randomised on the basis of being 
able to produce adequate number of stem cells. Even if a patient does not respond to 
mobilisation following G-SCF course he/she will not be transferred to the other leg of 
the study, but will be excluded from subsequent data analysis. The collected 
leucocytes will be treated by immunoselection for collection of CD34+ cells, which 
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will then be expanded in a cell factory under GMP conditions. The expanded CD34+ 
cells will be infused back into the same patient (autologous intracoronary infusion) at 
a set concentration depending upon the patient number within the trial. 
On the day of administration the cells will be labelled with iron oxide allowing the 
location of the cells to be identified by MRI scanning. Labelling of HPCs with iron 
oxides (MR contrast agents) that may be detected with a standard 1.5-T MR imager 
has been previously demonstrated (279). The same researchers were able to monitor 
the in vivo distribution of human iron oxide-labelled HPCs once administered 
intravenously in an experimental small animal model (280). 
A wide range of superparamagnetic iron oxides is available for clinical use. We have 
conducted in vitro work with Resovistg (Schering AG, Berlin, active ingredient: 
Ferucarbotran) and have achieved detectable levels of uptake once stem cells were 
MR imaged. Resovist(V is readily available within the NHS 
(http: //www. dmddownload. nhs. uk/dmd_intro. htm accessed 02/03/2008 16: 39). 
Efficacy will be assessed by physical examination/quality of life assessment and the 
measurement of MRI and Echo scan parameters (ejection fraction and reduction in 
lesion size in the two groups). A detailed pathway for every patient once enrolled in 
the study is provided in table 7.5.1. 
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7.5.2 Duration of study and follow-up 
The total period that each patient will participate in the study is 26 weeks and the total 
duration of this clinical trial is expected to be approximately 24 months. 
All patients will be assessed 4 weeks after coming off study whether from completion 
of the protocol or early withdrawal for whatever reason. They will also be monitored 
in the clinic for the rest of their lives. 
Patients who are withdrawn due to issues of toxicity will be followed until the adverse 
event is resolved or the outcome is known. Patients will then be followed up for four 
weeks after resolution and thereafter for life in the clinic. 
7.5.2.1 Study discontinuation 
Study discontinuation may be authorised under the following conditions: 
Patients may be withdrawn from the study if significant deterioration occurs. 
If serious and unexpected adverse events occur that are believed to be treatment 
related. 
Withdrawal of patient consent 
At the instigation of the Investigator when he/she believes continued participation is 
not in the best interests of the patient. 
At the instruction of the sponsor or the regulatory authority. 
7.5.3 Statistics 
Statistical calculations were undertaken by the Imperial College Statistical Advisory 
Service: A sample size of 18 in each group will have 90% power to detect a 
probability of 0.18 that an observation in Group I (group receiving stem cell therapy) 
is less than an observation in Group 2 (group receiving optimal medical treatment) 
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using a Mann-Whitney with a 0.05 two-sided significance level. In addition, Chi- 
square or Fisher's exact test will be used to compare the categorical variables for 
Quality of Life assessment. 
7.6 MEDICINES AND HEALTHCARE PRODUCTS 
REGULATORY AGENCY AND ETHICS COMMITTEE 
7.6.1 Medicines and Healthcare products Regulatory Agency 
Approval has been granted from the Medicines and Healthcare products Regulatory 
Agency (MHRA) to conduct the clinical trial as described. (Reference: 
22669/0001/001-00019 
HHSC/002) 
Eudract Number: 2006-000280-28, Protocol Number: 
7.6.2 Ethics Committee 
A favourable opinion has been given by the Hammersmith and Queen Charlotte's & 
Chelsea Research Ethics Committee to carry out "A phase 1/11 safety and tolerability 
dose escalation study following the autologous infusion of expanded adult 
haernopoietic stem cells to patients with established myocardial ischaernia". 
(REC Reference: 06/QO406/9 1, Eudract Number: 2006-000280-28) 
7.7 DISCUSSION 
At the time or writing this thesis the clinical trial is in the phase of active recruitment. 
This is the reason for not incorporating any pilot clinical data as initially intended. No 
study to date has provided substantial evidence for any possible mechanisms behind 
the improvements, if seen, in left ventricular function. While it is unlikely that bone 
marrow cells implanted after a recent or old myocardial infarction reconstitute a 
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substantial mass of contracting vascularised myocardium within the infarct border 
(186,190,192), there remains the possibility that revascularization is stimulated by 
endothelial precursors which make up part of the wide variety of progenitor cells 
present in the bone marrow mononuclear fraction. 
The proposed trial is likely to make two significant contributions: 1) a contribution to 
the proof-of-concept data on the potential beneficial effect of HPC therapy to cardiac 
function; and 2) better understanding of the mechanisms involved in determining the 
physical location/retention of the transplanted HSCs within the myocardium. The 
paramagnetic labelling of the HSCs and the subsequent MRI based tracking of the 
transplanted cells is a step which is likely to provide important insight into some of 
the underlying mechanisms. 
Finally another issue that has not been addressed in already published clinical data is 
that of the ideal number of cells to be delivered. The incorporation of dose escalation 
within this study will also provide insight into dose-dependent potential of stem cell 
therapy. 
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Discussion 
Selection of the optimal type of stem cell for delivery is one of the principal issues 
that arise during the design of any experimental or clinical transplantation protocol. 
The debate between crude or pre-selected BM-derived stem cell populations remains 
that of synergy versus specification. By definition crude preparations are less 
concentrated in potent stem cells and encompass a variety of different cell types. This 
in turn may expose subjects to unjustifiable procedure-associated risks with 
potentially unwanted side-effects (281). On the other hand pre-selected populations 
may require to undergo multiple population doublings in vitro prior to delivery in 
order to achieve sufficient cell counts (119). However, prolonged passaging in culture 
is not without concerns; replicative senescence (282), changes in multipotentiality 
(283), and spontaneous transformation (284) have all been associated with long-term 
in vitro culture. 
From a translational perspective the ideal candidate stem cell population must be 
known to exist in vivo and be easily harvested, i. e. form peripheral blood, with a 
known phenotype for prospective isolation. This must be a reproducible procedure 
with no requirement for prolonged cell culture in order to attain required numbers 
rapidly. We have investigated a novel subpopulation of adherent CD34+ stem cells 
that encompasses sufficiently the above. In addition, the candidate subpopulation of 
CD34+ cells may provide a population enriched in EPCs following appropriate 
cytokine stimulation in vitro. 
Studies have shown the connection between angioblasts residing within the bone 
marrow and neovascularization (107,108). The spectrum of ischaemic disease in 
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which treatment with EPCs may be beneficial ranges from peripheral vascular disease, 
as demonstrated by experimental hind limb ischaernia models (285,286), to 
myocardial ischaernia (152,245). CD34' cells have also been shown to improve 
blood flow in diabetic mice undergoing neovascularization due to hindlimb ischemia 
(287). EPCs have already entered the clinical trial setting with encouraging results. 
Intramuscular injection of BM mononuclear cells containing a CD34+ fraction into 
ischaernic limbs of patients led to increased blood flow in all patients randomly 
allocated to receive this treatment, compared to legs receiving peripheral blood 
mononuclear cells containing much smaller numbers of EPCs (288). Significant 
improvement in both left ventricular function and myocardial perfusion was reported 
by echocardiography and thallium scans following intramyocardial implantation of 
autologous CD133+ cells (169). In the TOPCARE AMI trial patients were allocated to 
two groups depending on the type of progenitor cell infused intracoronary, being 
either BM-derived or circulating progenitor cells (177). A significant improvement in 
left ventricular function with reduction of end-systolic volumes was documented for 
both goups. 
The percentage of EPCs in peripheral blood is well below I% with no specific targets 
for prospective immunoselection to date. The potential for expanded adherent CD34+ 
cells to act as an enriched endothelial progenitor population is extremely promising. 
Future work will include stimulation of the non-adherent fraction of the CD34+ stem 
cells in parallel with adherent cells as discussed in chapter 4. 
The existence of cardiac progenitor cell populations within the body is probably one 
of the most important 'discoveries' in the field of myocardial regeneration. Based on 
their anatomical location two distinct populations have been described. The first 
resides within the postnatal myocardium and can be identified by the expression 
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various markers such as the transcription factor islet-I (85). Further to this a few 
groups have identified and described cells expressing early cardiac markers residing 
within adult human BM (20). The mere expression of early cardiac markers does not 
obviously translate in "cardiomyogenic" potential. In knockouts of GATA-4, Nkx2.5, 
or MEF2C cardiac myocytes continue to arise (248). Acquisition of a certain 
phenotype does not solely rely on gene interaction as much as on the complex 
interactions between the components of the entire developmental matrix. The 
multidirectional communication avenues between cells, growth factors, extracellular 
matrix and physical stimuli form the basis for this conclusion. 
It appears that the differentiation pathways follow an instructive pattern; all stimuli 
lead to activation of genetic transcripts via cascades already present within cells. 
Evidence is provided by the demonstration of embryonic as well as adult stem cells 
differentiating into cardiomyocyte lineage phenotypes in vitro without stimulation. Of 
utmost significance is cell type definition of starting as well as end populations; not 
only should potent subpopulations be identified in order to increase yield and 
efficiency, but full characterization of the final cell product should be carried out in 
order to delineate targeted differentiation as much as to avoid unwanted side-effects 
(transplantation of pacemaker-type cells in ventricular tissue leading to arrhythmia 
generation). As the majority of stimuli reviewed herein appear to be time- and dose- 
dependent, besides being interconnected, the application of a process similar to 
combinatorial chemistry may prove extremely useful in identifying these very fine 
relationships (289). Main limiting factor for applying such processes within our study 
was restricted supply of human cells. Although we were unsuccessful in identifying 
transcripts for terminally differentiated cardiac proteins, quantitative real-time PCR 
will be the next screening process for cells stimulated under various conditions. Initial 
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assessment will include monitoring for upregulation of cardiac transcription factors 
that may indicate triggering of previously silent genes. 
Local inflammation or failure to 'home' to the site of injury may affect post- 
transplantation survival rates. Mode of delivery and phase of injury are crucial 
determinants in this process. It is therefore only reasonable to accommodate for these 
loses when calculating absolute numbers of delivered cells in any study design. If the 
desired effect is attributed to a certain subpopulation expansion ex vivo may be 
required to achieve adequate number of progenitors and avoid delivering suboptimal 
cell counts. In this context, studies with studies where a very small amount of whole 
bone marrow is delivered and no control groups exist should be perceived with 
caution, as the final effective population of cells delivered may be negligible. Our 
experiments did not detect an effective expansion protocol. At present we are 
investigating the role of the HOXB4 homeoprotein in order to achieve higher cell 
counts prior to transplantation (290). 
The experimental animal data were encouraging for improvement in cardiac function 
and engrafting of the transplanted cells within the host myocardium. In the next phase 
of rodent experimentation a less invasive approach such as tail vein injection of stem 
cells will be employed to assess the candidate stem cell population's ability of homing 
to injury. A large animal model will allow for more efficient functional assessment 
and cell tracking. A myocardial ischaemia protocol with a porcine model of 
myocardial ischaernia has been designed for this purpose. 
Delivery of bone marrow progenitor cells via either an intracoronary route using an 
intermittently occlusive percutaneous catheter or direct injections into the 
myocardium during concomitant CABG is relatively safe and does not often cause 
significant adverse events such as arrhythmias or procedure-related myocardial 
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infarction. However, the actual efficacy in improving cardiac pump function is either 
small but significant, or no more efficacious than standard medical treatment. 
Therefore, BM cell implantation into the heart cannot yet be advocated as a viable 
alternative or adjunct to current best medical and surgical therapy. Hopefully the 
clinical trial will demonstrate functional recovery in subjects as well as provide 
further information regarding stem cell fate after delivery. 
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APPENDIX 1 
Primer sequence and PCR conditions for genes used 
Gene accession RT-PCR PRIMERS NESTED PRIMERS 
Homo sapiens GATA NM002052 TTCCAGCAACTCCAGCAACG CCTGTCATCTCACTACGG(1625) 
binding protein 4 (GATA4) (1556) AGACGCATAGCCTTGTGG (1754) 
GTTGTTCTGGAGTCATTACC 
(1965) 
Homo sapiens NK2 BC025711 AGGACCCrAGAGCCGAAAAG(311) GCCGAAAAGAAAGAGCTGTG(322) 
transcription factor GCTCTGAACCGCATTCAAGT(915) ATAGGCGGGGTAGGCGTTAT (768) 
related, locus 5 
(Drosophila 
Homo sapiens natriuretic BC005893 ATGAGCTCCTTCTCCACCAC(1) TTACTGGCATTCCAGCTCCT(40) 
peptide precursor A TCGGTACCGGAAGCTGTTAC(456) TTGCTTTTTAGGAGGGCAGA (341) 
Homo sapiens myosin, N M002471 CAAGAAGAGGAGTGAGGC(500) TCTTCTCCATCTCCGACAACGC 
heavy polypepticle 6, ACTTCTCCAGCAGGTAGG (882) (529) 
cardiac muscle, alpha CT-rGTTCGCATTGGCATTGTCC 
(710) 
Homo sapiens myosin, NM000257 AAGTCAGAGAAGGAGCGG(138) TCACTGCCGAGACTGAGTATGG 
heavy polypeptide 7, TCTGGTCCTTCTTGCTGC(714) (262) 
cardiac muscle, beta GTTGACGGTGACACAGAAGAGG 
(464) 
Human Cardiac troponin I X54163 AAGGTGGATGAAGAGAGATACG AAGAGAGATACGACATAGAGGC 
(405)ATGTTCTTCCGCCAGTCTCC (415) 
(673) TGTCCTCCTTCTTCACCTGC(630) 
Homo sapiens ventricular X57542 TGGCACCTAAGAAAGCAAAGA(2) CAGAACAGGGATGGCTTCAT (112) 
myosin light chain 2 TTCTCTTCTCCGTGGGTGAT (491) TC-FGGTCAACCTCC`TCCTT (409) 
Human atrial myosin light X13955 AAGAAGCCTGAGCCTAAGAAGG TAAGAAGGAGGCAGCCAAGC(86) 
chain 1 (72) TAACTCTTCAATCTGC`TCGG (230) 
ACATTCATCTCTTCAGGCTTGG 
(385) 
Homo sapiens myocardin NM153604 TATGGACTCAGCCTACGC(843) AGCAGCAACACCGATTCAGC(923) 
(MYOCD) GGAGGCATCATTGAAGGTGTCC TAGAAGCCGTTGGACAGG(1340) 
(1437) 
Homo sapiens MADS box BC054520 CTATGAAGAAGGCGTATGAGCG TGAGCGTGCTATGTGACTGC (494) 
transcription enhancer (472) TGTCGCAGCCATTGAAGC(682) 
factor 2, polypepticle D TAC`TTGTCCTCCAGCAGG (740) 
(myocyte enhancer factor 
2D) 
Homo sapiens MAIDS box BC026341 GATGAAGAAGGCTTATGAGC(510) ATCTTCAACAGCACCAACAAGC 
transcription enhancer CCATCAGACCACCTGTGTTACC (565) 
factor 2, polypepticle C (1027) AACTGTTGTGACTGGACACTGG 
(myocyte enhancer factor (889) 
2C 
Homo sapiens clesmin BC010072 AGGTGCTCACTAACCAGC (570) TTCAGGAACAGCAGG-FCC (831) 
GTGTCGGTATTCCATCATCTCC GTCGTTGTTCTTGTTGGCTGCC 
(1048) (1006) 
Homo sapiens cadherin 5, NM001795 TAGGCATAGCATTGGATACTCC GAACTGGACAGAGAAGTCTACC 
type 2, VE-cadherin (1323) (1414) 
(vascular AGAGTAAGATGGCTACCAC-FGC GCCGTGTTATCGTGATTATCCG 
epithelium)(CDH5) (1939) (1721) 
Homo sapiens N M_000442 TGACGGAATCCTTCTCTACACC AGCACAGTGGCAACTACACG 
platelet/enclothelial cell (879) (1083) 
adhesion molecule (CD31 ACGACTATCTGGACTGTGTTGC ATCGTATCTFCCTTCTGGATGG 
antiqen) (PECAM1) (1404) (1287) 
Homo sapiens NM001146 
angiopoietin I (ANGPT1), 
transcript variant I 
Homo sapiens NM139290 CTGCCATTCTGACTCACATAGG CAGAACACGATGGCAAC`TGTCG 
angiopoietin 1 (ANGPT1), (500) (611) 
transcript variant 2 TGAAGGACACTGTTGTTGGTGG AGGCTGGTTCCTATCTCC (869) 
(1211) 1 
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Homo sapiens von NM 000552 00552 CAACAGGACCAACACTGG (5029) TACCTCTCTGACCACAGC(5060) 
Willebrand factor(VWF) CGTCAATGGTGGTGATGCTTCC GGTGGTGATGCTTCCATACTGC 
(5537) (5530) 
Homo sapiens kinase NM_002253 TATGATGTGGTTCTGAGTCC(973) ACACTGTCATCCTTACCAATCC 
insert domain receptor (a GGAGGAATGGCATAGACC (1658) (1490) 
type III receptor tyrosine GAGGAATGGCATAGACCG (1657) 
kinase) (KDR) 
Homo sapiens actinin, BC047901 ATGAGATTCGGAGACTGGAGCG TCAACGCACGAGACTTGG(1383) 
alpha 2 (1324) -FTCTCrCCTCTTCrGAGTAAGC 
CTGAATCACCTTCTCCACCTCG (1658) 
(1913) 
Homo sapiens nebulin N M004543 GCCAACTACAGACAGTCATACC TCATACCACCACTACACTCTCC 
(NEB) (5337) (5352) 
TGTGGAAGGAGGTCTTGG (6009) AAGTGCCTGTTCCATTGTGTCC 
(5606) 
Homo sapiens clesmin NM001927 TGGAGGTGCTCACTAACC (497) TTCAGGAACAGCAGGTCC (761) 
(DES) GTGTCGGTATTCCATCATCTCC ATTCCATCATCTCCTGCTrGGC 
(978) (970) 
Homo sapiens selectin P NM003005 AGAGAGTGTGGAGAACTTGAGC ATGCTTGGCTTCFGGAATCTGG 
(granule membrane (592) (729) 
protein 140kDa, antigen ATAGC. C I CALAGGTTGGCAAGG AGTGAGCGGATGAACACAGTCC 
CD62) (SELP) (1151) (1026) 
Homo sapiens MADS box NM005587 TGAACAAGAAGGAACACAGAGG AC-FACAGACCTCACAGTGCC(631) 
transcription enhancer (263) TCATTCCAAGATTACCACCACC 
factor 2, polypeptide A ATTCCTCTTCCTCCGATAGTGG (799) 
(myocyte enhancer factor (880) 
2A) (MEF2A) 
Homo sapiens natriuretic NM006172 GGATTTCAAGAATTTGCTGGAC GGAT7TCAAGAATTTGCTGGAC 
pepticle precursor A (213) (213) 
(NPPA) GGAAGTCACCATCAAACCACTT CTCCCTGGCTGTTATCTTCAGT 
(752) (572) 
Homo sapiens calponin 1, NM001299 TGTCCTCTGC-FCACTTCAACCG(2) TGTCCTCTGCTCACTTCAACCG(2) 
basic, smooth muscle GATGAAGTTGCCGATGTTCTCC TGAAGTTGTTGCCGATGCGACG 
(CNN1) (276) (151) 
H. sapiens titin protein X90568 AACACCACCGTCTATTGCTGCC CCATCAGGTCTGTTAGGTCTCC 
(clone hhl-hh54) (798) (950) 
ATCACTGGTTCTCTCACTCTGG TCAACGGCAGCAACAACAGTCG 
(1328) (1301) 
Homo sapiens NM002667 CTGCCAAGGCTACCTAAAAGAA GCTGGTATCATGGAGAAAGTCC 
phospholamban (PLN) (72) (173) 
TATTGTTTTCCTGTCTGCATGG CTGCA I U(j(jA I bACAGATT71-A 
(419) (405) 
Homo sapiens Tie-2 AB086825 TCAAGATGTGACCAGAGAATGG GAGGAGAGGCAATCAGGATACG 
mRNA for receptor (331) (426) 
protein tyrosine kinase ATCCTCGGTATGCCTTCATTGC AGTTCACAAGCCTTCTCACACG 
(1020) (876) 
Homo sapiens chemokine NM003467 GTCAACCTCTACAGCAGTGTCC CCTTCATCAG-FCTGGACC (471) 
(C-X-C motif) receptor 4 (440) TGTAGTAAGGCAGCCAACAGGC 
(CXCR4) TTCCAGGAGGATGAAGGAGTCG (857) 
(892) 
Homo sapiens T-cell NM_003189 GAGATGGAGATTACTGATGG AGTTGTGCGGCGTATCTTCACC 
acute lymphocytic (1100) (1132) 
leukemia 1 (TAL1) TCCTCCTGGTCATTGAGC(1320) TCCTGG I CA II UAUCAGC (1317) 
Homo sapiens NM000873 AAGATTCTGCTGGACGAACAGG AATGCCACTTCACCTGCTCC(325) 
intercellular adhesion (252) GAGACATCAAGTCCAGCACAGC 
molecule 2 (ICAM2) CACCACCGTGACTATGATGACC (651) 
(749) 
Homo sapiens vascular NM003376 ATTGGAGCC-FFGCCTTGC (1064) TTGCCTTGCTGCTCTACC (1073) 
endothelial growth factor GCTCATCTCTCCTATGTGCTGG GTGATGTTGGACTCCTCAGTGG 
(VEGF) (1401) (1346) 
Homo sapiens CD34 BC039146 GAAGCCTAGCCTGTCACCTG(402) TGCAACATCTCCCAC-FAAACC(459) 
antigen TCCACCGTTTTCCGTGTAAT(1005) GAATAGCTCTGGTGGCTTGC 
I . 
(860 ) 
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Homo sapiens NM001147 TGGTAGAGATACAGCAGAATGC TGGTAGAGATACAGCAGAATGC 
angiopoietin 2 (675) (675) 
(ANGPT2) TTGGATGATGTGCTTGTCTTCC AATCAACGCTGCCATCCTCACG 
(964) (1352) 
Homo sapiens NK2 NM004387 
transcription factor 
related, locus 5 
(Drosophila)(NKX2-5) 
Homo sapiens selectin E NM000450 TGGAGCCTGGTCTTACAACACC GCTATGACT-FATGATGAGGC (204) 
(endothelial adhesion (173) GGTCTCTACACATTCACCGTGG 
molecule 1) (SELE) AGCACTCCATTCTCCAGAGG (812) (587) 
Homo sapiens nitric NM000620 CTACAAGGTCCGATTCAACAGC TCTCCTCCTACTCTGACTCC(2558) 
oxide synthase 1 (2535) TTGTGGACATTGGATAGACC(2981) 
AGACGk_. AUUAAUAl'AGTTGACC 
(3065) 
Homo sapiens tyrosine NM005424 CTATGGCTGCTCTTGTGG(864) AAGCCAGTGCCAAGAAGC(897) 
kinase with ACTGTCCGCAAGAACCAAGC(1263) GTCTTCTCTGGCTCCACAATGG 
immunoglobulin-like (1220) 
and EGF-like 
domains 1 (TIE1) 
Homo sapiens GATA NM002052 TAATCTFCCCTCTTCCCTCCTC GAAGTCGACAATCTGGTTAGGG 
binding protein 4 (1845) (1982) 
(GATA4) TGTATGTCACACCCCACAATTT 
(2382) 
Homo sapiens GATA NM002052 CTCCTACTCCAGCCCCTACL(468) ATGGGACGGGTCACTATCTG (692) 
binding protein 4 TCGCACTGACTGAGAACGTC(11651 CTGTGCCCGTAGTGAGATGA(11301 
(GATA4) 
Human ATP synthase D16562 TTATTGGTGTGTCCTCAGATCG TGTGTGGTGCTATTCATTCCTC 
gamma-subunit (L-type) (309) (336) 
CTC-IT17G-rGATGACAGC17GG TGATG17GGCCAGATTGTATTC 
(889) (743) 
Homo sapiens connexin AF151980 TCTATG-FGATGCGAAAGGAAGA AAACTGATGGTGTCAATGTGGA 
43(CX43)gene (290) (350) 
AGTAACCAGCTTGTACCCAGGA TTAACGCCCTTGAAGAAAACAT 
(870) (710) 
TTCGTTGTAACACTCAGCAACC TCTATGTGATGCGAAAGGAAGA 
(155) (290) 
TTAACGCCCTTGAAGAAAACAT AGAGAGGAAACAGTCCACCTGA 
(710) (603) 
Homo sapiens AC133 
antigen 
AF027208 TACAACACTACCAAGGACAAGG 
(692) 
TCAGCAGAGAGCAGATGACC (1373) 
ACAATGTAACTCAGCGTCTTCC 
(1218) 
AGAGAGCAGATGACCAGG (1368) 
Typical RT-PCR is 500C 1hr, 950C 3min, (950C 1min, 620C Imin, 720C 1min 
for 35 cycles), 720C 10min and typical nested PCR condition is 950C 3min, 
(950C 1min, 620C Imin, 720C 1min for 35 cycles), 720C 10min. 
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Probesets 
Gene 
Symbol Gene Title ftest 
Fold 
change 
- untreated VS treated with 5- 
aza 
201427 s at SEPP1 selenoprotein P, plasma, 1 0.04273 -13.067 
202388 at RGS2 regulator of G-protein signalling 2,24kDa 0.00123 -7.997 
209395 at CH131-1 chitinase 3-like 1 (cartilage glycoprotein-39) 0.01841 -7.823 
209396 s at CH131_1 chitinase 3-like 1 (cartilage glycoprotein-39) 0.03414 -6.924 
204271 S at EDNRB endothelin receptor type B 0.00872 -5.865 
243296 at PBEF1 
_ _Pre-B-cell 
colony enhancing factor 1 0.00598 -5.783 
216950 s at FCGR1A Fc fragment of IgG, high affinity la, receptor (CD64) 0.02951 -5.603 
205922 at VNN2 vanin 2N vanin 2 0.00344 -5.508 
205119 s at FPR1 
formyl peptide receptor 1 /// formyl peptide receptor 
1 0.03984 -5.233 
214511 x at FCGR1B Fc fragment of IgG, high affinity lb, receptor (CD64) 0.01706 -4.970 
228285 at TDRD9 tudor domain containing 9 0.02186 -4.687 
1553706 at HTRA4 HtrA serine peptidase 4 0.02321 -4.524 
212158 at SDC2 
syndecan 2 (heparan sulfate proteoglycan 1, cell 
surface-associated, fibroglycan) 0.01810 -4.519 
217739 s at PBEF1 pre-B-cell colony enhancing factor 1 0.02529 -4.493 
208146 S at CPVL 
carboxypeptidase, vitellogenic-like /// 
carboxypeptidase, vitellogenic-like 0.00788 -4.388 
209189 at FOS 
v-fos FBJ murine osteosarcoma viral oncogene 
homolog 0.02021 -4.108 
229560 at TLR8 toll-like receptor 8 0.04336 -4.070 
217738 at PBEFI pre-B-cell colony enhancing factor 1 0.01756 -4.012 
212560 at C1 1 orf32 chromosome 11 open reading frame 32 0.00269 -4.007 
212956 at TBC 1 D9 
TBC1 domain family, member 9 (with GRAM 
domain) 0.02102 -4.003 
203066 at 
GALNAC4S- 
6ST B cell RAG associated protein 0.01803 -3.834 
210423 s at SLC1 W 
solute carrier family 11 (proton-coupled divalent 
metal ion transporters), member 1 0.01623 -3.805 
200665 s at SPARC 
secreted protein, acidic, cysteine-rich (osteonectin) 
/// secreted protein, acidic, cysteine-rich 
(osteonectin) 0.03144 -3.700 
205568 at A QID 9 aquaporin 9 0.00682 -3.698 
225897 at --- Homo sapi ns, clone IMAGE: 5547644, mRNA 0.02815 -3.658 
229228 at CREB5 cAMP responsive element binding protein 5 0.02983 -3.632 
201005 at CD9 CD9 molecule 0.03720 -3.567 
1559776 at --- CDNA FLJ36989 fis, clone BRACE2006753 0.04390 -3.555 
210166 at TLR5 toll-like receptor 5 0.01048 -3.513 
225579 at PQLC3 PQ loop repeat containing 3 0.03621 -3.483 
231697 s at TMEM49 Transmembrane protein 49 0.03643 -3.481 
1566342 at --- Transcribed locus 0.03939 -3.460 
202464 s at PFKFB3 
6-phosphofructo-2-kinase/fructose-2,6- 
biphosphatase 3 0.01635 -3.331 
226039 at MGAT4A 
mannosyl (alpha- 1,3-)-g lycoprotein beta-1,4-N- 
acetylglucosaminyltransferase, isozyme A 0.04086 -3.329 
1569003 at TMEM49 transmembrane protein 49 0.03866 -3.258 
204099 at SMARCD3 
SWl/SNF related, matrix associated, actin 
dependent regulator of chromatin, subfamily d, 
member 3 0.00285 -3.247 
205237 at FCN1 ficolin (collagen/fibrinogen domain containing) 1 0.04904 -3.208 
228758 at BCL6 B-cell CLUlymphoma 6 (zinc finger protein 51) 0.03424 -3.105 
207610 s at - , 
EMR2 
egf-like module containing, mucin-like, hormone 
_ 
0.01102 -3.076 - 
383 at 
r=2 
2 9 
ýýDNA FELýJý34016 fis, clone FCBBFý20025141 
... 
J C, ' 
_OQ. 
02727 -3.073 
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206028 s at MERTK c-mer proto-oncogene tyrosine kinase 0.01907 -3.057 
201670 s at MARCKS 
myristoylated alanine-rich protein kinase C 
substrate 0.04943 -3-052 
208771 s at LTA4H leukotriene A4 hydrolase 0.03206 -3.004 
228497 at SLC22A15 
solute carrier family 22 (organic cation transporter), 
member 15 0.03374 -3.001 
229635 at --- CIDNA clone IMAGEA800262 0.03222 -2.987 
1555167 s at PBEF1 pre-B-cell colony enhancing factor 1 0.03799 -2.974 
219574 at 01-Mar membrane-associated ring finger (C3HC4) 1 0.03216 -2.953 
215891 s at GIV12A GM2 ganglioside activator 0.04828 -2.947 
204567 s at ABCGII 
ATIP-binding cassette, sub-family G (WHITE), 
member 1 0.02331 -2.901 
203509 at SORL1 
sortilin-related receptor, L(DLR class) A repeats- 
containing 0.00059 -2.896 
223454 at CXCL1 6 chemokine (C-X-C motif) ligand 16 0.04946 -2.841 
214693 x at 
CALCA /// 
CALCB M 
NBPF14 N 
DKFZP564008 
23 W NBPF1 N 
PARD313M 
KIAA1245 N 
NBPF1 1 
NBPF 15 
NBPF20 
NBPF9 N 
NBPF10M 
NBPF8 N 
LOC728936 
LOC728980 
LOC730476 
calcitonin/calcitonin-related polypeptide, alpha M 
calcitonin-related polypeptide, beta M 
neuroblastorna breakpoint family, member 14 
DKFZP56400823 protein /// neuroblastorna 
breakpoint family, member 1N par-3 partitioning 
defective 3 homolog B (C. elegans) /// KIAA1 245 N 
neuroblastoma breakpoint family, member 11 /// 
neuroblastoma breakpoint family, member 15 N 
neuroblastorna breakpoint family, member 20 N 
neuroblastorna breakpoint family, member 9N 
neuroblastorna breakpoint family, member 10 N 
neuroblastorna breakpoint family, member 8N 
similar to CGII 0522-PA N hypothetical protein 
LOC728980 N hypothetical protein LOC730476 0.00188 -2.826 
228188 at --- --- 0.00345 -2.826 
218319 at PELI 1 pellino homolog 1 (DrosoPhila) 0.01708 -2.814 
212587 s at PTPRC protein tyrosine phosphatase, receptor type, C 0.01245 _ -2.809 
203651 at ZFYVE16 zinc finger, FYVE domain containing 16 0.04995 -2.796 
226137 at --- 
MRNA; cDNA DKFZp566MO947 (from clone 
DKFZp566MO947) 0.01924 -2.787 
215716 s at ATP2131 ATPase, Ca++ transporting, plasma membrane 1 0.00204 -2.748 
214719 at LOC283537 hypothetical protein LOC283537 0.04110 -2.748 
203973 s at CEBPD CCAAT/enhancer binding protein (C/EBP), delta 0.03953 -2.743 
203591 s at CSF3R 
colony stimulating factor 3 receptor (granulocyte) 1H 
colony stimulating factor 3 receptor (granulocyte) 0.04112 -2.738 
211795 s at FYB FYN binding protein (FYB-120/130) 0.00155 -2.722 
226804 at FAM20A family with sequence similarity 20, member A 0.01063 -2.712 
238429 at TMEM71 transmembrane protein 71 0.00352 -2.710 
217028 at CXCR4 chemokine (C-X-C motif) receptor 4 0.00200 -2.707 
219471 at C1 3orfl 8 chromosome 13 open reading frame 18 0.01409 -2.690 
214770 at MSR1 macrophage scavenger receptor 1 0.02155 -2.678 
201963 at ACSL1 acyl-CoA synthetase long-chain family member 1 0.02137 -2.667 
1554503 a at OSCAR osteoclast-associated receptor 0.04981 -2.645 
219452 at DPEP2 dipeptidase 2 0.01075 -2.629 
201940 at CIPID carboxypeptidase D 0.00657 -2.608 
203760 s at SLA Src-like-adaptor N Src-like-adaptor 0.03126 -2.601 
208982 at PECAM1 
platelet/endothelial cell adhesion molecule (CD31 
antigen) 0.02102 -2.596 
1553723 at GPR97 G protein-coupled receptor 97 0.01247 -2.574_ 
227930 at EIF2C4 Eukaryotic translation initiation factor 2C, 4 0.00372 -2.554 
226142 at GLIPRI GLI pathogenesis-related 1 (glioma) 0.04666 -2.552 
225016 at APCDD1 adenomatosis polyposis coli down-regulated 1 0.00654 -2.545 
205627 at CDA cytidine deaminase 0.02112 -2.534 
204961 s at 
NCF1 
NCF1Bffl 
N F1C 
neutrophil cytosolic factor 1, (chronic 
granulornatous disease, autosomal 1) N neutrophil 
cytosolic factor 1B pseudogene /// neutrophil 
cytosolic factor 1C pseudogene 0.01051 -2.530 
1558924 s at RSN 
I 
restin (Reed-Steinberg cell-expressed intermediate 
filament-associated pro ein) 
1 
0.01828 
1 
-2.519 
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211911 X at HLA-B 
major histocompatibility complex, class 1, BM major 
histocompatibility complex, class 1, B 0.01349 -2.516 214683 s at CLK1 CDC-like kinase 1 0.01550 -2.511 229373 at --- Transcribed locus 0.01106 -2.509 228153 at IBRDC2 OR domain containing 2 0.02672 -2.495 216268 s at JAG1 Jagged 1 (Alagille syndrome) 0.04088 -2.494 235798 at --- --- 0.03165 -2.484 222218 s at PILRA paired immunoglobin-like type 2 receptor alpha 0.04147 -2.479 228094 at AMICA1 adhesion molecule, interacts with CXADR antiqen 1 0.03231 -2.476 
203508 at TNFRSF1B 
tumor necrosis factor receptor superfamily, member 
1B 0.04586 -2.474 
238327 at 
GCLM /// 
LOC440836 
glutamate-cysteine ligase, modifier subunit N 
similar to MGC52679 protein 0.03234 -2.467 205997 at ADAM28 ADAM metal lopeptidase domain 28 0.03860 -2.460 1554406 a at CLEC7A C-type lectin domain family 7, member A 0.04974 -2.459 212794 s at KlAA1 033 KIAA1033 0.01727 _ -2.455 227152 at C12orf35 chromosome 12 open reading frame 35 0.02943 -2.451 212386 at --- CDNA FLJ1 1918 fis, clone HEMBB1 000272 0.00032 -2.443 205285 s at FYB FYN binding protein (FYB-120/130) 0.00722 _ -2.432 242405 at MAML2 Mastermind-like 2 (Drosophila) 0.01840 -2.432 
207111 at EMR1 
egf-like module containing, mucin-like, hormone 
receptor-like 1 0.00478 -2.429 
202336 s at PAM peptidylglycine alpha-amidating monooxygenase 0.04447 -2.422 
208944 at TGFBR2 
transforming growth factor, beta receptor 11 
(70/8OkDa) 0.04522 -2.422 
225524 at ANTXR2 anthrax toxin receptor 2 0.04695 -2.410 
214500 at H2AFY H2A histone family, member Y 0.04842 -2.409 
222572 at PPM2C 
protein phosphatase 2C, magnesium-dependent, 
catalytic subunit 0.01856 1 -2.393 
208981 at PECAM1 
platelet/endothelial cell adhesion molecule (CD31 
antigen) 0.00903 -2.391 
223940 x at MALAT1 
metastasis associated lung adenocarcinoma 
transcript 1 (non-coding RNA) 0.02883 -2.390 
231600 at CLEC12B C-type lectin domain family 12 member B 0.03003 -2.377 
229287 at --- 
Full-length cDNA clone CSODKO1 OYA20 of HeLa 
cells Cot 25-normalized of Homo sapiens (human) 0.00352 -2.374 
117 at HSPA6 heat shock 70kDa protein 6 (HSP70B') 0.01855 -2.363 
1559034 
- at 
SlRPB2 signal-regulatory protein beta 2 0.03593 -2.361 
235457 at MAML2 mastermind-like 2 (Drosophila) 0.03782 -2.356 
203778 at MANBA mannosidase, beta A, lysosomal 0.03886 -2.351 
210119 at KCNJ15 
potassium inwardly-rectifying channel, subfamily J, 
member 15 0.02839 -2.345 
224568 X at MALAT1 
metastasis associated lung adenocarcinoma 
transcript 1 (non-coding RNA) 0.01387 -2.344. 
208729 x at 
- HLA-13 major histocompatibility complex, class 1, B 0.02056 -2.343_ 
200904 at 
- HLA-E major histocompatibility complex, class 1, E 0.03473 -2.341 
210075 at 02-Mar membrane-associated ring finger (C3HC4) 2 0.02402 -2.331 
229584 at LRRK2 leucine-rich repeat kinase 2 0.04364 -2.321 
229510 at NYD-SP21 MS4A13 protein 0.04520 -2.313 
226106 at RNF141 ring finger protein 141 0.04695 -2.312 
229101 at LOC150166 Hypothetical protein LOC 150166 0.02373 -2.309 
219546 at BMP2K BMP2 inducible kinase 0.01957 -2.307 
206765 at KCNJ2 
potassium inwardly-rectifying channel, subfamily J, 
member 2 0.01354 -2.305 
206701 x at EDNRB endothelin receptor type B 0.04742 -2.305 
209459 s at ABAT 4-aminobutyrate aminotransferase 0.03593 -2.304 
226136 at GLIPR1 GLI pathogenesis-related 1 (glioma) 0.04832 -2.303 
235009 at FAM44A family with sequence similarity 44, member A 0.00757 -2.301 
239571 at MEF2A 
MAIDS box transcription enhancer factor 2, 
polypeptide A (myocyte enhancer factor 2A) 0.01299 -2.300 
203979 at CYP27A1 
cytochrome P450, family 27, subfamily A, 
polypeptide 1 0.02402 -2.293 
215313 X at HLA-A ý®r histocompatibility complex, class 1, A 0.02297 -2.291 
204981 at SL 22A18 
ým 
s( Sol ute carrier family 22 (organic cation transporter), 0.02250 -2-290 
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member 18 
224567 x at MALAT1 
metastasis associated lung adenocarcinoma 
transcript 1 (non-coding RNA) 0.02349 -2.287 
203547 at CID4 CID4 molecule /// CID4 molecule 0.01960 -2.286 
211794 at FYB FYN binding protein (FYB-120/130) 0.01072 -2,283 
202651 at LPGAT1 lysophosphatidylglycerol acyltransferase 1 0.04455 -2.283 
208792 s at CLU clusterin 0.04184 -2.276 
220404 at GPR97 G protein-coupled receptor 97 0.03353 -2.273 
208835 s at CROP 
cisplatin resistance-associated overexpressed 
protein 0.01895 -2.272 
210254 at MS4A3 
membrane-spanning 4-domains, subfamily A, 
member 3 (hematopoietic cell-specific) 0.03647 -2.266 
223591 at RNF135 ring finger protein 135 0.04085 -2.264 
226277 at COL4A3BP 
Collagen, type IV, alpha 3 (Goodpasture antigen) 
binding protein 0.04062 -2.259 
200905 x at HLA-E major histocompatibility complex, class 1, E 0.04067 -2.258 
223502 s at TNFSF13B 
tumor necrosis factor (ligand) superfamily, member 
13b 0.03602 
_ 
-2.258 
35626 at SGSH N-su Ifog I ucosa mine sulfohydrolase (sulfamidase) 0.03019 -2.256 
214459 x at HLA-C major histocompatibility complex, class 1, C 0.04145 -2.249_ 
225056 at SIPA11_2 signal-induced proliferation-associated 1 like 2 0.03876 -2.24 1_ 
227040 at RIP I 1-50D 16.3 similar to RI KEN cDNA 8030451 K01 0.00380 -2.239 
204118 at CD48 CD48 molecule /// CD48 molecule 0.03382 -2.220 
208488 s at CRII 
complement component (3b/4b) receptor 1 (Knops 
blood group) 0.01291 -2.215 
203278 s at PHF21A PHD finger protein 21A 0.01261 -2.213. 
216563 at ANKRD12 Ankyrin repeat domain 12 0.01483 -2.211 
226425 at RSNL2 restin-like 2 0.04344 -2.197 
241353 s at KIAA0773 KIAA0773 gene product 0.01020 -2.191 
59644 at BMP2K BMP2 inducible kinase 0.02349 -2.182 
225230 at TMEM77 transmembrane protein 77 0.01344 -2.176 
205931 s at CREB5 cAMP responsive element binding protein 5 0.01611 -2.173 _ 
238320 at TncRNA trophoblast-derived noncoding RNA 0.00891 -2.172 _ 
208812 x at 
HLA-C 
LOC732037 
major histocompatibility complex, class 1, CN 
similar to major histocompatibility complex, class 1, 
C 0.04020 -2.171 
243222 at ALPKII Alpha-kinase 1 0.02588 -2.169 
229937 x at LILRB1 
Leukocyte immunoglobulin-like receptor, subfamily 
B (with TM and ITIM domains), member 1 0.03923 -2.159_ 
223553 s at DOK3 docking protein 3 0.02606 -2.155 
230214 at MRVI1 murine retrovirus integration site 1 homolog 0.00421 -2.14 
8_ 
224698 at FAM62B 
family with sequence similarity 62 (C2 domain 
containing) member B 0.04588 -2.146 
220466 at CCDC15 coiled-coil domain containing 15 0.02150 
201943 s at CPD carboxypeptidase D 0.00476 -2.127 
1554153 a at PHF21A PHD finger protein 21A 0.02817 -2.126 
204994 at MX2 myxovirus (influenza virus) resistance 2 (mouse) 0.02572 -2.12' 
223058 at FAM107B family with sequence similarity 107, member B 0.04088 -2.119 
1558173 a at LUZP1 leucine zipper protein 1 0.00829 -2.117 
1558569 at MAML2 Mastermind-like 2 (Drosophila) 0.00664 -2.112 
221511 x at CCPG1 cell cycle progression 1 0.03246 -2.099 
202990 at PYGL 
phosphorylase, glycogen; liver (Hers disease, 
glycogen storage disease type VI) 0.04666 -2.097 
202191 s at GAS7 qrowth arrest-specific 7 0.01982 -2.092. 
225956 at LOC 153222 adult retina protein 0.04976 -2.090_ 
209515 s at RAB27A RAB27A, member RAS oncogene family 0.04393 -2.082 
224611 s at DNAJC5 DnaJ (Hsp40) homolog, subfamily C, member 5 0.02120 -2.081 
218223 s at 
228624_at 
214681 at 
202192 s at r2 -3 -3-1,7 
7sat 
PLEKHO1 
TMEM144 
GK 
GAS7 
PNKD 
pleckstrin homology domain containing, family 0 
member 1 
transmembrane protein 144 
qlycerol ki ase 
qrowth arrest-specific 7 
paroxysmal nonkinesiogenic dyskinesia 
0.00427 
0.02629 
0.00721 
0.04622 
0.00172 
-2.080 
-2.079 
-2.073 
-2.071 
-2.069 
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227792 at LOC162073 Hypothetical protein LOC162073 0.04330 -2.068 204806 x at 
_ 
HLA-F major histocompatibility complex, class 1, F 0.00257 -2.066 227929 at --- CDNA clone IMAGE: 5277945 0.00860 -2.064 
229296 at TG ulin 0.00043 -2.057 
227125 at MORB Interleukin 10 receptor, beta 0.01195 -2.050 
242931 at --- --- 0.04487 -2.046 
209960 at HGF 
hepatocyte growth factor (hepapoietin A; scatter 
factor) 0.04714 -2.041 
228617 at BIRC413P XIAP associated factor-1 0.04510 -2.040 
204950 at CARD8 caspase recruitment domain family, member 8 0.03353 -2.040 
221875 x at HLA-F major histocompatibility complex, class 1, F 0.01220 -2.038 203233 at IL4R interleukin 4 receptor 0.04170 -2.036 
222156 x at CCPG1 cell cycle progression 1 0.03580 -2.035 
225041 at HSMPP8 M-phase phosphoprotein, mpp8 0.02802 -2.032 
226068 at SYK Spleen tyrosine kinase 0.01219 -2.021 
222934 s at CLEC4E C-type lectin domain family 4, member E 0.02130 -2.019 
212007 at UBXD2 UBX domain containing 2 0.00428 _ -2.016 
209345 S at P14KII phosphatidylinositol 4-kinase type 11 0.03410 -2.010 
218090 s at BRWD2 bromodomain and WD repeat domain containing 2 0.03508 -2.006 
236583 at GIMAP5 GTPase, IMAP family member 5 0.04831 -2.006 
219229 at SLC03A1 
solute carrier organic anion transporter family, 
member W 0.02730 -2.005 
212993 at --- 
MRNA; cDNA DKFZp667B1718 (from clone 
B1718) 0.04149 -2.004 
1552398 a at CLEC12A C-type lectin domain family 12, member A 0.02078 -1.998 
212496 s at JMJD2B jumonji domain containing 2B 0.02977 -1.997 
223217 s at NFKBIZ 
nuclear factor of kappa light polypeptide gene 
enhancer in B-cells inhibitor, zeta 0.02184 -1.996 
213355 at ST3GAL6 ST3 beta-galactoside alpha-2,3-sialyltransferase 6 0.04602 -1.993 
208130 s at TBXAS1 
thromboxane A synthase 1 (platelet, cytochrome 
P450, family 5, subfamily A) /// thromboxane A 
synthase 1 (platelet, cytochrome P450, family 5, 
subfamily A) 0.03084 -1.990 
242946 at CD53 CD53 molecule 0.03712 -1.989 
208965 s at IF116 interferon, gamma-inducible protein 16 0.02741 -1.988 
210664 s at TFPI 
tissue factor pathway inhibitor (lipoprotein- 
associated coagulation inhibitor) 0.04698 -1.984 
207574 s at GADD45B growth arrest and DNA-damage-inducible, beta 0.04955 -1.983 
204897 at PTGER4 prostaglandin E receptor 4 (subtype EP4) 0.04612 -1.981 
204276 at TK2 thymidine kinase 2, mitochondrial 0.02767 -1.976 
222909 s at BAG4 BCL2-associated athanogene 4 0.04239 -1.971 
1553297 a at CSF3R colony stimulating factor 3 receptor (granulocyte) 0.03603 -1.969 
1554447 at LOC554203 hypothetical LOC554203 0.01554 -1.968 
234701 at ANKRD1 1 ankyrin repeat domain 11 0.03586 -1.965 
207075 at NLRP3 NLR family, pyrin domain containing 3 0.02130 -1.963 
217497 at ECGF1 endothelial cell growth factor 1 (platelet-derived) 0.00450 -1.963 
210873 x at APOBEC3A 
apolipoprotein B mRNA editing enzyme, catalytic 
polypeptide-like 3A 0.00179 -1.959 
203045 at NINA ninjurin 1 0.02249 -1.958 
202604 x at ADAM10 ADAM metal lopeptidase domain 10 0.04345 -1.958 
208700 s at TKT transketolase (Wernicke-Korsakoff syndrome) 0.01793 -1.957 
227785 at SDCCAG8 serologically defined colon cancer antigen 8 0.02342 -1.957 
202323 s at ACBD3 acyl-Coenzyme A binding domain con_aining 3 0.02161 -1.955 
227184 at --- --- 
0.01917 -1.953 
213385 at CHN2 chimerin (chimaerin) 2 0.04149 -1.951 
202197 at MTMR3 myotubularin related protein 3 0.04520 -1.950 
213733 at MY01F myosin IF 0.04243 -1.949 
213280 at GARNL4 GTPase activating Rap/RanGAP domain-like 4 0.04689 -1.946 
215856 at CD331_3 CD33 molecule-like 3 0.03400 -1.945 
230263 s at DOCK5 dedicator of cytokinesis 5 0.04981 -1.945 
214464 at CDC42BPA CDC42 binding protein kinase alpha (DMPK-like) 0.0311536 -1.944 
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215434 x at 
NBPF1 M 
NBPF10 
neuroblastoma breakpoint family, member 1N 
neuroblastoma breakpoint family, member 10 0.00697 -1.938 1555736 a at AGTRAP angiotensin 11 receptor-associated protein 0.02818 -1.937 220832 at TLR8 toll-like receptor 8 0.01156 -1.937 
214084 x at ABIR Active BCR-related gene 0.00229 -1.936 227565 at --- Transcribed locus 0.01260 -1.933 
218660 at DYSF 
dysferlin, limb girdle muscular dystrophy 2B 
(autosomal recessive) 0.04816 -1.931 
213817 at --- CDNA FLJ13601 fis, clone PLACE1010069 0.02699 -1.928 
211474 s at SERPIN136 
serpin peptidase inhibitor, clade B (ovalbumin), 
member 6 0.04988 
_ 
-1.921 217513 at C17orf6O chromosome 17 open reading frame 60 0.01016 -1.918 218287 s at ElF2C1 eukaryotic translation initiation factor 2C, 1 0.02391 -1.918 214748 at RP1 1-298P3.3_ 
_CGO16 
0.01996 -1.916 
208859 s at 
ATRX N 
LOC728849 
alpha thalassemia/mental retardation syndrome X- 
linked (RAD54 homolog, S. cerevisiae) N similar to 
transcriptional regulator ATRX isoform 1 0.02444 -1.909 
211919 s at CXCR4 
chemokine (C-X-C motif) receptor 4N chemokine 
(C-X-C motif) receptor 4 0.00505 -1.907 210346 s at CLK4 CDC-like kinase 4 0.00021 -1.906 74694 s at RABEP2 rabaptin, RAB GTPase binding effector protein 2 0.04774 _ -1.904 
235593 at ZFHX1B zinc finger homeobox 1b 0.04463 -1.901 
213137 s at PTPN2 protein tyrosine phosphatase, non-receptor type 2 0.03049 -1.899 
38671 at PLXND1 plexin DII 0.02851 -1.898 
206244 at CR1 
complement component (3b/4b) receptor 1 (Knops 
blood group) 0.03402 -1.897 
226337 at SCYL1BP1 SCY1-like 1 binding protein 1 0.02620 -1.891 
221985 at KLHL24 kelch-like 24 (Drosophila) 0.04526 -1.886 
219460 s at TMEM127 transmembrane protein 127 0.03638 -1.883 
208918 s at NADK NAD kinase 0.00102 -1.879 
213839 at KIAA0500 KIAA0500 protein 0.01496 -1.878 
212667 at SPARC secreted protein, acidic, cysteine-rich (osteonectin) 0.03501 -1.876 
228325 at KIAA0146 KIAA0146 0.03685 -1.875 
209127 s at SART3 
squamous cell carcinoma antigen recognized by T 
cells 3 0.00269 -1.871 
238480 at C1 8orf17 Chromosome 18 open reading frame 17 0.03868 -1.871 
1552798 a at TLR4 toll-like receptor 4 0.00942 -1.870 
202155 s at NUP214 nucleoporin 214kDa 0.01171 -1.869 
236533 at DDER development and differentiation enhancing factor 1 0.01646 -1.869 
202450 s at CTS cathepsin K 0.02209 -1.868 
219316 s at C1 4orf58 chromosome 14 open reading frame 58 0.00596 -1.866 
244008 at --- --- 0.00990 -1.863 
212311 at KIAA0746 KIAA0746 protein 0.00851 -1.863 
201765 s at HEXA hexosaminidase A (alpha polypeptide) 0.03556 -1.861 
225637 at FLJ20186 hVpothetical protein FLJ20186 0.03798 -1.858 
222294 s at --- CDNA clone IMAGE: 5745639 0.04313 -1.855 
1568609 s at 
FAM91A2 
FLJ39739 ffl 
LOC727820 
family with sequence similarity 91, member A2 
FLJ39739 protein N hypothetical protein 
LOC727820 0.03979 -1.855_ 
209688 s at CCDC93 coiled-coil domain containing 93 0.04769 -1.854 
227046 at SLC39A11 
solute carrier family 39 (metal ion transporter), 
member 11 0.03834 -1.853 
202864 s at SP100 SP1 00 nuclear antigen 0.02999 -1.852 
204241 at ACOX3 acyl-Coenzyme A oxidase 3, pristanoyl 0.01042 -1.851 
202898 at SDC3 sVndecan 3 (N-syndecan) 0.00675 -1.849 
212706 at RASA4 RAS p2l protein activator 4 0.02940 -1.849 
205639 at AOAH acyloxyacyl hydrolase (neutrophil) 0.01355 -1.846 
209166 s at MAN2131 mannosidase, alpha, class 2B, member 1 0.02284 -1.841 
228453 at KLAA1 632 KIAA1632 0.03105 -1.838 
219183 s at 1 PSCD4 
pleckstrin homology, Sec7 and coiled-coil domains 
4 0.03077 -1.837 
224771 at I NAV1 neuron navigator 1 0.04416 -1.831 
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222616 S at 
_ 
USP1 6 ubiquitin specific pepti ase 16 0.03920 -1.831 240392 at CARD14 Caspase recruitment domain family, member 14 0.03520 -1.828 
204220 at GMFG glia maturation factor, gamma 0.03708 -1.824- 
202193 at LIMK2 LIM domain kinase 2 0.01318 -1-823- 
224909 s -at 
PREM 
phosphatidylinositol 3,4,5-trisphosphate-dependent 
RAC exchanger 1 0.02322 -1.819 
202263 at CYB5R1 cytochrome b5 reductase 1 0.04424 -1-817 
1559263 s at ZC3H12D zinc finger CCCH-type containing 12D 0.01115 -1-817 
209761 s at Spi 10 SP1 10 nuclear body protein 0.04318 -1.816 
213891 s at --- CDNA FLA 1918 fis, clone HEMBB1 000272 0.00275 -1.813 
225701 at AKNA AT-hook transcription factor 0.01835 _ -1.813 
204861 s at 
NAIP M 
LOC728519 
NLR family, apoptosis inhibitory protein N similar to 
Baculoviral IAP repeat-containing protein 1 
(Neuronal apoptosis inhibitory protein) 0.03025 -1.812 
212958 x at PAM peptidylglycine alpha-amidating monooxygenase 0.00442 -1.812 
210218 S at SPI100 SP1 00 nuclear antigen 0.04594 -1.810 
226982 at ELL2 elongation factor, RNA polymerase ll, 2 0.02603 -1.810 
235625 at VPS41 _ vacuolar protein sorting 41 homolog (S. cerevisiae) 0.04235 -1.807 
207540 S at SYK spleen tvrosine kinase 0.04324 _ -1.805 
211993 at WNK1 
WNK lysine deficient protein kinase 1N WNK 
lysine deficient protein kinase 1 0.01130 -1.804 
214151 s at CCPG1 cell cycle progression 1 0.00693 -1.804 
238601 at --- Transcribed locus 0.03669 -1.803 
215489 x at HOMER3 homer homolog 3 (Drosophila) 0.02024 -1.800 
201867 s at TBL1X transducin (beta)-like 1X-linked 0.02359 -1.795 
227624 at KlAA1 546 KlAA1 546 0.04586 -1.791 
226879 ýat HVCN1 hydrogen voltage-gated channel 1 0.03370 -1.790 
224877 s at MRPS5 mitochondrial ribosomal protein S5 0.04907 _ -1.788 
201085 S at SON SON DNA binding protein 0.01247 -1.784 
206170 at ADRB2 adrenergic, beta-2-, receptor, surface 0.01132 -1.782 
222315 at --- Transcribed locus 0.03507 -1.782_ 
208485 x at CIFLAR CASP8 and FADD-like apoptosis regulator 0.04939 -1.778 
209088 s at UBN1 ubinuclein 1 0.01123 -1.778 
205787 x at ZC3H11A zincfinger CCCH-type containing 11A 0.00899 -1.778_ 
210564 x at CIFLAR CASP8 and FADD-like apoptosis regulator 0.04419 -1.777 
243648 at --- --- 0.02221 -1.775_ 
218913 S at GMIP GEM interacting protein 0.02781 -1.775 
204076 at ENTPD4 ectonucleoside triphosphate diphosphohydrolase 4 0.0485 -1.771 
226607 at C20orfl 94 chromosome 20 open reading frame 194 0.00393 -1.766 
219394 at PGS1 phosphatidylglycerophosphate synthase 1 0.01440 -1.765 
201502 s at 
_ 
NFKBIA 
nuclear factor of kappa light polypeptide gene 
enhancer in B-cells inhibitor, alpha 0.04944 -1.764 
229115 at DYNC11-11 dynein, cytoplasmic 1, heavy chain 1 0.00788 -1.761 
233167 at RP3-402G 11.5 selenoprotein 0 0.00872 -1.758 
242429 at ZNF567 zinc finger protein 567 0.02372 -1.758 
221581 s at LAT2 linker for activation of T cells family, member 2 0.01038 -1.757 
212492 S at JMJD2B jumonji domain containing 2B 0.04708 -1.757 
206600 s at SLC16A5 
solute carrier family 16, member 5 (monocarboxylic 
acid transporter 6) 0.03882 -1.754_ 
213850 s at SFRS21P 
splicing factor, arginine/serine-rich 2, interacting 
protein 0.00682 -1.753 
34206 at CENTD2 centaurin, delta 2 0.04186 -1.752 
213618 at CENTID1 centaurin, delta 1 0.04200 -1.750 
209216 at WDR45 WD repeat domain 45 0.04700 -1.749 
203920 at NR1 H3 nuclear receptor subfamily 1, group H, member 3 0.00165 -1.747 
208983 S at PECAM1 
platelet/endothelial cell adhesion molecule (CD31 
antigen) 0.04899 -1.745 
211792 x at HLA-C major histocompatibility complex, class 1, C 0.03629 -1.744 
202066_at PPFlA1 I 
protein tyrosine phosphatase, receptor type, f 
polypeptide (PTPRF), interacting protein (liprin), 
alpha 1 0.03873 -1.743 
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204613 at PLCG2 
phospholipase C, gamma 2 (phosphatidylinositol- 
specific) 0.02921 -1.743 
228986 at OSBPL8 oxysterol binding protein-like 8 0.01549 -1.738 
223952 x at DHRS9 dehydrogenase/reductase (SDR family) member 9 0.04274 -1.737 
209201 x at CXCR4 chemokine (C-X-C motif) receptor 4 0.02098 -1.736 
222387 s at VPS35 vacuolar protein sorting 35 homolog (S. cerevisiae) 0.04176 -1.732- 
201818 at AYTL2 acyltransferase like 2 0.01208 -1.730- 
225221 at --- CDNA FLJ32068 fis, clone OCBBF1 000114 0.04362 -1.730- 
218380 at NLRP1 NLR family, pyrin domain containing 1 0.02234 -1.728 
226740 x at 
NBPF14 
NBPF1 /// 
NBPF1 1N 
NBPF15M 
NBPF10M 
NBPF8 M 
LOC728936 
LOC728980 N 
LOC730476 
neuroblastoma breakpoint family, member 14 
neuroblastorna breakpoint family, member 1 /// 
neuroblastorna breakpoint family, member 11 
neuroblastorna breakpoint family, member 15 N 
neuroblastoma breakpoint family, member 10 N 
neuroblastorna breakpoint family, member 8N 
similar to CGII 0522-PA N hypothetical protein 
LOC728980 /// hypothetical protein LOC730476 0.02019 
_ 
-1.728 
239843 at RIT1 Ras-like without CAAX 1 0.04294 -1.727 
224648 at GPBP1 GC-rich promoter binding protein 1 0.04354 -1.727 
1569069 s at TDRD3 tudor domain containing 3 0.04598 -1.726 
223393 sat TSHZ3 teashirt family zinc finger 3 0.04436 -1.726 
208988 at FBXL11 F-box and leucine-rich repeat protein 11 0.00475 -1.725 
225014 at LOC389203 hypothetical gene supported by BC032431 0.01161 -1.724 
229399 at C1 Oorfl 18 chromosome 10 open reading frame 118 0.00881 -1.720 
217104 at LOC40041 0 similar to cervical cancer suppressor-1 0.02696 -1.720 
217456 x at HLA-E major histocompatibility complex, class 1, E 0.02645 -1.718 
209099 x at JAGII jagged 1 (Alagille syndrome) 0.03711 -1.717 
228771 at ADRBK2 adrenergic, beta, receptor kinase 2 0.02748 -1.715 
225390 s at KLF13 Kruppel-like factor 13 0.03986 -1.711 
1565566 a at STX7 Syntaxin 7 0.04927 -1.711 
201454 s at NPEPPS aminopeptidase puromycin sensitive 0.04326 -1.708 
219872 
- at 
C4orfl 8 chromosome 4 open reading frame 18 0.02765 -1.706 
209155 s at NT5C2 5'-nucleotidase, cytosolic 11 0.04447 -1.705_ 
225624 at LOC92017 similar to RI KEN cDNA 4933437KII 3 0.00233 -1.702 
225558 at GIT2 G protein-coupled receptor kinase interactor 2 0.01533 -1.702 
1555852 at --- --- 0.01548 -1.702 
214919 s at 
EIF4EBP3 N 
MASK-BP3 
eukaryotic translation initiation factor 4E binding 
protein 3 /// MASK-4E-BP3 alternate reading frame 
gene 0.00139 -1.702_ 
213612 x at 
NBPF1 5 /// 
NBPF10M 
NBPF8 /// 
LOC728936 N 
LOC728980 
neuroblastorna breakpoint family, member 15 /// 
neuroblastoma breakpoint family, member 10 N 
neuroblastorna breakpoint family, member 8 /// 
similar to CGII 0522-PA M hypothetical protein 
LOC728980 0.03817 -1.701 
218130 at C1 7orf62 chromosome 17 open reading frame 62 0.04974 -1.700 
213526 s at F25965 protein F25965 0.04006 -1.700 
201070 x at SF3B1 splicing factor 3b, subunit 1,155kDa 0.00110 -1.699 
214703 s at MAN2132 mannosidase, alpha, class 213, member 2 0.04899 -1.699 
211529x at HLA-G HLA-G histocompatibility antigen, class 1, G 0.01831 -1.697 
202982 s at 
ACOT2 N 
ACOT1 acyl-CoA thioesterase 2N acyl-CoA thioesterase 1 0.02479 I -1.695 
223303 at URP2 UNC-1 12 related protein 2 0.03078 -1.692 
213309 at PLCL2 phospholipase C-like 2 0.00278 -1.691 
1558299 at SIRPA Signal-regulatory protein alpha 0.04240 -1.689 
214305 sat SF3B1 splicing Lactor 3b, subunit 1,155kDa 0.00012 -1.688 
213136 at PTPN2 protein tyrosine phosphatase, non-receptor type 2 0.01392 -1.688 
228479 at --- 0.01576 -1.687 
209734 at NCKAP1 L NCK-associated protein 1 -like 0.03893 -1.686 
213541 s at ERG 
v-ets erythroblastosis virus E26 oncogene homolog 
(avian) 0.0182-1 -1.684 
222024 s at AKAP1 3 A kinase (PRKA) anchor protein 13 0.00088 -1.682 
203470s at PLEK pleckstrin 0.00474 -1.682 
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229419 at FBXW7 
F-box and WD-40 domain protein 7 (archipelago 
homolog, Drosophila) 0.01394 -1.681 
201103 X at 
NBPF1 1N 
NBPF15 
NBPF 10 
NBPF8 N 
LOC728936 
LOC728980 
neuroblastoma breakpoint family, member 11 
neuroblastoma breakpoint family, member 15 
neuroblastoma breakpoint family, member 10 
neuroblastoma breakpoint family, member 8N 
similar to CG1 0522-PA ffl hypothetical protein 
LOC728980 0.01899 -1.680 
203380 x at SFRS5 splicing factor, arginine/serine-rich 5 0.03306 -1.679 
202416 at DNAJC7 DnaJ (Hsp40) homolog, subfamily C, member 7 0.01288 -1.677 
212332 
- at 
RBI-2 retinoblastoma-like 2 (p130) 0.02929 _ -1.677 
227112 
_at 
TMCC1 transmembrane and coiled-coil domain family 1 0.02648 -1.676 
201296 s at WS131 WD repeat and SOCS box-containing 1 0.03471 -1.675 
209933 s at CD300A CID300a molecule 0.03399 -1.673- 
227354 
_at 
PAG1 
phosphoprotein associated with glycosphingolipid 
microdomains 1 0.00773 -1.671 
237444 at --- Transcribed locus 0.04459 -1.670- 
212770 
- at 
TLE3 
transducin-like enhancer of split 3 (E(spl) homolog, 
Drosophila) 0.02300 -1.669 
227150 at MTR metal-regulatory transcription factor 1 0.02898 -1.668 
204206 at MNT MAX binding protein 0.02149 -1.667 
229699 at --- CIDNA FLJ45384 fis, clone BRHIP3021987 0.02708 -1.666 
242352 at NIPBL 
- 
Nipped-B homolog (Drosophila) 0.02701 -1.665 
203044 at CHSY1 carbohydrate (chondroitin) synthase 1 0.02095 -1.665 
204225 at HIDAC4 histone deacetylase 4 0.04140 -1.664 
235761 at --- CIDNA FLJ36553 fis, clone TRACH2008478 0.02197 -1.663 
1558747 at SMCHID1 
structural maintenance of chromosomes flexible 
hinge domain containing 1 0.02938 
_ 
-1.663 
227749 at Transcribed locus 0.00587 -1.662 
232231 at RUNX2 runt-related transcription factor 2 0.01730 -1.662 
212854 x at NBPF10 neuroblastoma breakpoint family, member 10 0.02228 -1.661 
203513 at KIAM 840 KIAA1840 0.03966 -1.661 
226441 at --- CIDNA FLJ36574 fis, clone TRACH2012376 0.02505 -1.660 
201558 at RAE1 RAE1 RNA export 1 homolog (S. pombe) 0.01531 -1.660 
228642 at Homo sapiens, clone IMAGE: 5019307, mRNA 0.04640 -1.659 
227041 at --- CIDNA FLJ31513 fis, clone NT2RI1000127 0.01839 -1.658 
204555 s at PPP1R3D protein phosphatase 1, regulatory subunit 3D 0.02539 -1.658 
223466 x at COL4A3BP 
collagen, type IV, alpha 3 (Goodpasture antigen) 
binding protein 0.04504 -1.657 
212230 at PPAP213 phosphatidic acid phosphatase type 2B 0.04757 -1.657_ 
232333 at MAMI-2 Mastermind-like 2 (Drosophila) 0.02420 -1.656 
202082 s at SECUL1 SEC14-like 1 (S. cerevisiae) 0.02398 -1.656 
213527 s at ZNF688 zinc finger protein 688 0.02074 -1.655 
205882 x at AIDID3 adducin 3 (gamma) 0.03343 -1.655 
226430 at LOC253981 hypothetical protein LOC253981 0.04205 -1.655 
209258 s at SMC3 structural maintenance of chromosomes 3 0.04916 -1.651 
228499 at PFKFB4 
6-phosphofructo-2-kinase/fructose-2,6- 
biphosphatase 4 0.00264 -1.650 
212632 at STX7 Syntaxin 7 0.04273 -1.649 - 
1559502 s at LRRC25 leucine rich repeat containing 25 0.03538 9 -1.64 
1 9 
217741 s at ZFANID5 zinc finger, AN 1 -type domain 5 0.03441 -1.649_ 
208611 s at SPTAN1 spectrin, alpha, non-erythrocytic 1 (alpha-fodrin) 0.04240 -1.647 
223440 at C16orf7O chromosome 16 open reading frame 70 0.04758 -1.644 
206219 s at VAV1 vavl oncogene 0.01396 -1.644 
212994 at THOC2 THO complex 2 0.04469 -1.641 
236487 at SCLT1 Sodium channel and clathrin linker 1 0.01512 -1.640 
208942 s at TLOC1 translocation protein 1 0.00308 -1.640 
229021 at --- CIDNA: FLJ23331 fis, clone HEP12664 
0.01240 -1.639 
235056 at ETV6 ets variant gene 6 (TEL oncogene) 0.01293 -1.638 
226885 at --- Transcribed locus 0.02198 -1.636 
226'63 at SESTD1 SEC14 and spectrin domains 1 0.04096 -1.634 
212208 at _ 
THRAP2 thyroid hormone receptor associated protein 0.00920 -1.633 
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214722 at NOTCH2NL Notch homolog 2 (Drosophila) N-terminal like 0.00182 -1.632 224218 s at TRPS1 trichorhinophalangeal syndrome 1 0.03170 -1.631 
212651 at RHOBTBI Rho-related BTB domain containing 1 0.03420 -1-628 
228120 at ElF2C1 Eukaryotic translation initiation factor 2C, 1 0.00211 -1.625 
212754 s at MON2 MON2 homolog (S. cerevisiae) 0.00272 -1.625 
1553955 at CCDC128 coiled-coil domain containing 128 0.00833 -1.624 
208710 s at AP3D1 adaptor-related protein complex 3, delta 1 subunit 0.03105 -1.623 228071 at GIMAP7 GTPase, IMAP family member 7 0.03816 -1.621 
242990 at WDFY3 WD repeat and FYVE domain containing 3 0.01040 -1.621 
204808 s at TMEM5 transmembrane protein 5 0.00350 -1.621 
222439 s at THRAP3 thyroid hormone receptor associated protein 3 0.01993 -1.621 
222062 at IL27RA interleukin 27 receptor, alpha 0.03847 -1.619 
217297 s at MY09B myosin lXB 0.01672 -1.618 
223741 s at TTYH2 tweety homolog 2 (Drosophila) 0.03183 -1.617 
206918 S at CPNE1 copine 1 0.03949 -1.617 
240173 at --- Transcribed locus 0.03291 -1.610 
230462 at NUMB numb homolog (Drosophila) 0.00977 -1.610 
201935 s at ElF4G3 eukaryotic translation initiation factor 4 gamma, 3 0.02464 -1.608 
212447 at KBTBD2 kelch repeat and BTB (POZ) domain containing 2 0.02538 -1.608 
219457 s at RIN3 Ras and Rab interactor 3 0.00333 -1.608 
235461 at KlAA1 546 KlAA1 546 0.01854 -1.608 
226956 at LOC400924 hypothetical gene supported by AK056895 0.03525 -1.608 
209473 at --- --- 0.00747 -1.607 
211528 x at HLA-G HLA-G histocompatibility antigen, class 1, G 0.00841 -1.605 
217299 s at NBN nibrin 0.01389 -1.604 
33197 at MY07A myosin VIIA 0.02017 -1.604 
235408 x at ZNF1 17 Zinc finger protein 117 0.01340 -1.603 
225411 at TMEM87B Transmembrane protein 87B 0.04307 -1.603 
218312 s at ZNF447 zinc finger protein 447 0.03430 -1.602 
229297 at --- 
Full-length cDNA clone CSOCAP006YPO8 of 
Thymus of Homo sapiens (human) 0.04902 -1.600 
217751 at GSTK1 qlutathione S-transferase kappa 1 0.03493 -1.600 
221139 s at CSAD cysteine sulfinic acid decarboxylase 0.01406 -1.599 
211947 s at BAT2D1 BAT2 domain containing 1 0.02029 -1.599 
241817 at C3orf62 chromosome 3 open reading frame 62 0.04592 -1.596 
202294 at STAG1 stromal antigen 1 0.04693 -1.596 
1552611a_at 
JAM /// 
ZC3H13 
Janus kinase 1 (a protein tyrosine kinase) N zinc 
finger CCCH-type containing 13 0.01629 -1.596 
203879 at PlK3CD 
phosphoinositide-3-kinase, catalytic, delta 
polypeptide ffl phosphoinositide-3-kinase, catalytic, 
delta polypeptide 0.00164 -1.594 
201612 at ALDH9A1 aldehyde dehydrogenase 9 family, member Al 0.04642 -1.594. 
231550 at --- Transcribed locus 0.00497 -1.593 
218184 at TULP4 tubbV like protein 4 0.02436 -1.592 
207677 s at NCF4 
neutrophil cytosolic factor 4,40kDa M neutrophil 
cytosolic factor 4,40kDa 0.02399 -1.591 
224935 at ElF2S3 
eukaryotic translation initiation factor 2, subunit 3 
gamma, 52kDa 0.03897 -1.591 
211068 x at 
FAM21 C 
LOC653450 
family with sequence similarity 21, member CN 
family with sequence similarity 21, member C 
hypothetical LOC653450 /// hypothetical 
LOC653450 0.03755 -1.590j 
221578 at RASSF4 Ras association (RaIGDS/AF-6) domain family 4 0.03294 -1.590 
211316 x at CFLAR CASP8 and FADD-like apoptosis regulator 0.02222 -1.589 
228726 at --- 0.04305 -1.588 
227290 at CDNA FLJ 13598 fis, clone PLACE 1009921 0.03373 -1.586 
225961 at KLHDC5 kelch domain containing 5 0.00076 -1.586 
202605 at GUSB glucuronidase, beta 0.04654 -1.584 
209514 s at RAB27A RAB27A, member RAS oncogene family 0.02393 -1.584 
_ 514 x at 210 HLA-G HLA-G histocompatibility antigen, class 1, G 0.00459 -1.583 ý 
50221 at TFEB transcription factor EB 0.02048 -1.581 
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1553274 a at C6orf1 51 chromosome 6 open reading frame 151 0.02744 -1-580 
40420 at STK1 0 serine/threonine kinase 10 0.01371 -1.578 
218606 at ZDHHC7 zinc finger, DHHC-typ containing 7 0.00841 -1.577- 
210140 
' at 
CST7 cystatin F (leukocystatin) 0.03887 -1-577- 
212420 at ELF1 E74-like factor 1 (ets domain transcription factor) 0.01105 -1.576- 
217507 at SLC1 W 
solute carrier family 11 (proton-coupled divalent 
metal ion transporters), member 1 0.01207 -1.576 
223567 at SEMA613 
sema domain, transmembrane domain JM), and 
cytoplasmic domain, (semaphorin) 6B 0.04748 -1.576 
202386 s at KIAA0430 KIAA0430 0.01329 -1.576 
223268 
_at 
C 11 orf54 chromosome 11 open reading frame 54 0.02506 -1.575 
224871 at FAM79A family with sequence similarity 79, member A 0.03678 -1.574 
1568619 s at --- CIDNA clone IMAGE: 4402981 0.01872 -1.570 
202215 
-s- at 
NFYC nuclear transcription factor Y, gamma 0.03220 _ -1.570 
201968 s at PGM 1 phosphoglucomutase 1 0.03247 -1.568 
217576 x at SOS2 son of sevenless homolog 2 (Drosophila) 0.00151 -1.567 
211009 s at ZNF271 zinc finger protein 271 0.04279 -1.567 
225102 at MGLL monoglyceride lipase 0.02274 -1.567 
227250 at KREMEN1 kringle containing transmembrane protein 1 0.02748 -1.567_ 
227069 at CUTL1 
Cut-like 1, CCAAT displacement protein 
(Drosophila) 0.02718 -1.566 
222413 s at MLL3 myeloid/lymphoid or mixed-lineage leukemia 3 0.01887 -1.565 
208322 s at ST3GAL1 ST3 beta-galactoside alpha-2,3-sialyltransferase 1 0.01148 -1.565_ 
209341 s at lKBKB 
inhibitor of kappa light polypeptide gene enhancer 
in B-cells, kinase beta 0.03399 -1.565 
214274 s at ACAA1 
acetyl-Coenzyme A acyltransferase 1 (peroxisomal 
3-oxoacyl-Coenzyme A thiolase) 0.03822 -1.565 
201056 at GOLGB1 
Golgi autoantigen, golgin subfamily b, macrogolgin 
(with transmembrane signal), 1 0.04515 -1.563 
1554670 at GGA1 
golgi associated, gamma adaptin ear containing, 
ARF binding protein 1 0.02985 -1.562 
208954 s at LARP5 La ribonucleoprotein domain family, member 5 0.04628 -1.561 - 
202951 at STK38 serine/threonine kinase 38 0.01108 -1.559 
203269 at NSMAF 
neutral sphingomyelinase (N-SMase) activation 
associated factor 0.01888 -1.559 
239243 at ZNF638 Zinc finger protein 638 0.02283 -1.558 
212948 at CAMTA2 Galmodulin binding transcription activator 2 0.03780 -1.557 
1554690 a at TACC1 transforming, acidic coiled-coil containing protein 1 0.02318 -1.556 
218271 s at PARL presenilin associated, rhomboid-like ' 
0.02694 -1.556 
212717 at PLEKHM1 
pleckstrin homology domain containing, family M 
(with RUN domain) member 1 0.03381 -1.555 
211323 s at ITPR1 inositol 1,4,5-triphosphate receptor, type 1 0.03358 -1.555 
1570301 at CIDNA clone IMAGE: 4696931 0.01937 -1.554 
212483 at NIPBL Nipped-B homolog (Drosophila) 0.03646 -1.553 
218282 at EDEM2 
ER degradation enhancer, mannosidase alpha-like 
2 0.01786 -1.551 
213572 s at SERPINB1 
serpin peptidase inhibitor, clade B (ovalbumin), 
member 1 0.02397 -1.549 
218388 at PGLS 6-phosphogluconolactonase 0.00522 -1.548 
228647 at NINJ2 Ninjurin 2 0.03941 -1.548 
213883 s at TM2D1 TM2 domain containing 1 0.04448 -1.548 
211572 s at SLC23A2 
solute carrier family 23 (nucleobase transporters), 
member 2 0.04846 -1.548 
225738 at RAPGEF1 Rap guanine nucleotide exchange factor (GEF) 1 0.02932 -1.546 
201918 at SLC25A36 Solute carrier family 25, member 36 0.04625 -1.545 
223482 at TWIT 
transmembrane protein induced by tumor necrosis 
factor alpha 0.02765 -1.544 
204550 x at GSTM1 qlutathione S-transferase M1 0.04426 -1.544 
223272 s at 
227190 at 
219190_s at 
242907at 
228719 at 
C1 orf57 
TMEM37 
ElF2C4 
GBP2 
SWS1 
chromosome 1 open reading frame 57 
transmembrane protein 37 
eukaryotic translation initiation factor 2C, 4 
guanylate binding protein 2, interferon-inducible 
SWIM-domain containinq Srs2 interacting protein 1 
0.02522 
0.01951 
0.01133 
0.01855 
0.03932 
-1.544 
-1.542 
-1.539 
-1.538 
-1.537 
-210- 
Appendix 2 
218821 at NPEPL1 aminopeptidase-like 1 0.01446 -1.537 
224933 S at JMJD1C jumonji domain containing 1C 0.00001 -1.533 
206743 s at ASGR1 asialoglycoprotein receptor 1 0.04252 -1.532 
223145 S at C6orf 166 chromosome 6 open reading frame 166 0.03529 -1.531- 
203884 s at RAB11FIP2 RAB1 1 family interacting protein 2 (class 1) 0.00504 -1-530 
202530 at MAPK14 mitogen-activated protein kinase 14 0.01267 -1.530 
203610 s at TRIM38 tripartite motif-containing 38 0.03922 -1.528 
208325 S at AKAP13 A kinase (PRKA) anchor protein 13 0.01818 -1.525 
224981 
_at 
LOC 124446 hypothetical protein BCO 17488 0.01120 -1.524 
203377 S at CDC40 cell division cycle 40 homolog (S. cerevisiae) 0.03611 -1.523 
231283 
_at 
MGAT4A 
mannosyl (alpha- 1,3+glycoprotein beta-1,4-N- 
acetylglucosaminyltransferase, isozyme A 0.00964 -1.522 
222613 at C12orf4 chromosome 12 open reading frame 4 0.04067 -1.521 
212288 at FNBP1 formin binding protein 1 0.04396 -1.520 
209610 s at SLC1A4 
solute carrier family 1 (glutamate/neutral amino acid 
transporter), member 4 0.04333 -1.520 
234351 x at TRPS1 trichorhinophalangeal syndrome 1 0.01297 -1.520 
222644 s at GLT25D1 glycosyltransferase 25 domain containing 1 0.02176 -1.518 
218805 at GIMAP5 
GTPase, IMAP family member 5M GTPase, IMAP 
family member 5 0.01832 -1.515 
226795 at LRCH1 
Leucine-rich repeats and calponin homology (CH) 
domain containing 1 0.03288 -1.513 
230747 S at C1 8orfl 7 Chromosome 18 open reading frame 17 0.01551 -1.513 
1555837 s at POLR213 
polymerase (RNA) 11 (DNA directed) polypeptide B, 
140kDa 0.03312 -1.513 
221571 at TRAF3 TNF receptor-associated factor 3 0.00347 -1.512 
219799 S at DHRS9 dehydrogenase/reductase (SDR family) member 9 0.01590 . -1.512_ 
201960 s at MYCBP2 MYC binding protein 2 0.00049 -1.511 
233656 s at VPS54 vacuolar protein sorting 54 homolog (S. cerevisiae) 0.03072 -1.510 
227908 at TBC1D24 TBC1 domain family, member 24 0.00006 -1.509 
228416 at ACVR2A activin A receptor, type IIA 0.03528 -1.504 
1553928 at ELMOD2 ELMO/CED-12 domain containing 2 0.04874 -1.503 
208178 x at TRIO triple functional domain (PTPRF interacting) 0.00260 -1.503 
210589 s at GBA///GBAP 
glucosidase, beta; acid (includes 
glucosylceramidase) /// glucosidase, beta; acid, 
pseudogene 0.03240 -1.503 
230735 at IFNAR2 Interferon (alpha, beta and omega) receptor 2 0.02893 -1.503 
230970 at SSH2 Slingshot homolog 2 (Drosophila) 0.03011 -1.501 
228238 at GAS5 growth arrest-specific 5 0.02705 1.500 
1558164 s at PEX13 Peroxisome biogenesis factor 13 0.01146 1.501 
202886 s at PPP2R1B 
protein phosphatase 2 (formerly 2A), regulatory 
subunit A (PR 65), beta isoform 0.03922 1.501 
202107 s at MCM2 
MCM2 minichromosome maintenance deficient 2, 
mitotin (S. cerevisiae) 0.02934 1.501 
206364 at KIF14 kinesin family member 14 0.01781 1.502 
235545 at --- --- 0.01953 
1.503 
231024 at 
- LOC572558 hypothetical locus LOC572558 0.01512 1.506 
222848 at CENPK centromere protein K 0.02503 
1.507 
202458 at PRSS23 protease, serine, 23 0.00154 
1.509 
230002 at CLCC1 Chloride channel CLIC-like 1 0.03843 
1.512 
244733 at USP33 Ubiquitin specific peptidase 33 0.00227 
1.512 
_ 
237703 at RPS10 Ribosomal protein S10 0.01359 
1.512 
_ 
206576 s at CEACAM1 
carcinoembryonic antigen-related cell adhesion 
molecule 1 (biliary glycoprotein) 0.01509 1.513 
232441 at KRR1 
KRR1, small subunit (SSU) processome 
component, homolog (yeast) 0.00269 1.517 
243857 at MORF41-2 Mortality factor 4 like 2 0.04375 
1.518 
208584 at SNCG synuclein, gamma (breast cancer-specific protein 1) 0.04611 
1.519 
219105 x at ORCK origin reco nition complex, subunit 6 like (yeast) 0.04018 
1.519 
200790 at ODC1 ornithine decarboxylase 1 0.03108 1.519 
523 S at 224 C3orf26 
chromosome 3 open reading frame 26 M 
chromosome 3 open reading frame 26 0.00013 1.519 
ý _ 207823 S at AlF1 I allograft inflammatory factor 1 0.03168 1.523 
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219110 at NOLM 
nucleolar protein family A, member 1 (H/ACA small 
nucleolar RNPs) 0.04516 1.526 
213599 at OlP5 Opa interacting protein 5 0.03114 1.527 
234698 at HEMK2 HemK methyltransferase family member 2 0.03033- 
- 1.529- 
239630 at TAS2R14 Taste receptor, type 2, member 14 0.04105 1.531 
239469 at FNBP4 Formin binding protein 4 0.02841 1.533- 
204887 s at PLK4_ polo-like kinase 4 (Drosophila) 0.01857 1.536- 
224320 s at MCM8 
MCM8 minichromosome maintenance deficient 8 
(S. cerevisiae) 0.03692 1.537 
1566923 at --- CDNA: FLJ20971 fis, clone ADSU01 565 0.03244 1.539 
222037 at MCM4 
MCM4 minichromosome maintenance deficient 4 
(S. cerevisiae) 0.02166 
_ 
1.540 
240247 at FAM7A2 
_ _Family 
with sequence similarity 7, member A2 0.01706 1.542 
1565716 at FUS 
fusion (involved in t(12; 16) in malignant 
liposarcoma) 0.01255 1.543 
235828 at MGC21644 hypothetical protein MGC21644 0.00691 1.545 
212142 at MCM4 
MCM4 minichromosome maintenance deficient 4 
(S. cerevisiae) 0.02378 1.545 
203228 at PAFAH1133 
platelet-activating factor acety1hydrolase, isoform 
lb, qamma subunit 29kDa 0.02581 
_ 
1.554 
213262 at SACS spastic ataxia of Charlevoix-Saguenay (sacsin) 0.02550 1.557 
231594 at --- --- 0.01391 1.560 
227717 
_at 
FLJ41603 FLJ41603 protein 0.04790 1.563 
230006 s at 
DKFZp3l3A24 
32 hypothetical protein DKFZp313A2432 0.00550 1.565 
237652 at IQSEC2 IQ motif and Sec7 domain 2 0.01079 1.566 
219000 s at DCC1 
defective in sister chromatid cohesion homolog 1 
(S. cerevisiae) 0.00718 1.567 
209714 s at CDKN3 
cyclin-dependent kinase inhibitor 3 (CDK2- 
associated dual specificity phosphatase) 0.02574 
. 
1.567 
241932 at PHGDHL1 Phosphoglycerate dehydrogenase like 1 0.02296 1.569 
213270 
- at 
MPP2 
membrane protein, palmitoylated 2 (MAGUK p55 
subfamily member 2) 0.03850 
_ 
1.569 
205636 
_at 
SH3GL3 SH3-domain GRB2-like 3 0.02264 1.571 
233402 at SNX24 Sorting nexing 24 0.02234 1.573 
222078 
_at --- 
Transcribed locus 0.02767 1.577_ 
215806 x at 
TRGC2 N 
TRGV9 ffl 
TARP 
T cell receptor gamma constant 2 /// T cell receptor 
gamma variable 9 /// TCR gamma alternate reading 
frame protein 0.01574 1.577 
241843 at SNORA28 small nucleolar RNA, H/ACA box 28 0.00573 1.580 
221606 s at NSBP1 nucleosomal binding protein 1 0.04394 1.584 
202309 at MTHFD1 
methylenetetrahydrofolate dehydrogenase (NADP+ 
dependent) 1, methenyltetrahydrofolate 
cyclohydrolase, formyltetrahydrofolate synthetase 0.00369 1.588_ 
234177 
- at 
FARS2 Phenylalanine-tRNA synthetase 2 (mitochondrial) 0.04285 1.589 
208744 x at HSPHII heat shock 105kDa/1 1 OkDa protein 1 0.02756 1.595 
226528 
-at 
MTX3 metaxin 3 0.02620 1.596 - 
242207 at IPPK Inositol 1,3,4,5,6-pentakisphosphate 2-kinase 0.02150 1.598 
1554986 a at SNX19 sortinq nexin 19 0.04528 1.606 
227928 at C1 2orf48 chromosome 12 open reading frame 48 0.01687 1.608 
204444 at KIR 1 kinesin family member 11 0.02227 1.609 
217444 at --- 
MRNA; cDNA DKFZp564Jl 762 (from clone 
DKFZp564Jl762) 0.03132 1.609 
227350 at HELLS Helicase, lymphoid-specific 0.01220 1.613 
223245 at STRBP spermatid perinuclear RNA binding protein 0.04068 
1.623 
207828 s at CENPF centromere protein F, 350/400ka (mitosin) 0.03045 1.627 
244797 at --- Transcribed locus - 
0.02967 1.632 
223556 at HELLS helicase, lymphoid-specific 0.04756 
1.632 
201014 s at PAICS 
phos phori bosylaminoi mid azole carboxylase, 
phosphoribosylarni noi mid azole 
succinocarboxamide synthetase 0.00932 1.633 
218 44 at PLEK2 pleckstrin 2 0.02085 1.638 
213570 at ElF4E2 
eukaryotic translation initiation factor 4E family 
member 2 0.02391 1.640 
242438_at_ --- --- 
1 0.00695 1.645 
-212- 
Appendix 2 
232759 at --- 0.00966 1.647- 
226287 at CCDC34 coiled-coil domain containing 34 0.04893 1.651 
209537 at EXTL2 exostoses (multiple)-like 2 0.01043 1.653 - 
243303 at ECHDC1 Enoyl Coenzyme A hydratase domain containing 1 0.04138 1.657 
234643 x at --- CDNA: FLJ21798 fis, clone HEP00573 0.00745 1.660 
242146 at SNRPA1 Small nuclear ribonucleoprotein polypeptide A' 0.03362 1.665 
239328 at RCSD1 RCSD domain containing 1 0.00472 1.675 
1556797 at LOC386597 hypothetical protein LOC386597 0.04149 1.677 
233271 
-at 
LOC399761 Hypothetical protein LOC399761 0.01371 1.680 
221258 s at KIF18A 
kinesin family member 18A /// kinesin family 
member 18A 0.03589 1.684 
222781 s at C9orf4O chromosome 9 open reading frame 40 0.00610 1.687 
210052 S at TPX2 
TPX2, microtubule-associated, homolog (Xenopus 
laevis) 0.04637 1.688 
224870 at KIAA01 14 KIAA01 14 0.00790 1.706 
239238 at SMARM 
SWI/SNF related, matrix associated, actin 
dependent regulator of chromatin, subfamily c, 
member 1 0.01795 1.707 
204603 at EX01 exonuclease 1 0.01717 1.725 
206976 S at HSPH1 heat shock 105kDa/1 1 OkDa protein 1 0.02792 1.771 
240263 at TFB1M Transcription factor B1, mitochondrial 0.00044 1.788 
1555758 a at CDKN3 
cyclin-dependent kinase inhibitor 3 (CDK2- 
associated dual specificity phosphatase) 0.02815 1.791 
220011 at Clorf`135 chromosome 1 open reading frame 135 0.01232 1.802 
214710 s at CCNB1 cyclin B1 0.00707 1.815 
209709 s at HMMR hyaluronan-mediated motility receptor (RHAMM) 0.02085 1.818 
209406 at BAG2 BCL2-associated athanogene 2 0.03852 1.833 
205046 at CENPE centromere protein E, 312kDa 0.03588 1.860 
203764 at DLG7 discs, large homolog 7 (Drosophila) 0.04907 1.870 
1559078 at BCL1 1A B-cell CLUlymphoma 1 1A (zinc finger protein) 0.01760 1.883 
226446 at HES6 hairy and enhancer of split 6 (Drosophila) 0.03301 1.932 
223229 at UBE2T ubiquitin-conjugating enzyme E2T (putative) 0.04285 1.938 
242201 at --- 0.02548 1.947 
233445 at BUB1 
BUB1 budding uninhibited by benzimidazoles 1 
homolog (yeast) 0.00826 1.948 
220085 at HELLS helicase, lymph oid-specific 0.00235 1.958 
222036 S at SLC12A4 
Solute carrier family 12 (potassium/chloride 
transporters), member 4 0.01253 1.993 
230312 at --- Transcribed locus 0.04564 
2.005_ 
238156 at RP SS 63 Ribosomal protein S6 0.02066 
2.066 
219148 
-at 
PBK PDZ binding kinase 0.02939 2.105 
209433 sat PPAT phosphoribosyl pyrophosphate amidotransferase 0.01059 2.440 
The shown fold change depicts the ratio of the antilog (base 2) of the RMA 
normalised expression values (averaged) of the two given conditions (if [untreated 
with 5-aza] > [treated with 5-aza] then fold ratio < -1, otherwise fold ratio > 1; 2 or -2 
= two fold). Student t-test p-value (unpaired, unequal variance assumed) for the given 
comparison is also given. 
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Summary 
Coronary artery disease leading to ischaemia of the human myocardium is one of the chief causes of morbidity and mortality in the western 
world. Cellular transp[antation has recently been proposed as a novel alternative treatment modality. Adult bone marrow-derived autologous 
cells are one of the key cell types under investigation in both the experimental and clinical setting. A range of theories has been proposed with 
regard to the observed myocardial function improvement in both human and animal studies. A concerted interest in scientific questions needs to 
be constructed on the regenerative information made available throughout the last years. It is only now that we begin to fully understand this fast 
growing body of research and how it may have wide ranging implications for the treatment of ischemic heart disease. 
(0 2005 Elsevier B. V. All rights reserved. 
Keywords: Stem cells; Ischemic heart disease; Myocardial infarction; Myocardial injury; Cellular transplantation 
1. Introduction 
Congestive heart failure (CHF) is the common pathophy- 
siologic endpoint of a number of diseases that affect the 
human myocardium. Degenerative changes can be identified 
at multiple levels including the nuclear (altered gene 
expression), the cellular (cardiomyocyte hypertrophy) and 
organ level (pump failure). Persistently high incidence and 
prevalence of heart failure in the western world can explain 
the growing interest of the scientific community in devel- 
oping more effective treatment modalities [1-3]. Although 
cardiac transplantation remains the sole radical treatment 
for end stage CHF, shortage of donors along with immuno- 
supression complications pose severe limitations to this 
approach. Techniques involving reshaping of the dilated left 
ventricle have been described and involve either endoven- 
tricular circular patch plasty (Dor procedure) or passive 
constraint and shape change [4,5]. Left ventricular assist 
devices serving mainly as a bridge to cardiac transplantation 
cannot be considered a long-term solution. 
Coronary artery disease with its clinical sequetae 
continues to be one of the leading causes of CHF. Following 
myocardial infarction, cardiornyocyte death and segmental 
scarring eventually contribute to the development of 
replacement fibrosis. The impact of myocardial fibrosis on 
the remaining healthy myocardium may range from sub- 
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clinical to detrimental. The remodelling process initiated will 
eventually lead to impairment of left ventricular function 
[6]. In an attempt to reverse the natural progress of the 
disease several alternative novel approaches are being 
considered. These include cellular transplantation in which 
de novo introduced cells are expected to repopulate areas of 
diseased myocardium. 
2. Challenging old dogmas: regenerative potential of 
native human myocardium 
Adult cardiornyocytes have traditionally been considered 
post-mitotic end -differentiated cells lacking the ability of 
division and proliferation following ischaernic injury. Cardi- 
omyocyte hypertrophy has been regarded the sole mechan- 
ism of compensation for loss of functional myocardium. 
Cellular proliferation has been theoretically restricted to 
endothetial and fibroblast cell populations leading to the 
development of collateral circulation and scar formation, 
respectively. A recent influx of experimental as welt as 
clinical data is questioning the above postulates. Even though 
from a quantitative point of view these events may be of very 
limited magnitude they should be mentioned in brief as they 
shed light on myocardial cell biology. 
The ability of terminally differentiated cells to re-enter 
the cell cycle has been already illustrated by Endo and Nada 
Ginard [7]. Interestingly, when Kajstura et at. examined 
control human hearts by confocal microscopy about 14x 106 
1010-7940/$ - see front matter (0 
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myocytes were seen in mitosis. These figures were increased 
nearly tenfold in end stage ischaernic heart disease and 
idiopathic dilated cardiomyopathy [8]. It is apparent that a 
slow turnover of myocytes exists providing a possible 
explanation of why pathologies linked with myocyte death, 
such as diabetic cardiomyopathy do not lead to myocardial 
cellular 'wipe-out' [9]. In addition, Bettrami etaL by means 
of labelling for the nuclear antigen Ki-67 in post-mortem 
infarcted hearts demonstrated 4% of myocyte nuclei under- 
going mitosis in the infarct border [10]. 
The origin of these cells undergoing cellular division 
remains to be ascertained. Whether arising from a resident 
cardiac stem cell population or having been recruited within 
the heart from the systemic circulation, ultimately being 
derived from the bone marrow awaits to be answered. 
Resident cardiac stem cells capable of self -renewal and 
myocardial regeneration have been identified in rodent 
hearts by at least two groups. In one of these studies Lin c- 
kit I cells were able to differentiate in vitro into all three 
main myocardial cell types (myocardial, endothetiat and 
smooth muscle cells) as well as form de novo myocardium 
when injected into ischaernic rat myocardiurn [11 ]. Oh et at. 
published similar data by administering intravenously Sca-1 + 
cells isolated from mouse hearts into ischaernic mice [12]. 
Only recently, however, have Laugwitz et at. identified a 
resident population of cells within the murine, rat and human 
heart that is directly derived from a cardiac progenitor cell 
population [13]. These cells are characterised by the 
expression of the islet-1 gene and can be traced in the 
myocardium from the early embryonic stage. 1s1-1+ cells 
maintain the ability to setf-renew and grow into mature 
cardiac myocytes under appropriate conditions. 
Evidence is also accumulating in favour of cell recruitment 
from the systemic circulation within the myocardium. Bayes- 
Genis et at. reported the presence of cardiac chimerism in 
recipients of peripheral blood and bone marrow stem cells 
with the use of a sensitive potymerase chain reaction assay 
for donor and recipient genotyping [14]. Furthermore, 
homing of recipient progenitor cells in the myocardium has 
been shown in sex-mismatched cardiac transplantations 
[15,16]. Based on their observations, Quaini et aL hypothe- 
sise that the donor heart harbours a population of resident 
primitive cells as well as attracting a second population of 
progenitor cells from the recipient. 
More importantly Kucia et at. have demonstrated that the 
postnatal BM harbours; a non-haernatopoietic population of 
cells that express markers for cardiac differentiation. They 
hypothesise that it may be these cells that are responsible for 
any observed myocardial regeneration attributed to bone 
marrow-derived stem cells (17]. 
3. Overview of stem cells in myocardial regenerative 
studies 
single cell to differentiate into cells of the tissue of origin and 
at least one different cell type, and functional differentia- 
tion in vivo into cells of the tissue of origin and at least one 
cell type other than the tissue of origin [18]. At least two 
distinct populations of stem cells reside within the adult bone 
marrow: haernatopoietic stem cells (HSCs) and mesenchymal 
stem cells (MSCs). The former are the precursors of all blood 
lineages and the latter give rise to stromat cells of the bone 
marrow including osteogenic, chondrogenic and adipogenic 
lineages. It has recently been suggested that the bone 
marrow harbours additionally non-haernatopoietic tissue- 
committed stem cells; these cells appear to be highly mobile 
and express mRNA/proteins for various markers of early 
tissue-committed stem cells [19]. 
The sole assay available at present for identification of 
HSCs remains the reconstitution of the haematopoietic 
system of a myeloablated host. Surface markers such as 
CD34 or the more primitive CD133 (AC133) help in 
distinguishing subpopulations enriched in HSCs in humans; 
these include the CD34+CD38- cell population as well as the 
side population. The latter cell type may reside in various 
organs besides the bone marrow and there is conflicting data 
as to the origin of these cells with some evidence supporting 
the fact of them actually being bone marrow-derived HSCs 
rather than tissue-specific [20,21 ]. As murine progenitor cells 
do not express the same surface markers, lineage depletion 
(Lin-) is the main criterion to identify enriched populations 
[22]. Endothelial progenitor cells or angioblasts and HSCs are 
thought to share a common precursor, the haernangioblast 
[23]. Studies have shown the connection between angioblasts 
residing within the bone marrow and neovascularization 
[24,25]. MSCs (also known as marrow stromat cells) have two 
main characteristics: the ability to adhere to culture dishes 
as well as to differentiate into a variety if tissues under the 
appropriate conditioning. In addition, they appear uniformly 
negative for typical 'haematopoietic' surface markers. 
Avery appealing adult bone marrow-derived population of 
high plasticity was reported by the Minnesota group [26]. 
These cells which are known as multipotent adult progenitor 
cells (MAPCs) were isolated from mesenchymal stem cell 
cultures and maintain the ability to differentiate in vitro in 
cells of the three germ layers. Only recently has another 
group reported the identification of a similar subpopulation 
from adult human bone marrow [27]. Intramyocardial 
transplantation of these cells in a rodent myocardial 
infarction model lead to in vivo differentiation into multiple 
lineages including cardiac, endothetial and smooth muscle 
cell phenotypes. 
Besides, the bone marrow several sources of adult stem 
cells are known. Zuk et at. have demonstrated that adipose 
tissue contains both HSCs and mesenchymal stem cell 
populations [281. Peripheral blood is also a source of HSCs 
and endothetial progenitor cells. The latter may be isolated 
from blood and used for cellular transplantation. 
3.1. Adult bone marrow-derived stem cells 
The attractive feature of adult stem cells for researchers 
in the field of myocardial regeneration is their innate 
plasticity. Minimal criteria for stem cell plasticity as outlined 
by Verfailtie include capability for self -renewal, ability of a 
3.2. Other stem cell types 
Even though this review focuses on adult bone marrow- 
derived stem cells it should be mentioned that the 
armamentarium of potential donor cells is not strictly 
confined to this group. Ethical considerations continue to 
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be the chief argument against clinical or even laboratory 
research involving embryonic stem cells. These totipotent/ 
pluripotent cells may be derived from embryos at the 100- 
cell-stage btastocyst and are capable of differentiation into 
all somatic cell types in vitro, including cardiornyocytes. 
Other issues complicating clinical adaptation include insuffi- 
cient availability, associated disadvantages of allograft 
transplantation, unpredictable electrical behaviour as well 
as the risk of tumour formation. 
Umbilical cord blood stem cells comprise another promis- 
ing group of cells. Compounding a relatively immature nature 
with potential for autologous cell transplantation they may 
pose in the future as a patien t- specific donor cell type 
immediately available from cryopreservation tissue banks. 
An autologous population of established phenotype that 
overcomes most of the above restrictions is skeletal 
myoblasts. These precursor cells residing within skeletal 
muscle can be easily obtained by muscle biopsy. They may be 
expanded in culture, are ischaernia resistant and provide 
fatigue resistant, slow-twitch fibres. When compared to 
CD133+ bone marrow-derived haernatopoietic progenitor 
transplantation in an animal model similar results of 
functional improvement were recorded [29]. Encouraging 
phase I clinical trial data also exists incorporating both 
transepicardial and trans-coronary-venous approaches 
[30,31]. The main concern of introduging skeletal myobtasts 
within myocardial tissue is the lack of electrical commu- 
nication with native myocytes. There has been no demon- 
stration of gap junction formation post- tran splan tation, 
which may potentially contribute to the generation of 
arrhythmias seen in patients receiving these cells. Recently, 
genetic modification of myoblasts to express the gap junction 
protein connexin43 has been proposed as an antiarrhythmic 
measure [32]. Once again it may be questioned why would 
anyone attempt 'connecting' to the native electrical circuit 
cell groups with an unpredictable electrical behaviour. 
4. Homing of stem cells to injured myocardium 
Little is known with regard to the regulatory mechanisms 
that control the homing and holding of haernatopoietic 
progenitor cells within the bone marrow. Of significant 
clinical importance and relevance is the CXCR4/SDF-1 
chemotactic axis. Stromat cett-derived factor-1 (SDF-1/ 
CXCL12) is a marrow stroma and bone-derived chemokine 
thought to form a decreasing gradient from the extravascular 
toward the intravascutar compartment within the bone 
marrow. Implicated in bringing about the relocation of fetal 
haernopoiesis from the liver to the bone marrow [33,34], in 
adult life it is known to promote engraftment of transplanted 
haernatopoietic stem celts within the recipient's bone 
marrow [35]. The chernotactic effects of SDF-1 are mediated 
by its receptor CXCR4 as can be demonstrated in vitro [36]. 
Bone marrow-derived progenitor cells are well known to 
migrate to localised areas of injury following ischaernic 
insults. Two factors that seem to be associated with this 
process are SDF- 1 /CXCL1 2 and vascular endothelial growth 
factor (VEGF) [37,38]. It has been demonstrated by Ceradini 
et at. that SDF- 1 gene expression is partially controlled by the 
transcription factor hypoxia-inducibte factor-1 (HIF-1) trans- 
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lating thus to increased levels in the presence of tissue 
hypoxia [39]. HIF-1 is also an early transcription factor for 
VEGF, which is also up-regulated in myocardial infarction 
[40,41]. This has been confirmed in human ventricular 
biopsies taken during surgical revascularization procedures 
following myocardial infarction [42]. Locally delivered SDF-1 
may enhance vasculogenesis and subsequently contribute to 
ischaernic neovascularization as shown in an ischaemic hind 
limb model [43]. Finally, by blocking the binding of SDF-1 to 
receptor CXCR4 in a rodent myocardial infarction model 
inhibition of stem cell homing has been seen [44]. 
It has been suggested that the establishment of a positive 
concentration gradient between ischaernic tissue and bone 
marrow promotes mobilization and subsequent homing to 
sites of injury [45]. In theory, this would be in agreement with 
the observation that granulocyte colony-stimulating factor 
(G-CSF) achieves bone marrow mobilization by decreasing 
the bone marrow levels of SDF-1 [46]. Kucia et at. have only 
recently suggested that the bone marrow actually may act as 
a 'hideout' for non-haematopoietic CXCR4+ tissue-com- 
mitted stem cells opening new areas of research [19]. 
It is apparent that mobilization and subsequent homing of 
stem cells is a dynamic process involving various chemokines, 
cellular surface receptors, meta Roprotei nases, and adhesion 
molecules in addition to remodelling of the extracettutar 
matrix. Besides, the aforementioned factors a variety of 
factors and mediators are produced as a result of ischaemic 
injury [47]. Even if not directly involved in generating homing 
signals their significance may lie in creating the appropriate 
microenvironment required for integration of the homed 
cells. 
5. Representative small animal studies 
The contribution of small animal myocardial infarction 
models has proven invaluable in assessing various cell 
populations for potential myocardial regenerative capability. 
It was not than from a small number of studies that the initial 
encouraging data of myocardial regeneration following 
cellular transplantation of bone marrow-derived stem cells 
emerged. In one of the earlier reports, the transplantation of 
autologous bone marrow cells (BMCs) was documented to 
stimulate angiogenesis in the recipient ischaernic myocar- 
dium [48]. Having been [abetted previously with bromodeox- 
yuridine (BrdU) cells were implanted directly into a 
myocardial scar created by cryoinjury three weeks earlier. 
When explanted hearts were examined eight weeks post 
transplantation, increased capillary density was seen in 
comparison to the control group, with BrdU positive cells 
present within the wall of the newly formed vessels. 
Functional improvement was observed only in the recipients 
of the mesenchymat stem cells that had been treated with 5- 
azacytidine. 
Undisputedly, the most important paper of this era was 
published two years later by Orlic and co-workers in 2001 
[49]. In a mouse ligature-induced myocardial infarction 
model, the transplantation of autotogous lineage negative 
(Lin-) bone marrow cells in the acute ischaernia phase was 
assessed. Cells were isolated from mate transgenic mice 
expressing enhanced green fluorescent protein and the 
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receptor for stem cell factor (c-kit+) and injected directly 
into the myocardium of female mice 3-5 h after coronary 
ligation. When hearts were removed 9 days post transplanta- 
tion, proliferating myocytes and vascular structures occupied 
68% of the infarcted segment of the left ventricle. The 
authors concluded that Un- c-kit+ bone marrow cells have 
the capability of regenerating acutely significant amounts of 
contracting myocardium. 
An interesting protocol to investigate the regenerative 
capacity of the side population (highly enriched haemato- 
poietic stem cell fraction residing within the bone marrow) 
was developed by Jackson and colleagues [50]. Lethally 
irradiated mice transplanted with side population cells were 
subsequently rendered ischaernic by transient coronary 
occlusion and reperfusion. Mice were sacrificed at two to 
four weeks after injury. Examination of the hearts once more 
suggested that the bone marrow cells were able to 
transdifferentiate and engraft into myocardium and 
endothelial cells. In another model of myocardial ischaernia, 
systemic infusion of human bone marrow-derived endothetiat 
cell precursors was able to intercept the remodelling process 
of the left ventricle [51 ]. The observed neovascularization 
prevented apoptosis of hypertrophied myocytes reducing 
cottagen deposition and subsequent scar formation. Post- 
transplantation ventricular function improved as well. 
Taking their previous work a step further Ortic et at. 
hypothesised that cytokine mobilization of the animals own 
bone marrow should increase the trafficking of desirable cells 
to the site of myocardial injury [52]. Not surprisingly for 
them, a 68% decrease in mortality with significant haemo- 
dynamic improvement was documented when cytokine (stem 
cell factor and G-CSF) mobilization was undertaken in 
ligature - induced ischaernic mice. 
In all the above studies, cell administration was performed 
by direct intramyocardial injection. Owing to technical 
difficulties, intracoronary infusion in a rodent model cannot 
be performed in the same way as in large animal models or 
humans. In an attempt to reproduce intracoronary delivery, 
two weeks after coronary artery ligation Wang et at. infused, 
under direct vision, mesenchymal stem cell suspensions in 
briefly occluded ascending aortas [53]. Injected cells could be 
identified after three weeks as cardiomyocytes or fibroblasts. 
Once more it was concluded that cells migrated through the 
coronary circulation to sites of injury and under the effect of 
the local microenvironment transdifferentiated into required 
phenotypes. 
The above studies constitute a mere representative 
sample of small animal studies involving adult bone 
marrow-derived stem cell populations. A vast number of 
projects are continuing to be published since these reports 
investigating a variety of cell types in conjunction with 
various cytokines or even gene therapy techniques. Whole 
bone marrow [54,55], mononuclear cell fractions [56], MSCs 
[57-59], angioblasts [60,61] and even novel subpopulations 
[62] are being scrutinised. 
6. Representative large animal studies 
Even though small animal models can offer great insight in 
cellular transplantation it is large animal constructs that 
resemble humans the closest. Unquestionably it is non- 
human primate models that are most similar to humans. A 
remarkable similarity exists between the porcine and human 
coronary anatomy making this model favourable to scientists. 
Finally, the canine and ovine models should not be over- 
looked as they may provide useful alternatives. Apart from 
anatomic and physiologic proximity these models provide the 
ability to perform minimally invasive procedures (angiogra- 
phy, coil embolization, etc. ) with instrumentation developed 
and used in human subjects. In addition, periprocedural 
assessment may be performed with conventional imaging 
techniques thus avoiding the need for developing or even 
adapting equipment to the anatomic and physiologic 
standards of small animals. 
Autologous bone marrow-derived cells were injected by 
Fuchs et at. via the transendocardial route guided by 
ventricular electromechanical mapping in pigs previously 
rendered ischaernic [63]. Regional wall thickening was 
increased in the order of 50% as measured by echocardio- 
graphy in the cell transplanted group while no significant 
change was seen in the control group. Of interest is the fact 
that the only observed improvement in myocardial perfusion 
was localised entirely in injected ischaernic areas. In neither 
group was a positive effect in regional myocardial blood flow 
demonstrated. Histopatho logical examination revealed a 
100% increase in total endothelial cell area in the ischaernic 
collateral -dependent zone compared with the non-ischae- 
mic territory of the cell treated group. 
Four weeks after occlusion of the left anterior descending 
artery with coils and Getfoam sponge Tomita et at. injected 
directly into porcine ischaernic myocardium BrdU [abetted 
marrow stromal cells [64]. Animals were sacrificed 4 weeks 
after cellular transplantation. Tissue slices from trans- 
planted areas contained a number of BrdLI [abetted cells 
that stained positive for troponin 1; some endothelial cells 
from the same areas also stained positively for BrdU. 
Although the authors were unable to identify any junctions 
between these cells and host cardiornyocytes, once more a 
significant improvement both in myocardial blood flow and 
left ventricular performance was shown by scintigraphy in 
the cell transplant group compared to the control animals 
Shake et at. also demonstrated engraftment, using double 
staining for membrane and muscle-specific proteins, along 
with functional improvement [65]. This was once again 
performed with transplantation of mesenchymal stromal 
cells in pigs with left anterior descending coronary artery 
ligature-induced ischaernia. 
The toxicity and therapeutic potency of autologous bone 
marrow cell transplantation has been also assessed in a 
canine chronic coronary occlusion model by Hamano et at. 
[66]. Thirty days after left anterior descending coronary 
artery ligation autologous BMCs were introduced directly into 
infarcted, marginal as well as healthy myocardium. The 
control group received injections of phosphate- buffered 
saline in respective sites. Cardiac function along with local 
wall motion was evaluated by echocardiography thirty days 
after implantation. Angiogenesis was measured by micro- 
vessel counting under light microscopy. A significant increase 
in local wall thickening and density of microvessels was 
documented only in the marginal area of the BMC treated 
group. No further differences were seen between the two 
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groups. Once again no systemic or local toxicity was 
observed. 
investigating whether increased cardiac nerve density can 
contribute to improved cardiac function Pak et at. observed 
overexpression of cardiac tenascin, increased cardiac nerve 
sprouting and amplified magnitude of atria[ sympathetic 
hyperinnervation two months post transplantation of 
mesenchymal stem cells [67]. 
in a non-human primate model, mate and female baboons 
were treated with haernatopoietic growth factors following 
ligation of the lateral branches of the circumflex coronary 
artery [68]. Norot et at. showed regeneration of vascular 
structures in treated animals, but no evidence of cardiac cell 
differentiation. Although in a few animals regional myocar- 
dial blood flow for the infracted area increased, no overall 
improvement was seen in myocardial function between the 
two groups. 
A controversial study in a canine model carried out by 
Vuttiet et at. reported microinfarctions in subjects following 
intracoronary infusion of mesenchymal stromat cells [69]. 
Early passage cells were infused into the circumflex coronary 
artery of healthy dogs. Hearts were examined after 7 days 
and the presence of microinfarctions in areas supplied by the 
circumflex artery was documented. 
A great interest has also been shown in similar models to 
develop reliable techniques that will facilitate implantation 
and continuous tracking of stem cells into myocardial tissue 
[70-72]. A percutaneous transvenous approach through the 
coronary venous system has also been described and 
demonstrated in a porcine model [73]. 
7. Human trial data 
The abovementioned pre-clinical data have encouraged 
clinicians to initiate clinical studies/trials of adult stem cell 
transplantation in myocardial ischaernia (Table 1). All 
research protocols must be in accordance with the Declara- 
tion of Helsinki for medical research involving human 
participants [74]. Crucial aspects of every study design 
include the selection of the cell type to be delivered, timing 
of delivery with regard to the natural progress of the disease 
as well as the optimal route of delivery. Factors guiding 
researchers are the phase of disease (acute myocardial 
infarction or welt-established myocardial ischaernia) and 
patient's clinical status (end-stage heart failure patients 
cannot be enrolled in a trial were cell delivery is combined 
with open-chest surgery). 
7.1. Transepicardial delivery 
First clinical confirmation of the safety of adult bone 
marrow stem cell transplantation was demonstrated by 
Hamano et at. [75]. The five patients enrolled in this pilot 
study underwent local implantation of the mononuclear 
fraction of autologous bone marrow in conjunction with 
standard coronary artery bypass graft (CABG) surgery. 
Bone marrow harvested and processed during the CABG 
procedure was injected directly into ischaernic myocardial 
areas not amenable to grafting. The control group 
consisted of thirty patients having standard CABG during 
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the same period. All participants made an uncomplicated 
recovery with no new-onset arrhythmia or significant 
bleeding seen. Significant improvement was documented 
in 60% of patients at one-year follow-up as assessed with 
myocardial scintigraphy. An observation worth mentioning 
is that computed tomography one year after treatment 
did not reveal the presence of calcification or mass in the 
injected myocardium. 
Clinical safety and enhancement of cardiac function 
has been reported from one more group following a very 
similar protocol [76]. Before sternal split, 5-7 ml of bone 
marrow was aspirated from the sternum of 14 patients. 
CABG was carried out once again while the bone marrow 
was prepared by an aseptic technique. All scarred areas in 
the left ventricle besides the ones residing within the 
intraventricular septum were injected with an unmani- 
pulated cell preparation. Functional improvement was 
only seen in areas were auto transplantation was 
combined with bypass grafting. Once again no complica- 
tions were documented and benefit was maintained at ten 
months of follow-up. 
In mid 2001 the Rostock group recruited patients for the 
first phase-1 study of autologous BMC intramyocardial 
implantation [77,78]. Having aspirated autologous bone 
marrow the day before surgery, selection of CD133+ cells 
took place. From the previously isolated mononuclear 
fraction CD1 33' cells were selected with the use of specific 
monoclonal antibodies conjugated to superparamagnetic 
particles and passage through a CliniMACS Magnetic 
Cell Separation device (Miltenyi Biotech, Germany). The 
final cell suspension was injected the following day in 
the border zone of an infarct that was not accessible 
to routine revascularization. All participants made an 
uncomplicated recovery with no procedure- related com- 
plications recorded up to 14 months after transplantation, 
including new arrhythmias or neoplastic changes. A 
significant improvement in both left ventricular function 
and myocardial perfusion was reported by echocardiogra- 
phy and thallium scans. 
In an attempt to reduce manual cell handling under GMP 
compliant conditions, Ghodsizad and coworkers published a 
refined method that enables intraoperative isolation and 
processing of BMCS in patients simultaneously undergoing 
coronary surgery [79). Following standard CABG, LASER 
channels were shot in predefined areas within the hibernat- 
ing myocardium. CD133+ cell separation and processing was 
concurrently performed in an area connected to the 
operating room where the patients underwent surgery. The 
purified autologous fraction was subsequently injected 
around the laser channels. Cellular transplantation in the 
emergency setting is, therefore, a theoretical possibility as 
suggested by the authors. 
The feasibility of combining off-pump coronary artery 
and autologous bone marrow-derived CD34+ transplanta- 
tion was shown by Nagamine et at. [80]. Using the Isolex 
300i magnetic cell selection system, CD34+ were selected 
and injected directly into ischaernic myocardium. 
Improved perfusion of ungraftable ischaernic areas was 
reported - 
The method of cell collection in the above studies has 
been solely bone marrow harvest, mainly from the iliac 
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crests. In a very recent publication, Pompilio et at. have 
performed intramyocardial delivery of bone marrow mobi- 
Used stem cells obtained via subcutaneous administration of 
G-CSF [81]. Once mobilised, patients were subjected to 
aphaeresis with subsequent CD1 33+ cell fraction isolation by 
means of a CliniMACS device (Miltenyi Biotech, Germany). 
out of the four patients included in this study three had 
accompanying off-pump coronary artery bypass grafting 
performed. In the fourth patient, cells were delivered via a 
minimally invasive transdiaphragmatic approach without any 
additional treatment. Patients tolerated both procedures 
well and made uncomplicated postoperative recoveries. 
Promising preliminary follow-up data has been reported once 
more. 
Mobilised peripheral mononuclear cells were also trans- 
planted in six patients with end-stage congestive heart 
failure [82]. Participants shared a reduced left ventricular 
ejection fraction (LVEF<25%) and were not suitable for 
standard CABG. Interestingly, the cell suspension collected 
by aphaeresis was not only delivered to the injured non- 
fibrotic myocardial tissue directly, but was also infused via 
the coronary arteriotornies while performing the bypass graft 
surgery. Significant improvement was noted in patients' 
symptoms during follow-up with some benefit documented 
also on echocardiography, thailium scintigraphy, and positron 
emission tomography. 
7.2. Intracoronary delivery 
Adult stem cell therapy has also taken its place in the 
centre of clinical research in the field of interventional 
cardiology. Trying to cash in from the possible regenerative 
processes at the myocardial level a vast number of studies 
incorporating intracoronary infusion have been employed. 
The preponderance of these entails delivery within the first 
days after an acute coronary episode thus attempting to 
interrupt the natural progress of the infarction. 
Strauer et at. i nf used autologous mononuclear BMCs in ten 
patients after they received standard therapy for acute 
myocardial infarction [83]. Bone marrow was harvested 
under local anaesthesia the day before transplantation and 
mononuclear cells isolated. The cell suspension was infused 
at high pressure under stop-flow conditions into the infarct- 
related artery above the infarct border zone. Significant 
improvement was seen in left ventricutar function at three 
months follow-up in comparison to the control group. A 
considerable decrease in the perfusion defect was recorded 
as weR on scintigraphy. 
Six-month follow-up data from the BOOST trial was 
published by the Hanover group in mid2004 [84]. Having 
received standard treatment following acute ST-segment 
elevation myocardial infarction sixty patients were randomly 
assigned to a whole BMC infusion or control group, 
respectively. After routine bone marrow harvesting and 4.8 
days on average post myocardial infarction cells were infused 
via the central tumen of an over-the-wire balloon catheter in 
the infarct-related artery. Mean global left ventricutar 
ejection fraction had increased by 6.7% in the cett-infusion 
group compared to 0.7% in the control group. Left- 
ventricutar function was notably enhanced in myocardial 
segments adjacent to the infarcted areas. 
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During the same period the Frankfurt group reported the 
one year follow-up results of the TOPCARE AMI trial (85] of 
which preliminary data had already been announced to the 
medical community [86,87]. The 69 patients were allocated 
to two groups depending on the type of progenitor cell 
infused, being either bone marrow-derived or circulating 
progenitor cells. A significant improvement in left ventricular 
function with reduction of end-systolic volumes was 
documented. No early or late procedure- related comptica- 
tions were seen. 
in another study from China 69 patients having been 
treated for acute myocardial infarction were once again 
randomised to receive either autotogous bone marrow MSCs 
or saline as the control arm [88]. A considerable improve- 
ment was seen at three-month follow-up both in left 
ventricutar haemodynamics as well as in myocardial perfu- 
sion. 
Encouraging results from twenty patients transplanted 
with bone marrow-derived mononuctear cells was also 
reported by Aviles et at. [89,90]. In contrast to the previous 
reports, Kuethe et at. did not reveal any significant 
difference regarding left ventricular function or coronary 
flow reserve at three and twelve-month follow-up [91]. This 
study involved five patients with large anterior myocardial 
infarctions receiving mononuctear cell suspensions. One 
last study worth mentioning comes from a Korean group 
[92]. Investigators examined the efficacy of intracoronary 
delivery of cytokine mobilised peripheral stem cells. 
Despite some encouraging data an increased rate of 
in-stent restenosis was the cause of an early termination 
of this trial. 
7.3. Transendocardial delivery 
Advances in cardiac electrophysiotogy have allowed 
cardiologists to deliver cell suspensions in desired areas as 
seen on left ventricular electro- mechanical mapping. This 
theoretically could prove a valuable approach especially in 
the subgroup of patients with no other standard revascular- 
ization options. The first study in this set provided evidence 
of feasibility with demonstration of potential efficacy [93]. 
Perin et at. treated 14 patients with autologous bone 
marrow-derived cell suspension [94-96]. All had severe 
ischaernic heart failure with no alternative treatment options 
available. Patients were followed up at 2,6 and 12 months 
post implantation. There was significant improvement in 
exercise capacity and myocardial perfusion as compared with 
controls. Tse et at. recorded similar findings at three-month 
follow-up of eight patients of the same status treated with 
autologous mononuclear cell injections [97]. An increase in 
exercise capacity and myocardial volume oxygen consump- 
tion was also documented in five patients with end-stage 
heart failure awaiting transplantation [98]. 
It should be emphasised that all above studies have 
included limited numbers of subjects and with the exception 
of the BOOST trial lack randomisation, placebo controls and 
double blind assessment. All these parameters should be 
taken into consideration whilst undertaking interpretation of 
outcomes. The aftermath of this 'rush' to enter the clinical 
trial setting may backlash on the integrity of the whole study 
when critically analysed. 
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8. Discussion 
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Even if all the theoretical pathways of cell trafficking and 
homing to ischaernia generated signals were to be elucidated 
and fully understood, what takes place once the 'homed' 
cells reach or are directly introduced to their new 
microenvironment is a great mystery and topic of dispute. 
Functional improvement observed in animal and human 
studies may constitute manifestations of either direct 
mechanical reinforcement of the left ventricular wall, 
incorporation and integration of implanted stem cells into 
native myocardial tissue, improvement in neovasculariza- 
tion, or even be a result of paracrine factor production and 
delivery exerted by the implanted cells. Responsible 
mechanisms remain to be unravelled. 
The main attraction of bone marrow-derived stem cell 
transplantation for scientists remains their innate plasticity. 
Proof of principal has been shown by trans-differentiating 
marrow stromal cells into cardiornyocytes in vitro. This has 
mainly been accomplished by treating cells with chemicals 
promoting DNA demethylation, such as 5-aza- 
21deoxycytidine [99-101]. All cells were seen to express 
cardiomyocyte specific genes and could beat on the petri 
dishes. More surprisingly card iomyocyte - like cells have been 
reported to be obtained from adipose tissue-derived stem 
cells with and without pre-treatment [102,103]. In experi- 
mental studies ultimate evidence of successful engraftment 
and incorporation of pre-labetted cells is the identification of 
cells that stain for marker dyes as well as cardiac proteins. 
The perceived plasticity of transplanted cells has been 
attributed mainly to the mechanisms of milieu dependent 
differentiation. The double staining for marker dyes and 
cardiac proteins post transplantation can also be explained 
by cett-cell fusion. Recent work has shown that this 
phenomenon may actually have greater dimensions than 
acknowledged [104]. Celt-cell fusion has been documented 
for both stem cells and cardiornyocytes [105,106]. Finally, Oh 
et at. have shown the two phenomena to happen to a similar 
extent for murine cardiac stem cells transplanted into 
injured left ventricle [12]. 
At this point it should be mentioned that a few 
investigators have published work questioning the transdif- 
ferentiation of haernatopoietic cells transplanted into the 
injured myocardium [107-109]. When unfractionated bone 
marrow labelled with a fluorescent dye was transplanted in 
infarcted areas of myocardium in an ovine model no 
engraftment or transdifferentiation was seen [110]. As noted 
by the authors the discrepancy between results may be 
ascribed to differences in protocol design. 
The ultimate aim of cellular transplantation remains the 
regeneration of lost heart muscle along with reversal of the 
remodelling process. Functional myocardium is made up 
primarily of three cell types: cardiomyocytes, endotheliat 
and smooth muscle cells. Despite the accumulating data of 
the existence of cardiac stem cells and tissue specific stem 
cell subpopulations little information is usually provided in 
the human trials about the evidence of the multipotential 
phenotype of the injected cells. Expression of certain 
transcripts in these cells in conjunction with alterations in 
baseline levels of message as well as protein once tissue 
specific differentiation in vitro is demonstrated should 
probably be established as part of the pre-clinicat bench 
work. 
In addition to failing to identify the actual cell type 
responsible for the observed improvement, other cell-type 
specific complications will not be recognised and attributed. 
By transplanting crude bone marrow cell suspensions or the 
whole aphaeresis teukocyte yield adverse effects may take 
place as cells that do not take part in the regeneration 
process are introduced directly into the intracoronary 
circulation or myocardiurn [92]. 
Local inflammation or failure to 'home' to the site of 
injury may affect post-transptantation survival rates. Mode 
of delivery and phase of injury are crucial determinants in 
this process. It is therefore only reasonable to accommodate 
for these loses when calculating absolute numbers of 
delivered cells in any study design. If the desired effect is 
attributed to a certain subpoputation (CD1 331, MAPCs, etc. ) 
expansion ex vivo may be required to achieve adequate 
number of progenitors and avoid delivering suboptimal cell 
counts. In this context, studies with studies where a very 
small amount of whole bone marrow is delivered and no 
control groups exist should be perceived with caution, as the 
final effective population of cells delivered may be 
negligible. 
Local injury has been shown to be a pre-requirement for 
engraftment in animal studies. Cells delivered in control 
animals with no injury did not show any sign of engraftment 
[111]. Intracoronary infusion of cell suspension in healthy 
canines lead to micro- in farction s, as no local cues were 
available for cell homing and attraction, and there probably 
was no distinguishing factor between these cell boluses and 
systemic emboti [92]. The time of delivery should be at the 
cross over point in time where the local microenvironment is 
ready to receive cells at the optimum time of their 
development for that particular phase of the disease. Lu 
and coworkers have shown that following myocardial 
infarction in a rat model the local cues for homing of 
circulating cells at the site of injury are restricted to days 3 
and 7 post infarction [112]. They concluded that the 
potential for bone marrow-derived progenitor cell regenera- 
tion resides within the two first weeks. The degree of 
differentiation required should be established before 
transplantation. An immature, more plastic cell may be 
more effective than an ex vivo pre- differentiated, com- 
mitted cell and vice versa. Bittira et at. have actually shown 
that in the acute setting unmodified marrow stromal cells 
facilitate myocardial angiogenesis and myogenesis, whereas 
converting scar into myogenic tissue may be augmented by 
cell preprogramming before implantation [113]. 
Ischaernic myocardiurn constitutes a hostile environment 
for transplanted cell populations. In an effort to overcome 
this and improve cell survival during this stage many 
strategies are being developed. These include angiogenic 
pretreatment with injection of an adenovirus encoding 
VEGF [114], prevascutarization with gelatin microspheres 
containing various growth factors [115] and finally, ex vivo 
retroviral transduction of cells to overexpress prosurvival 
genes [59]. 
From the animal studies Kocher carried out to the Rostock 
experience, endothetiat progenitor cells have been shown to 
provide functional improvement of the injured left ventricle. 
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it remains unclear if the observed neovascularization is the 
direct result of trans-differentiation /incorporation of 
injected cells into newly formed vessels or the indirect 
effect of paracrine factor delivery. With the use of high- 
power laser scanning confocal microscopy two groups have 
demonstrated that double staining for marker dyes and 
endothelial proteins post- tran sp lantation with conventional 
light or fluorescence microscopy may be dubious [116,117]. 
Transplanted cells were not actually in the vessel wall but the 
perivascular space. 
A topic of concern associated with the observed 
angiogenesis following progenitor cell transplantation is 
the possible accelerated development of atheromatous 
plaques. Re-endothelialization and inhibition of neointimal 
hyperplasia are considered key functions of endothelial 
progenitor cell populations [118,119]. On the other hand 
promotion of neointimal hyperplasia has mainly been 
attributed to smooth muscle progenitor cells. Progenitor 
cell transplantation has been implicated in the promotion of 
neointimal hyperplasia either via direct differentiation of 
progenitor population into vascular smooth muscle cells or 
attraction of these cells via paracrine effects [120]. 
Lastly, the argument of an early paracrine effect being 
responsible for the observed myocardial functional improve- 
ment has been strengthened by the work of Dai et at. [121]. 
Following attogenic mesenchymat stem cett transplantation 
in postinfacted rat myocardiurn surviving mesenchymal stem 
cells were seen up to 6 months expressing muscle and 
endothelial phenotypes. The documented functional 
improvement was transient though being limited to the first 
four weeks. 
9. Closing comments 
It was more than thirty years ago when Sen described his 
'snake-heart operation', consisting of multiple full-thickness 
acupuncture of the ventricular wall to improve myocardial 
blood supply [122]. Today not only have researchers 
surpassed the concept of offering patients 'reptile' hearts, 
but are allowed to aim for de novo reconstitution of injured 
human myocardium. Identification of cell subpopulations 
responsible for the observed myocardial regeneration, 
improvement in cell expansion techniques along with 
development of in vivo dynamic cell tracking methods are 
areas of future research. Large, prospective, double blind 
randomised controlled trials are also warranted. Results f rom 
the laboratory and clinical front will decide if autologous 
cellular transplantation (atone or in conjunction with 
established therapies) will be offered routinely to patients 
suffering from ischaemic heart disease. 
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ABSTRACT 
A phase I study was performed to determine the safety 
and tolerability of injecting autologous CD34' cells into 
five patients with liver insufficiency. The study was based 
on the hypothesis that the CD34' cell population in gran- 
ulocyte colony -stimulating factor (G-CSF) -mobilized 
blood contains a subpopulation of cells with the potential 
for regenerating damaged tissue. We separated a candi- 
date CD34' stem cell population from the majority of the 
CD34' cells (99%) by adherence to tissue culture plastic. 
The adherent and nonadherent CD34' cells were distinct 
in morphology, immunophenotype, and gene expression 
profile. Reverse transcription-polymerase chain reaction- 
based gene expression analysis indicated that the adher- 
ent CD34' cells had the potential to express determinants 
consistent with liver, pancreas, heart, muscle, and nerve 
cell differentiation as well as hematopoiesis. Overall, the 
characteristics of the adherent CD34+ cells identify them 
as a separate putative stem/progenitor cell population. In 
culture, they produced a population of cells exhibiting 
diverse morphologies and expressing genes corresponding 
to multiple tissue types. Encouraged by this evidence that 
the CD34+ cell population contains cells with the poten- 
tial to form hepatocyte-like cells, we gave G-CSF to rive 
patients with liver insufficiency to mobilize their stem 
cells for collection by leukapheresis. Between 1X 106 and 
2x 10' CD34' cells were injected into the portal vein 
(three patients) or hepatic artery (two patients). No com- 
plications or specific side effects related to the procedure 
were observed. Three of the five patients showed improve- 
ment in serum bilirubin and four of five in serum albu- 
min. These observations warrant further clinical trials. 
STEM CELLS 2006; 24: 1822-1830 
INTRODUCTION 
Liver transplantation is the only current therapeutic modality for 
liver failure, but due to the shortage of organ donors, it is 
available to only a small proportion of patients. Adult stem cell 
therapy could solve the problem of degenerative disorders, 
including liver disease, in which organ transplantation is inap- 
propriate or there is a shortage of organ donors. This view is 
predicated upon the evidence that stem cells, particularly those 
in hematopoietic tissue, have the ability to develop into endoder- 
mal, mesodermal, and ectodermal cell types [1]. 
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Several sources of stem cells have been proposed as sources 
for cell therapy. Embryonic stem cells are the most potent in 
terms of their differentiation potential but may be turnorigenic 
when transplanted in vivo, and their use is beset by ethical issues 
[2,3]. Adult stem cells may be found in any tissue [1], but 
hematopoietic tissue is most accessible. Hematopoietic tissue 
contains two types of stem cells, the mesenchymal and hema- 
topoiefic stem cells. Mesenchymal stem cells (MSCs) were first 
described by Friedenstein et al. in 1974 [4]. More recently, MSC 
cultures were shown to contain multipotential adult progenitor 
cells (MAPCs) [5], unrestricted somatic stem cells (USSCs) [6], 
and rapidly self-renewing (RS) cells [7,8], all of which may 
represent early stages in MSC development. However, none of 
these cell types can be identified in fresh hematopoietic tissue 
[9]. In addition, they cannot be discriminated phenotypically 
from the bulk MSC population in culture, although Smith et al. 
[10] have separated RS cells from more mature cells in MSC 
cultures by flow cytometry based on the forward and side light 
scattering properties of the cells. 
Stem cells in hematopoietic tissue have been used for he- 
matological reconstitution for many years [I I]. These cells are 
CD34' and CD133' and give rise to all lineages of blood cell 
differentiation. Thus, they have the advantage that they can be 
prospectively isolated from hematopoietic tissue in known num- 
bers. Recently, they have been used to transplant patients with 
liver disease [12] or cardiac insufficiency [13]. These experi- 
ences led us to hypothesize that the regenerative activity of 
CD34/CD133' stem cells resided in a CD34' subpopulation. 
Here, we sought to identify and characterize the CD34' cells 
with regenerative potential and found that they could be sepa- 
rated from the majority of the CD34' cells by their plastic 
adherent properties. As we will show, these cells have a small 
lymphocyte-like morphology that has long been associated with 
primitive stem cell populations. In light of the knowledge that 
the CD34' cell population contained an identifiable candidate 
stem cell population, we used CD34' cells for a phase I study 
of cell therapy in patients with liver disease. 
MATERIALS AND METHODS 
Preclinical In Vitro Studies 
Cell Source. Granulocyte colony- stimulating factor (G- 
CSF)-mobilized peripheral blood cells were obtained from 
leukaphereses processed by the Stem Cell Laboratory, Ham- 
mersmith Hospital, in excess of clinical requirements. In- 
formed consent and local research ethics committee approval 
were granted in all cases. 
Cell Isolation. CD34' cells were diluted at 1: 4 in Hanks' buff- 
ered saline solution (HBSS; Gibco, Paisley, U. K., http: //www. 
invitrogen. com) before the mononuclear cells (MNCs) were sepa- 
rated by centrifugation over a Lymphoprep (Axis-Shield, 
Kimbolton, Cambridgeshire, U. K., http: //www. axis-shield. com) 
density gradient at 1,800 rpm for 30 minutes (Heraeus, Hanau, 
Germany, http: //www. heraeus. com). 'I'he MNC fraction was col- 
lected and washed first in HBSS, then with MACS (magnetic cell 
sorting) buffer (phosphate-buffered saline buffer supplemented 
with 0.5% bovine serum albumin and 5 mM EDTA, pH 7.2). 
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CD34' cells were isolated from MNCs, using the CD34+ positive 
cell selection kit (MiniMacs; Miltenyi Biotec, Bergisch Gladbach, 
Germany, http: //www. miltenyibiotec. com). 
Cell Culture. Isolated CD34' cells were plated on 35-mm' 
Petri dishes in a-minimal essential medium (a-MEM) supple- 
mented with 15% fetal bovine serum (FBS) and incubated for 2 
hours at 37'C and 5% C02. After 2 hours, the nonadherent cell 
fraction was removed by washing the plates three times. Adher- 
ent CD34' cells were cultured in a-MEM supplemented with 
30% FBS and cytokines (20 ng/ml stem cell factor [SCF], I 
ng/ml GM-SCF, 5 ng/ml IL-3, and 100 ng/ml G-CSF) at 37T 
in 5% C02 in air. 
Telomerase Assay. Cells were lysed in Ix 3-[(3-cholamido- 
propyl)dimethylammoniol-i-propanesulfonic acid (CHAPS) 
buffer, and the lysates were analyzed using the TRAPeze te- 
lomerase detection kit (InterGen, Burglington, MA, http: Hwww. 
intergen. com) according to the manufacturer's instructions. 
RNA Isolation. RNA was isolated from fresh cells and from 
cells that had been cultured for 7 days using the RNeasy Mini kit 
according to the manufacturer's instructions (Qiagen, Crawley, 
West Sussex, U. K., http: //wwwl. qiagen. com). To ensure purity 
of the RNA, the samples were treated with DNase (Promega 
UK, Southampton, U. K., http: //www. promega. com). The RNA 
was then purified using the Qiagen PCR Purification Kit ac- 
cording to the manufacturer's instructions. Total RNA concen- 
tration was determined by measuring the optical density at 260 
nm in a spectrophotometer (Eppendorf UK Limited, Cambridge, 
U. K., http: //www. eppendorf. com). 
Reverse Transcription-Polymerase Chain Reaction 
Reverse transcription-polymerase chain reaction (RT-PCR) was 
carried out using the One-step RT-PCR Kit (Qiagen). A master 
mix sufficient for 40 reactions was prepared in a 1.5-ml Eppen- 
dorf tube consisting of 300 tLI of 5X RT-PCR buffer, 60 Al of 
dNTP, 150 jil of Q solution, 650 Al of RNase-free water, and 80 
A] of RT-enzyme mix. Twenty microliters from the RT-PCR 
master mix was then aliquoted into each tube, with an overlay of 
50 tLI of mineral oil to prevent evaporation. 
Positive controls were a pool of RNA known to be 
positive for the genes of interest by RT-PCR and sequence 
verification by the Medical Research Council sequencing 
laboratory at the Hammersmith Hospital. Both negative con- 
trols and culture medium controls were used to exclude 
false-positive results. As an internal RNA standard, the 
housekeeping gene GAPDH (glyceraldehyde-3 -phosphate de- 
hydrogenase) was used. 
RT-PCR conditions used were as follows: RT at 500C for I 
hour; PCR activation at 950C for 15 minutes; three-step cycling 
at 95'C for I minute, NOC for I minute, and 72'C for I minute 
for 35 cycles; and final extension at 72'C for 10 minutes, where 
N is the gene-specific RT-PCR annealing temperature. 
Nested PCR. Nested PCR was performed by adding 2 gl of the 
corresponding RT-PCR product to each PCR tube along with 2 PI 
of the appropriate nested forward and backward primer mix and 20 
Al of nested PCR mix. For the genes a-] antitrypsin, c-nzet, 
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vimentin, a-fetoprotein, [3-cellulin, and CK19, a separate PCR mix 
containing 2.5 Al of 50 mM MgC'2 was prepared. Nested PCR 
conditions used were as follows: 50'C for I minute; 95'C for 15 
minutes-, and 35 cycles of 95'C for I minute, NT for I minute, and 
72'C for I minute, and 72T for 10 minutes, where N is the 
gene-specific nested PCR condition temperature. 
Gel Electrophoresis. RT- and nested PCR products were ana- 
lyzed by agarose gel electrophoresis and visualized under UV light 
on a transilluminator (Ultra-Violet Products Ltd., Cambridge, U. K., 
http: //www. uvp. com), and images were captured using a digital 
camera (Ultra-Violet Products Ltd. ) connected to a computer. 
Flow Cytometry. For surface staining, at least IX 10' cells 
were labeled with directly conjugated or unconjugated antibody. 
A fluorescein isothiocyanate (FITC)-conjugated secondary an- 
tibody was added to cells labeled with unconjugated primary 
antibody. A commercial cell fixation and permeabilization kit 
(Caltag Laboratories, Burlingame, CA, http: //www. caltag. com) 
was used for intracellular staining according to the manufactur- 
er's instruction. The antibodies used were CD34-phycoerythfin 
(PE) (BD Biosciences, San Diego, http: //www. bdbiosciences. 
com), CD54-PE (intercellular adhesion molecule I [ICAM-1]; 
BD Biosciences), CD184 CXCR4 (BD Biosciences), epithelia] 
cell adhesion molecule (EpCAM)-PE (Miltenyi Biotec), anti- 
mouse-FITC (Dako UK Ltd., Ely, Cambridgeshire, U. K., http: H 
www. dako. com), nestin (AbCam, Cambridge, U. K., http: //www. 
abcam. com), vascular endothelial growth factor receptor 2 
(VEGFR2), and vimentin (Dako UK Ltd. ). Appropfiate isotype 
controls were included in all cases. Stained cells were analyzed 
on a FACS Calibur flow cytometer (BD Biosciences). 
Clinical Study 
Patient Selection. Patients were recruited with ethics commit- 
tee approval and according to criteria determined by the Multi- 
disciplinary Treatment (MDT) committee of the Hammersmith 
Hospital. Informed consent was granted in all cases. Inclusion 
criteria were the following: age 20-65 years, chronic liver 
failure, abnormal serum albumin and/or bilirubin and/or pro- 
thrombin time, unsuitable for liver transplantation, World 
Health Organization performance status less than 2, women of 
child-bearing potential using reliable and appropriate contracep- 
tion, life expectancy of at least 3 months, and ability to give 
informed consent. Exclusion criteria were the following: pa- 
tients aged less than 20 or more than 65 years; liver tumors or 
history of other cancer; pregnancy or lactation; recurrent gas- 
trointestinal bleeding or spontaneous bacterial peritonitis; active 
infection, including HIV; and inability to give informed consent. 
Prospective patients were admitted for liver function tests, 
full blood count, coagulation profile, a-fetoprotein levels, com- 
puted tomography (CT) scan, visceral angiography, and a Du- 
plex Doppler scan. They were then discharged home pending a 
discussion by the MDT committee as to their suitability for 
inclusion in the study. 
Included patients were admitted and given subcutaneously 520 
Ag of G-CSF (Chugai Pharmaceuticals Co., Ltd., Tokyo, http: // 
www. chugai-pharm. co. jp) daily for 5 days to increase the number 
of circulating CD34+ cells. Leukapheresis was performed on day 
Stem Cells and Liver Insufficiency 
5. The leukapheresis product was transferred to the laboratory, 
where CD34' cells were immunoselected using the CliniMacs 
device (Miltenyi Biotech). The CD34' cells were then returned to 
the patient via the hepatic artery or portal vein in the Imaging 
Department. Patients were discharged after overnight bed rest. 
Patients returned to the outpatient clinic on days 7,15,30,45, 
and 60 after infusion for liver function tests, full blood count, 
coagulation profile, and ct-fetoprotein assay. In addition, on day 
60, ultrasound and CT scans of the liver were performed. 
RESULTS 
Adherent CD34' Cells Are Distinct from 
Nonadherent CD34' Cells 
Separation of plastic adherent cells from MNC fractions is a pro- 
cedure used to initiate MSC cultures. However, the MSCs rapidly 
outgrow any other cell types that may be present. Here, we purified 
CD34' cells and then subfractionated the population into adherent 
and nonadherent cells. By direct observation and cell counting, the 
adherent subpopulation comprises approximately I% of the total 
CD34' cell population. Morphologically, the adherent cells were 
small and lymphocyte-like with a high nuclear/cytoplasmic ratio, 
whereas the nonadherent cells exhibit a larger blast cell-like mor- 
phology (Fig. IA). Phenotypically, the adherent CD34' cells were 
99% pure and expressed uniformly low levels of CD38, CD33, and 
HLA-DR. In this characteristic, they differ from the nonadherent 
CD34' cells, which exhibit significantly greater variability in the 
expression of these antigens (Fig. 1B). 
We used RT-PCR to compare the gene expression profiles 
of the adherent and nonadherent CD34' fractions. Fifteen genes 
were analyzed, and all were expressed in the adherent CD34+ 
cells, whereas only two were expressed in the nonadherent 
CD34' cell fraction (Fig. I Q. These two were angiopoietin-2 
and ICAM-2, both of which are associated with hematopoietic 
cell differentiation [14,15]. 
Overall, these data show that the adherent and nonadherent 
CD34' cells are distinct populations that can be distinguished 
by their different morphologies, phenotypes, and gene expres- 
sion profiles. 
Adherent CD34+ Cells Are Primed to Generate 
Multiple Tissue Types 
Enver and colleagues [ 16] hypothesized that primitive stem cells 
express genes that indicate their potential to differentiate into 
different lineages and cell types. Accordingly, we examined the 
gene expression profile of the cells by RT-PCR using probes 
corresponding to genes known to be expressed in liver and in a 
range of other nonhematopoietic tissues. Figure 2A demon- 
strates the expression of genes associated with liver cell differ- 
entiation. As may be seen from Figure 2B, the cells also ex- 
pressed multiple genes associated with the stem cell state and 
genes associated with pancreatic, cardiovascular, muscle, and 
nerve cell differentiation. Expression at the protein level was 
demonstrated for CD34, VEGFR2, CD54, nestin, and EpCAM 
by flow cytometry (Fig. 2C-2H). 
Although none of the genes tested is exclusive to the stem 
cell state or tissue lineage differentiation, these results indi- 
cate that the adherent CD34' cell population is a putative 
stem/progenitor cell population that may have the potential to 
generate cells corresponding to a range of tissue types. 
STT-M CELLS 
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Diverse In Vitro Differentiation Potential of 
Adherent CD34+ Cells 
Adherent CD34+ cells have been isolated from 100% of the 
125 leukapheresis samples analyzed and have been cultured 
successfully in 98.4% of cases. At the initiation of the cul- 
ture, the cells did not express telomerase, as assessed by the 
telomere repeat amplification protocol (TRAP) assay, which 
is consistent with stem cell quiescence, but telomerase was 
detectable in 7-day-old cultures (Fig. 3A). During culture, the 
adherent cells increased in number and released nonadherent 
cells into the culture supernatant to achieve a 3-log increase 
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Figure 1. Comparison of adherent and non- 
adherent CD34' cells at isolation. (A): Mor- 
phologies of freshly isolated adherent (left 
panel) and nonadherent (right panel) CD34- 
cells. (B): Percentages of CD38_, CD33-, 
and HLA-DR_ cells in the adherent and 
nonadherent CD34' cell fractions. (Q: 
Polymerase chain reaction analysis of gene 
expression by adherent and nonadherent 
CD34' cells. (D): Flow cytometric analy- 
sis of rhodamine staining of adherent and 
nonadherent CD34' cells. x-axis, forward 
scatter, y-axis, fluorescence intensity. 
Cell within the gate stain brightly with 
rhodamine. 
Figure 2. Expression analysis of adherent 
and nonadherent CD34+ cells at isolation. 
(A): Expression of genes associated with 
liver cell differentiation by freshly isolated 
adherent CD34- cells. Lane 1: Fresh adher- 
ent CD34' cells. Lane 2: Negative control. 
Lane 3: Culture medium control. (B): Ex- 
pression of genes associated with stem cells 
and with pancreatic, cardiovascular, and 
nerve cell differentiation by freshly isolated 
adherent CD34' cells. (C-H): Flow cyto- 
metric analysis of freshly isolated CD34' 
cells. x-axis, forward scatter; y-axis, fluores- 
cence intensity. Antigen-positive cells are 
located within the gate. Abbreviation: bp, 
base pairs. 
in total cell number in 2-3 weeks (Fig. 313). The morphology 
of the majority of the adherent cells remained round and 
mononuclear for the first 3-5 days of culture, and clusters of 
adherent CD34' cells were also observed, indicating that the 
primitive cells can self-renew and maintain their phenotype 
(Fig. 3C). Morphological differentiation began after day 3, 
and the proportion of differentiated cells increased with time. 
The differentiated cells assumed various morphologies, in- 
cluding adherent spindle-shaped fibrobast-like cells (Fig. 
3C). In addition, large "colonies" of cells were seen floating 
in the culture supernatant. These colonies were picked out of 
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the cultures, cytospun onto glass microscope slides, and 
stained with May Grunwald-Giemsa. They consisted of gran- 
ulocytic, monocyte-macrophage, megakaryocytic, and ery- 
throid cells (Fig. 31)). The cells were also plated into a standard 
hematopoiefic colony assay. Typically, approximately 1% of the 
cells formed granulocyte-macrophage colonies (CFU-GM). Burst- 
forming units-erythroid (BFU-E), megakaryocytic CFU-Mk, and 
multipotential colony-forming unit-granulocyte, -erythrocyte, 
-monocyte, and -megakaryocyte (CFU-GEMM) were also seen. 
Extensive Gene Expression Is Maintained by 
Cultured CD34' Cells 
The expression of genes associated with liver cell differentiation 
was maintained in culture (Fig. 4A) as was expression of genes 
for cardiovascular, muscle, and nerve cell differentiation (Fig. 
4B). Expression at the protein level was demonstrated by flow 
cytometry and immunocytochernistry (Fig. 4C-4K). This main- 
tenance of gene expression by cultured cells indicated that the 
adherent CD34' cells may generate progeny capable of differ- 
entiating along multiple tissue lineages. C 
Clinical Study 
Five patients (four males and one female) aged 49-61 (mean 
49) years were recruited to the study and underwent the entire 
procedure. In three patients the cells were injected into the 
portal vein under CT scan, and in two patients they were 
injected via the hepatic artery. The etiology, diagnosis, clin- 
ical signs, results of investigations, cell concentrations, and 
postinfusion observations for each patient are shown in Ta- 
bles I to 3. 
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Figure 3. Characterization of cultured ad- 
herent CD34' cells. (A): Telomerase activ- 
ity in freshly isolated CD34' cells and in 
their progeny in culture. Telomerase activity 
was not found in fresh cells but was detected 
in cultured cells. (B): Growth curve of ad- 
herent CD34' cells and their progeny in 
culture showing cumulative and actual cell 
numbers. (Q: Morphologies of adherent 
CD34' cells and their progeny in culture. 
Top left and center panels show cells imme- 
diately after plating and after 3 days of cul- 
ture, respectively. (D): Morphology of cells 
recovered from "colonies" floating in the 
culture supernatant ([C], middle left panel). 
After G-CSF treatment, increased total white blood cell 
counts indicated mobilization of progenitor cells in all patients. 
All patients experienced thrombocytopenia (as expected after 
leukapheresis), but platelet counts returned to baseline within I 
week. Patients were given IX 106 -2 X 108 CD34' cells as a 
single bolus. No mortalities or specific side effects, except for 
mild pain and discomfort at the site of CD34' cell infusion, 
were recorded. In particular, there was no bleeding or infection 
of significant deterioration in liver function. CT scans showed 
no evidence of focal liver lesions in any patient either before or 
after treatment, and Duplex Doppler ultrasound scans showed 
patent portal veins with hepatopedal flow. 
Patient I showed initial improvement in serum bilirubin 
from 32 mM to normal, but this reverted to baseline by day 60; 
in patient 2, C-reactive protein (25-7 mg/1) and serum bilirubin 
(31-15 mM) normalized and serum albumin increased from 
33-37 g1l; the only changes recorded in patient 3 were decreased 
ALT (alanine aminotranferease) from 87-61 UA and AST (as- 
partate aminotransferase) from 131-92 U/1); patient 4 experi- 
enced an initial improvement in liver function, but this was 
interrupted due to a severe urinary tract infection that necessi- 
tated hospitalization and treatment with antibiotics; in patient 5, 
there was a dramatic improvement in serum bilirubin from 
126-25 jiM and an increase in serum albumin from 20-25 g/l. 
The levels of serum albumin and bilirubin for the individual 
patients are shown in Figure 5A-5E. Figure 5F and 5G shows 
the percentage changes in serum bilirubin and albumin levels for 
the entire group of five patients, and Figure 5H shows the 
disappearance of ascites as demonstrated by CT scan in 
patient 5. 
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Table 1. Etiology of patients in phase I trial 
Patient Patient Patient Patient Patient 
Criteria 12345 
Age 42 48 41 55 61 
Gender Male Male Male Female Male 
Diagnosis 
Cirrhosis Y Y Y Y Y 
Alcoholic Y Y Y Y N 
Hepatitis B Y N N N N 
Hepatitis C N N Y Y N 
Symptoms 
Jaundice N Y N Y Y 
Fever N N N N N 
Weight loss N N N Y N 
Fatigue Y Y N Y Y 
Abdominal pain N Y N N Y 
Constipation N N N N N 
Loose stools N Y N N N 
Abbreviations: N, no; Y, yes. 
DisCUSSION 
Cellular therapies based on stem cells and their derivatives are 
destined to revolutionize the practice of medicine in the near 
future. They hold the promise of cures for a great variety of 
conditions and diseases of tissue injury and degeneration rang- 
ing from Alzheimer's disease to trauma-induced injuries of the 
musculoskeletal system [171. The essential requirements for 
stem cell therapy are (a) an easily procurable source of the stem 
cells themselves, (b) identification and characterization of the 
stem cell properties, (c) ability to increase ("expand") cell 
numbers in culture reliably and reproducibly, (d) potential for 
differentiation of stem cell progeny into the desired tissue 
type, and (e) demonstration that the transplanted cells 
im- 
prove the function of damaged tissue. Other requirements 
that have been proposed are clonality and robustness. How- 
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Figure 4. Expression analysis of cultured 
adherent CD34' cells. (A): Expression of 
genes associated with liver cell differentia- 
tion by cultured adherent CD34' cells. Lane 
1: Cultured cells. Lane 2: Negative control. 
Lane 3: Culture medium control. (B): Ex- 
pression of genes associated with stem cells 
and with pancreatic, cardiovascular, and 
nerve cell differentiation by cultured adher- 
ent CD34' cells. (C-K): Flow cytometry 
and immunocytochernistry. Abbreviation: 
bp, base pairs. 
Table 2. Clinical signs and investigations of patients in 
phase I study 
Signs 
Patient 
1 
Patient 
2 
Patient 
3 
Patient 
4 
Patient 
5 
Pallor N N N y y 
Petechae N N N N N 
Jaundice N y y y y 
Pedal edema N y N y N 
Acites N y N y y 
Hepatomegaly N N N N N 
Splenomegaly y N y y N 
Investigations 
Cirrhosis y y y y y 
Acites N y N y y 
Splenomegaly y y y y 
Portal vein Patent Patent Patent Patent Patent 
Abbreviations: N, no; Y, yes. 
ever, even cloned cell populations develop heterogeneity as 
they proliferate [ 18,19]. It has been suggested, therefore, that 
cell population studies may be more important than clonality 
studies in defining the plasticity of stem cells, because plas- 
ticity may reflect the probability of stem cells differentiating 
into the appropriate lineage when they are placed in the 
correct microenvironment [9]. 
Adult human bone marrow and peripheral blood are easily 
available sources of stem cells. They contain two major types of 
stem cells, the hematopoietic stem cells and the MSCs. Classi- 
cally, the hernatopoietic stem cells are the source of all of the 
circulating mature blood cells, whereas the MSCs provide the 
stromal cells constituting the microenvironment within the mar- 
row cavities. More recent data indicate broader potential for 
MSCs [20] in particular. Herein, we describe evidence that 
CD34+ cells have the ability to improve liver function in 
patients with liver disease. 
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Table 3. Injection routes and cell concentrations plus postinjection observations 
Injection Patient I Patient 2 Patient 3 Patient 4 Patient 5 
Site Portal V Portal V Portal V Hep Arter Hep Arter 
Number CD34' cells Ix 106 2x 108 1x 106 2x log IX 106 
Postinjection 
Fever N N N N y 
Pain N y y y y 
Nausea y y y y y 
Vomiting N N y y N 
Jaundice N y y y y 
Acites N y N y y 
Bleeding N N N N N 
Abbreviations: Arter, artery-, Hep, hepatic, N, no-, V, vein, Y. yes. 
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Figure 5. Post-transplant follow-up of pa- 
tients in phase I trial. (A-E): Changes in 
serum bilirubin and albumin levels after 
cell infusion in patients I to 5 (normal 
ranges: albumin 33-47 g/l, bilirubin 3-21 
AM). (F): Percentage changes in serum 
bilirubin levels after cell infusion in pa- 
tients I to 5. Sustained reductions in bili- 
rubin were observed in three patients. (G): 
Percentage changes in serum albumin lev- 
els after cell infusion in patients I to 5. 
Increased levels of albumin were seen in 
four patients. (H): Computed tomography 
scans of the liver of patient 5 before and 
after cell infusion, showing resolution of 
the ascites 2 months after transplant. Ab- 
breviation: UTI, urinary tract infection. 
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Hematopoietic stem cells have been known to exist since 
the early studies of Till and McCulloch [21], whereas the 
MSCs were originally found in mouse bone marrow by 
Friedenstein et al. in 1974 [4] and later became known as 
bone marrow fibroblasts or stromal cells (reviewed in [22]). 
The term "mesenchymal stem cells" has been used only 
relatively recently. It has been known for a long time that 
cultures of bone marrow stromal cells may be induced to 
form adipocytes, osteoblasts, and endothelial cells [22] and 
that their phenotype includes expression of smooth muscle 
actin [23]. However, the phenotype of MSCs remains rela- 
tively poorly characterized [241 so that pure populations 
cannot be prospectively isolated from bone marrow. Simi- 
larly, the multipotential adult stem cells (MAPCs) [5] and 
USSCs [6] cannot be defined in freshly harvested hemato- 
poietic tissue but are only characterized after prolonged in 
vitro culture [9]. In contrast, adherent CD34' cells can be 
prospectively isolated from bone marrow or blood in known 
numbers and as a morphologically and immunophenotypi- 
cally defined cell population. We acknowledge, however, 
that even highly purified stem cells are heterogeneous with 
regard to their functional characteristics and that they may 
exhibit phenotypic changes during the cell cycle [9]. It is 
relevant, therefore, that G-CSF-mobilized CD34+ cells have 
been demonstrated to be predominantly quiescent [25,261, a 
feature that might be expected to contfibute to their relative 
uniformity at the time of isolation. 
The numbers of stem cells available to start a culture is a 
limiting factor in the progress of tissue regeneration from stem 
cells. Conveniently, there are large numbers of adherent CD34' 
cells in "mobilized" PBPC (peripheral blood progenitor cell) har- 
vests. Mobilization refers to the procedure whereby stem cells in 
the marrow are induced to enter the bloodstream when donors are 
treated with G-CSF and the circulating cells are harvested by 
leukapheresis. Typical yields of cells, obtained in our institution 
from donors for hematology patients, range from 5-10 X 10'0, of 
which most are MNCs and approximately I% are CD34' (5- 10 X 
108) . The CD34-' cells are separated using the 
CliniMACS device 
(a scaled-up version of the MiniMACS for clinical use). The 
adherent CD34+ cells constitute approximately 1% of the total 
CD34+ population so that a typical leukapheresis provides 5-10 X 
106 putative stem/progenitor cells, and they have been successfully 
isolated in 100% of cases tested. Yields of this magnitude reduce 
the degree of cell number expansion and the time required to 
generate a clinically useful product. 
In vitro culture of the adherent CD34' cell fraction indicates 
the option to transplant their more differentiated progeny, which 
may be appropriate for some clinical applications. A 3- to 4-log 
expansion in cell number is achievable within 1-2 weeks (Fig. 
3) and would provide 5-10 X 10' cells for clinical application. 
In our hands, the cells have been isolated in 100% of the cases 
tested. The cell expansion is also highly reliable and reproduc- 
ible and has been successful in 98.4% of the 125 cultures we 
have initiated. 
Both before and after culture, the adherent CD34' cells and 
their progeny express an array of gene products as revealed by 
RT-PCR analysis, flow cytometry, and immunocytochernistry 
and adopt morphologies consistent with the tissue lineages 
shown in Figure 3. The RT-PCR studies are particularly crucial 
because it has been shown that some proteins, like albumin and 
1829 
insulin, can be taken up by the cells from the culture medium 
and are detectable by immunocytochernistry and flow cytom- 
etry. The RT-PCR results indicate that adherent CD34' cells 
differentiate into cells expressing markers associated with, but 
not exclusive to, hematopoietic, hepatic, pancreatic, cardiovas- 
cular, and nervous tissues. 
The phase I clinical study demonstrated the safety of ad- 
ministering G-CSF followed by leukapheresis and reinfusion of 
CD34' cells in patients with liver insufficiency. It is important 
to note that the patients could respond to G-CSF treatment and 
that their white blood cell counts were increased in all cases, 
because this is a prerequisite for the remainder of the treatment 
protocol. However, the cell yields were lower than those ex- 
pected from donors for hematology patients. Clinically, the 
procedure was well tolerated with no observed procedure-re- 
lated complications. There were no cases of hepatorenal syn- 
drome, and injection of the CD34' cells into the hepatic artery 
or portal vein did not result in any thrombotic episode or 
bleeding after the percutaneous procedure. Importantly, there 
was some evidence of improvement in albumin and bilimbin 
levels, even though the trial was designed to be a safety and 
efficacy study. 
Administration of G-CSF to liver failure patients being 
treated with interferon--y did not result in any additional clinical 
improvement (N. Habib, unpublished data). Thus, whereas G- 
CSF-mobilized cells circulate through the liver, we propose that 
the relevant stem cells are only a tiny minority of the total 
population. Therefore, we speculate that stem cell engraftment 
in damaged liver is considerably enhanced by high concentra- 
tions of relevant stem cells delivered directly to the injured 
tissue. The distinct cellular and molecular properties of the 
adherent CD34+ cells lead us to believe that they, rather than 
nonadherent CD34+ cells, are responsible for the potential 
clinical benefit. At this stage, the mechanism for the effect on 
liver function is not clear but may reflect activation of genes 
corresponding to a hepatocyte differentiation program upon 
exposure to the injured liver environment. 
CONCLUSION 
Overall, these results are encouraging for the future develop- 
ment of stem cell therapy for patients with liver insufficiency. 
Currently, we are initiating a phase I/11 clinical trial to test the 
hypothesis that cells derived from adherent CD34' putative 
stem/progenitor cells are responsible for the clinical improve- 
ment seen in patients with liver damage. 
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Cell Culture Medium Composition and Translational Adult 
Bone Marrow-Derived Stem Cell Research 
IOANNis DIMARAKIS, NATASA LEVICAR 
Imperial College, Faculty of Medicine, Hammersmith Hospital Campus, London, United Kingdom 
ABSTRACT 
The growing body of adult bone marrow-derived stem cell 
research in regenerative medicine has recently entered the 
clinical transplantation setting. The need for a robust flow of 
data from basic to translational scientists is imperative. All 
animal- and/or human-derived products should ideally be 
excluded and synthetic recombinant alternatives used in- 
stead. A variety of reasons make such an approach favor- 
able, including achievement of sounder control levels, reduc- 
tion of any prion, viral, or zoonose contamination risk, 
avoidance of possible immunological reactions, as well as 
decrease in demand on animal supplies. At a preclinical 
level, investigative cell culture protocols must incorporate 
serum-free media groups alongside control conditions. Fi- 
nally, autologous serum should not be neglected until an 
"off-the-shelf" alternative becomes available in the future. 
STEM CELLS 2006; 24: 1407-1408 
We read with interest the article by Sotiropoulou and colleagues 
on defining optimal culture conditions for clinical-scale produc- 
tion of human mesenchymal stem cells [1]. Our attention was 
basically drawn to the fact that although the authors went to the 
length of assessing eight different culture media, all media were 
supplemented with fetal calf serum. No groups incorporating 
serum-free synthetic medium or even human serum (autologous 
or commercially available) were included in the study design. In 
a preclinical setting, all animal- and/or human-derived products 
should ideally be excluded and synthetic recombinant altema- 
tives used instead. Despite the very early recognition and adap- 
tation of this concept in clinical work [2], only recently has 
wider application been allowed in emerging areas of stem cell 
research [3,41. Mesenchymal stem cell research has not been 
unscathed by this principle; rat mesenchymal stem cells have 
been shown to retain their proliferation and differentiation po- 
tential when cultured in serum-free medium [5]. Under sim- 
ilar predefined conditions, mesenchymal stem cells were able 
to undergo directional differentiation toward the neuronal 
lineage [6]. 
Multiple reasons make such an approach favorable. Because 
serum is chemically ill-defined, a reduction of variability in 
qualitative and quantitative cell culture medium composition 
secondary to interbatch differences should be expected. This 
alone will eventually lead to a more robust level of quality 
control. The risk of prion, viral, or zoonose contamination will 
also be decreased in parallel with the demand on animals for 
product supply in accordance with the 3R principle of reduc- 
tion. Serum contains a variety of proteins that may attach to 
cells in culture and act as antigenic substrates for immuno- 
logical reactions once transplanted. This has been shown by 
Selvaggi et al. when patients infused with lymphocytes cul- 
tured in medium supplemented with fetal calf serum devel- 
oped arthus-like reactions [7]. The detection of newly formed 
antibodies to fetal calf serum is an indication that immune 
complex formation followed the cell infusions. In a more 
relevant clinical study, it has been hypothesized that the 
contact of skeletal myoblasts with fetal calf serum in culture 
was the cause of unexplained arrhythmias that led to signif- 
icant malignant ventricular arrhythmias and sudden deaths in 
patients [8]. 
Until a chemically defined serum-free medium is widely 
available, autologous serum supplementation should not be 
overlooked. This modality is particularly useful in the clinical 
setting on a single-patient basis and aids overcoming the above 
and many ethical considerations. Autologous serum not only has 
been shown to be indistinguishable from fetal calf serum with 
regard to both isolation and expansion of human mesenchymal 
stem cells, but also proved to be superior with respect to 
osteogenic differentiation [9]. In another study, autologous hu- 
man serum provided sufficient ex vivo expansion of human 
bone marrow-derived mesenchymal stem cells while maintain- 
ing higher cell motility compared with fetal calf serum [10]. In 
addition, switching to autologous human serum terminated the 
side effects associated with immune reactions in the aforemen- 
tioned studies [7,81. 
It is imperative that as adult bone marrow-derived stem 
cell research enters the realm of clinical research, guidelines 
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be implemented. There should be no rush to enter the clinical 
stage if the underlying basic research is not solid, this alone 
will lead to high-quality translational research. Cell culture 
medium composition should distance itself from animal prod- 
ucts. Although autologous serum is a reliable and safe solu- 
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tion for small clinical studies, it will not be appropriate for 
future "off-the-shelf" availability of stem cell therapy. 
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Stem cells; heart disease have lead to an explosion in the clinical trial realm. At present no consensus 
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Myocardial action for any clinical improvement observed. As de novo reconstitution of myocardial tissue 
ischaernia; from muttipotent stem cells is one of the working theories, the transdifferentiation potential 
Myocardial of cellular populations under investigation into cardiornyocyte lineage phenotypes must ideally 
regeneration be assessed in prectinicat bench work. Culture medium composition and a variety of growth 
factors are crucial determinants in this process. We discuss all relevant data acquired from in 
vitro work. 
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Introduction 
Heart disease was recognised as the most common cause 
of death in the western world as early as 1910 [1]. Con- 
gestive heart failure has become an increasing reason for 
hospital visits and more importantly hospitalization over the 
last decade [2,3]. Huge financial implications are also asso- 
ciated with this trend (3]. A fundamental shift in the aetiol- 
ogy of heart failure has taken place over the last decades. 
Hypertension and valvular heart disease have given place to 
coronary artery disease as the most common cause. In data 
analysed from 13 multicenter heart failure treatment tri- 
als, coronary artery disease was found to be the underlying 
aetiologic factor of heart failure in nearly 70% of the overall 
20,000 enrolled patients [4]. Furthermore, the true preva- 
tence of coronary artery disease among unselected heart 
failure patients is very likely to be underestimated due to 
the design of many of these studies [4]. 
Severe shortcomings are associated with current ther- 
apy of ischaernic heart disease, both in the acute as well 
as the chronic setting. In spite of advances in the treatment 
of acute myocardial infarction, including thrombolysis and 
percutaneous angioplasty/ sten ting, a considerable amount 
of irreversible myocardial injury occurs leading to adverse 
ventricular remodelling and myocardial dysfunction. Clinical 
concerns are even more obvious when dealing with estab- 
tished congestive heart failure of ischaernic aetiology. Once 
pharmacological treatment has been exhausted, clinicians 
do not have many viable options. More recently cardiac 
resynchronization therapy has been established as another 
palliative treatment but data on survival are still pending 
[5]. Surgical remodelling procedures are of limited app(ica- 
tion as the potentially superior effect of surgery compared 
to medical treatment alone remains to be shown [6]. The 
concept of an artificial mechanical heart remains remote 
with assist devices providing mainly a bridging solution at 
present. Despite the potential benefit of allotransplantation 
serious limitations apply to donor availability. The number of 
patients registered on the active transplant list on 31 March 
2004 in the United Kingdom for a cardiothoracic transplant 
had decreased by 36% since 1995 (7]. 
Stem cell transplantation 
Stem cell transplantation is being currently explored as a 
therapeutic approach to regenerate injured myocardium. 
Research is conducted at both the level of experimental 
animal and clinical human transplantation, with a variety 
of stem cell types being investigated [8]. Two stem cell 
populations appear to attract most interest owing to their 
degree of perceived plasticity. These include the totipo- 
tent/pluripotent embryonic stem cells and the multipotent 
adult stem cells. 
The majority of the data accumulated to date origi- 
nates from in vivo studies with plasticity of transplanted 
cells being attributed mainly to the mechanisms of milieu- 
dependent differentiation or cell to cell fusion. This may 
provide researchers with some optimism, but all underlying 
mechanisms continue to remain within the realm of medical 
hypothesis. The development of in vitro protocols to direct 
stem cell differentiation towards the cardiornyocyte lineage 
does not only assist in deciphering molecular signal pathways 
of differentiation, but also augments in creation of safer and 
more efficient stem cell transplantation models. 
A plethora of molecular pathways is implicated in stem 
cell differentiation into functional myocardial cells once 
transplanted in vivo. Soluble chemokines, cell surface 
receptors, extracellutar matrix substrata as well as inter- 
cellular gap junctions, are all potential cofactors. On the 
other hand as cell fusion has been shown to also take place 
[9] the molecular signalling pathways initiating this process 
have not been clarified. To be able to elucidate this process 
at a cellular and molecular level in vitro would translate 
to the ability to initiate and direct the differentiation pro- 
cess to a predefined point prior to clinical transplantation. 
Once the differentiation blueprints have been mapped out 
manipulation in a stepwise fashion will be feasible. 
As expected by definition, stem cells demonstrate the 
inclination to undergo site-specific differentiation into mul- 
tipte cell types once transplanted in vivo [10]. This may 
easily lead to suboptimal absolute cell counts regenerating 
the cell type of interest. In addition, a varying percentage of 
cells may be lost, e. g. due to local inflammation or because 
they do not 'home' to the site of injury. In order to over- 
come these issues it would be of major theoretical benefit 
to deliver pre-committed stem cell populations. Bittira et 
at. have actually shown that converting scar into myogenic 
tissue may be augmented by cell pre-programming before 
implantation [11 ]. 
Amongst the arguments opposing the use of undifferenti- 
ated embryonic stem cells in in vivo models is their potential 
to form teratomas once transplanted [12]. Although adult 
stem cells have not been associated with the development 
of tumour-tike growths under routine ex vivo expansion 
conditions, prolonged in vitro culture of human mesenchy- 
mat stem cells has been Linked with spontaneous malignant 
transformation [13]. This is of extreme importance if 
populations like the muttipotent adult progenitor cells 
(MAPCs) (14] are to be considered for myocardial regener- 
ation. Finally, Wang et at. demonstrated that bone marrow 
stromat cells can traffic through the coronary system to 
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the injured heart and form cardiornyocytes or fibroblasts, 
depending on the specific microenvironment [15]. This 
will sequentially lead to propagation of the myocardial 
fibrous scar, an opposite effect from the one desired. In at( 
cases previous in vitro instigation of directional differen- 
tiation towards the cardiomyocyte lineage would prevent 
complications. 
Predefined cell culture conditions 
in a prectinical setting all human and/or animal derived 
products should ideally be excluded and synthetic recom- 
binant alternatives used instead. Interbatch differences 
in addition to the chemically ill-defined nature of serum 
can be held responsible for variability in qualitative and 
quantitative cell culture medium composition, which may 
lead to suboptimal levels of quality control. Elimination of 
this parameter will not only reduce the risk of prion, viral or 
zoonose contamination, but will also decrease in parallel the 
demand on animals for product supply in accordance with 
the 3Rs principle of Reduction. Serum contains an array of 
proteins that may act as antigenic substrates for immunolog- 
ical reactions once transplantation takes place. Selvaggi et 
M. associated the infusion of lymphocytes cultured in fetal 
calf serum supplemented medium with the development of 
arthus-tike reactions by detecting newly formed antibodies 
to fetal calf serum in these patients [16]. It has further 
been hypothesised that the contact of skeletal myoblasts 
with fetal calf serum in culture lead to significant malignant 
ventricutar arrhythmias and sudden deaths in patients 
[17]. 
Despite the very early recognition and adaptation of this 
concept in clinical work [18] it has proven extremely diffi- 
cult to rid embryonic stem cell culture protocols of feeder 
layers and/or serum supplements [19-22]. Assessment of 
bone marrow-derived stem cell cultures under serum-free 
conditions has also been carried out at an experimental 
level; rat mesenchymat stem cells were shown to retain 
their proliferation and differentiation potential when 
cultured in serum-free medium [23]. Another aspect of the 
nature of serum is the possible presence of unrecognised 
inhibitory factors. Cardiomyocyte differentiation of human 
embryonic stem cells in a cocutture protocol was shown 
to be enhanced 24-fotd in the absence of fetal calf serum 
when compared with the presence of 20% fetal calf serum 
[24]. The authors justly raise the point of serum-free 
conditions providing the ideal environment for assessing 
potential cardiogenic factors with no interference from 
serum-derived modulatory factors. Autotogous serum may 
also prove particularly useful until a chemically defined 
serum-free medium becomes available "off-the-shetf". 
Isolation and expansion of human mesenchymat stem cells 
with autotogous serum was indistinguishable from fetal calf 
serum, with the former proving to be superior with respect 
to osteogenic differentiation [25]. Sufficient ex vivo expan- 
sion of human bone marrow-derived mesenchymat stem 
cells with higher cell motility preservation has also been 
reported (26]. Worth mentioning is the fact that switching to 
autotogous human serum terminated the side-effects asso- 
ciated with immune reactions in the aforementioned studies 
[16,17]. 
109 
Cytokines and growth factors 
Cellular proliferation, differentiation and three-dimensional 
structural organization outline the process of cardiogen- 
esis in embryonic life. Within the core of this process is 
the activation of certain transcription factors (examples 
include FOG-2, members of the GATA family, Nkx2.5, etc. ) 
via morphogenetic proteins (e. g. members of the bone mor- 
phogenetic protein family). The range of molecules and 
pathways involved in cardiogenesis is actively widening to 
incorporate more transcriptional activators such as serum 
response factor (27] and morphogenesis- controlling path- 
ways such as the wnt pathway [28,29]. A plethora of growth 
factors has been shown to initiate this process via a variety 
of pathways (Table 1). A valid approach in the attempt to 
generate optimal conditions for directional differentiation 
of stem cells is the in vitro reproduction of these already 
identified signalling pathways. This is mainly achieved via 
supplementation of the culture medium with soluble regu- 
tator molecules trying to promote phenotypic commitment 
via signalling cascades. 
Bone morphogenetic proteins 
Bone morphogenetic protein-2 (BMP2) plays a pivotat role 
in mammalian cardiac development as shown by Mang and 
Bradley [30]. Abnormal cardiac development was shown to 
ensue the generation of a homozygous nuR mutation of BMP2 
in a murine embryonic model. Schultheiss et at. were able to 
demonstrate full cardiac differentiation in non-cardiogenic 
tissue by administration of soluble BMP2 or BMP4 to explant 
cultures [31 ]. Data have been produced for the discreet roles 
of BMP2 and BMP4 in the developing mouse heart. It appears 
that BMP2 is (inked to the formation of the atrioventricular 
junction and valves, with BMP4 involved in the development 
of the outflow tract myocardium and of the endocardiat 
cushion [32]. Furthermore the addition of Noggin, a known 
BMP antagonist, resulted in inhibition of cardiac differenti- 
ation of the precardiac mesoderm [31 ]. Even though BMPs 
play a crucial role in both processes of mesodermal induction 
[33] and cardiornyocyte differentiation [30], there seems to 
be a transient but essential inhibitory phase of BMP signalling 
between them [34]. 
Transforming growth factors-p 
The transforming growth factor-p (TGFp) superfamily con- 
sists a large and divergent group of potypeptide morphogens 
including, besides the TGFps themselves, members such 
as the activins and the aforementioned BMPs (35]. TGFp2 
deficient mice demonstrate in addition to a high perinatat 
mortality a wide range of congenital cardiovascular anoma- 
ties comparable to malformations seen in humans [36]. Even 
though all three recognised TGFp isoforms (pl, P2, P3) are 
expressed within the developing murine heart [37], each 
isoform appears to exert specific functions the other two 
cannot compensate for [38]. Combined application in vitro 
of TGFp and BMP2 to undifferentiated murine embryonic 
stem cells lead to upregulation of both mesodermal and 
cardiac specific transcription factors; likewise, in vivo trans- 
plantation lead to cardiac differentiation only in animals 
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with an intact TGFO/BMP2 signalling pathway [39]. Kumar 
and Sun compared the effects of the three isoforms on 
cardiornyocyte differentiation from embryonic stem cells 
[40]. A significant increase in embryoid body proliferation 
as well as spontaneous beating was noticed only in the 
TGF02 subgroup. Finally, in a murine myocardial infarction 
model, transplantation of TGFp pretreated bone marrow- 
derived CD1 17+ cells revealed superior functional improve- 
ment compared to untreated cell transplantation [41 ]. Most 
importantly, newly formed myocardial tissue was seen on 
histology only in the TGF pretreated group. 
Activins 
Another member of the TGFP superfamily that has been 
studied less extensively consists of the activins. Exhibit- 
ing similar activities to TGFp, activin has been shown to 
promote cardiac myogenesis in avian embryonic cells not 
otherwise of cardiac fate [42]. The authors submit evi- 
dence of activin/TGFp signalling lying upstream of BMP 
signalling in the cardiac myogensis pathway; the hypoth- 
esis is raised of TGFý acting via upregulation of activin 
expression. More interestingly activin A-stimulated human 
arnniotic mesenchymal cells were shown to express a vari- 
ety of card iomyocyte- specific genes including Nkx2.5, ANP, 
and (x-MHC [43]. None of the marker genes mentioned above 
appeared to be expressed in the samples without stimula- 
tion. 
Fibroblast growth factors 
When Lough et at. examined if BMP2 atone is capable of 
inducing cardiac differentiation in chicken embryo precar- 
diac and non-precardiac mesoderm the results were not 
encouraging [44]. Based on their previous work involving the 
effects of the fibroblast growth factor (FGF) family on car- 
diogenesis [45,46], the inclusion of FGF4 in the predefined 
medium produced dramatic results. Cardiac differentiation 
was documented by the formation of contractile muiticellu- 
tar vesicles that stained positive for the sarcomeric marker 
wactin, indicating a synergistic function between these 
two growth factors in order to induce cardiogenesis. Fur- 
ther work from the same group has produced exciting data 
regarding which members of the BMP and FGF families are 
crucial in this process, the exact concentrations required 
for in vitro studies along with a precise timetable of growth 
factor supplementation for maximal results [47]. The impor- 
tance of growth medium supplementation with optimized 
concentrations in relation to time has been further demon- 
strated in murine embryonic stem cells [48]. Cardiogenic 
differentiation was achieved only when FGF2 and/or BMP2 
were added at precise concentrations for the first 3 days of 
cell culture. The FGF family consists of a large and diverse 
group of small potypeptide growth factors. FGF2 has been 
also shown to control the differentiation of a murine cardiac 
resident precursor cell population in vitro and in vivo [491. 
Although FGF2 and FGF4 appear to be the most promising 
members in the process of cardiogenesis, other members 
have been shown to be implicated [50,51]. The multiple 
effects of this interesting family of growth factors 
is medi- 
ated via an equally diverse set of receptors, the 
importance 
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Tabie 1 Principat growth factor-mediated signatting 
pathways 
Growth factor Main signatting 
pathway 
Transforming growth factor-P Smad/p38/TAK1 /ERK/ 
superfamity (BMPTGF 0, Activin) JNK/MAPK 
[53-56] 
Fibroblast growth factor (57] PLC-y/Ras/MAPK 
Insulin-like growth factor-I [58] ERK/JAK-STAT/Pl3K 
Platelet- derived growth factor JAK/Pl3K/MAPK 
[59,60] 
Leukaemia inhibitory JAK-STAT/MAPK 
factor/ Cardiotrophi n-1 [61] 
Erythropoietin [62] JAK-STAT/Akt 
At indicates protein kinase B; ERK, extraceitular signal- 
regulated kinase; JAK, janus kinase; JNK, c-Jun N-terminal 
kinase; MAPK, mitogen activated protein kinase; P13K, phos- 
phatidylinositol 3-kinase; PLC-y, phosphotipase C--y; STAT, signal 
transducer and activator of transcription; TAK1, tyrosine kinase 
1. 
of which has been recognized for in vitro cardiornyocyte 
development from murine embryonic stem cells [52]. 
Insulin and insulin-like growth factors 
Gene expression for insulin receptors and insulin-like growth 
factors (IGFs) with their cognate receptors has been docu- 
mented from the early phases of murine embryonic life [63]. 
Not only is IGH essential for normal embryonic growth and 
development in mice [64], but severe deficiency may affect 
the functional maturation of the cardiovascular system [65]. 
Antin et at. have suggested that insulin and IGFs may pro- 
mote avian cardiac development in vivo by both autocrine 
and paracrine mechanisms [66]. Addition of recombinant 
IGH to a pre transplantation murine embryonic stem cell 
suspension was associated with increased in vivo expression 
of a cardiornyocyte phenotype and functional improvement 
[67]. Thus, besides their well described role involving linear 
growth, glucose metabolism and organ homeostasis, these 
pteiotropic hormones appear to be involved in early phases 
of cardiogenesis. 
Platelet derived growth factor 
Platelet derived growth factor (PDGF) consists of two struc- 
turally similar A and B polypeptide chains which in turn com- 
bine forming homodimers (AA, BB) as well as heterodimers 
(AB). This generally acknowledged connective tissue cell 
mitogen that shares topological similarities with TGFp [68], 
was associated with the myogenic differentiation process 
in human myobtast clones more than a decade ago [69]. 
PDGF-AB treatment of rodent bone marrow derived stem 
cells enhances cardiornyocyte generation in vitro and, when 
co-detivered with bone marrow cells in a post infarc- 
tion myocardial ligation model, promotes the formation of 
independent cardiac myocyte islands [70]. Sachinidis and 
coworkers reported an increase in the expression of car- 
diac specific myosin heavy chain alpha and beta in embryoid 
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bodies when stimulated with PDGF; a parallel increase in 
the number of beating embryoid bodies was also seen [71 ]. 
Leukaemia inhibitory factor and Cardiotrophin-1 
Leukaemia inhibitory factor (LIF) has been shown to exert 
differentiation factor properties, besides being a well 
described growth factor for haernatopoiesis, bone and lipid 
metabolism and neuronal tissue development [72]. This 
pleiotropic cytokine, essential for the survival of the normal 
pool of stem cells [73], is known to inhibit differentiation of 
embryonic stem cells in vitro [74]. Kodama et at. demon- 
strated LIF to induce cardiac hypertrophy by stimulating 
the JAK-STAT (janus-kinase-signal transducer and activa- 
tor of transcription) pathway in cardiornyocytes [75]. Two 
forms of this cytokine have been recognized, one diffusible 
and one bound to the extracetlular matrix [76]. Interesting 
results were obtained when the effects of LIF on differ- 
entiating embryonic bodies were examined. Commitment 
to a cardiornyocyte phenotype required complete absence 
of all forms of this cytokine [77]. Minimal concentrations 
of diffusible LIF are necessary for induction of differen- 
tiation, but following the inductive event, LIF attenuates 
cardiornyocyte differentiation in a dose-dependent fashion. 
However, once differentiation is complete, LIF promotes 
proliferation and longevity. Following myocardial infarction 
in a murine model, intramuscular injection of LIF not only 
caused local regeneration but also enhanced mobilization of 
bone marrow cells to the heart and their differentiation into 
cardiomyocytes [78]. Cardiotrophin-1 (CT-1) [79] is another 
cytokine with the ability to stimulate cardiac hypertrophy in 
vivo [79-81], while exerting various cardioprotective func- 
tions [82-86]. CT-1 has been shown to stimulate cardiomyo- 
genesis and increase nuclear expression of the proliferation 
marker Ki-67 in pturipotent murine embryonic stem cells 
[87]. 
Both aforementioned cytokines belong to the interleukin- 
6 cytokine superfamity with their respective functional 
receptor complexes sharing the low-affinity LIF recep- 
tor (LIF-R) and the gp130 signal transducing component 
[88,89] which is a possible reason for the functional over- 
lap observed in the above studies. Targeted mutation models 
have been developed for both components of the LIFR-gpl 30 
heterodimer. Both knockout models proved incompatible 
with life, with additional evidence of hypoptastic ventric- 
ular myocardium 16.5 days postcoitum and later in embryos 
homozygous for the gpl 30 mutation [90,91 ]. These results 
highlight the necessity of investigating genetic maniputa- 
tion/targeting of the LIF-R/gpl 30 receptor complex in order 
to promote stem cell differentiation down a cardiomyocyte 
lineage. 
Erythropoietin 
Besides being the main regulatory cytokine of erythro- 
poiesis, erythropoietin (EPO) has shown evidence of car- 
dioprotective properties [92]. On binding with the specific 
erythropoietin receptor (EPO-R) an array of signalling path- 
ways may be initiated (summarized in Table 1), leading 
to the activation of various genetic transcripts responsi- 
ble for cardiornyocyte proliferation /differentiation. 
Both 
ill 
EPO-/- and EPOR-/- knockout mice are embryonic lethal 
and die in uteri [93]. They were shown to suffer from 
ventricular hypoplasia and intraventricular septum defects. 
Endothelial progenitor cells from congestive heart failure 
patients treated with EPO demonstrated enhanced prolif- 
eration rates along with a trend to adhere to cultured 
endothelial cells [94]. When the same investigators cutti- 
vated human endothetial progenitor cells in vitro with EPO, 
a dose-dependent increase in proliferation and adhesion 
to fibronectin, cultured endotheliai cells, and cardiomy- 
ocytes was observed. From this data it is quite obvious that 
although EPO influences cardiogenesis, it also may prove 
useful in 'preconditioning' stem cells prior to delivery within 
the injured myocardium to increase engraftment and post- 
transplantation survival. 
Other cytokines 
Several other cytokines have been reported to play an active 
role in cardiogenesis. Treatment of murine P19 embry- 
onic stem cells with oxytocin promoted the formation of 
rhythmically beating cells resembling primary cardiomy- 
ocytes, an effect not seen in the presence of an oxytocin 
inhibitor [95]. Finally, the vascular cytokine endothelin-1 
was reported to shift differentiation of embryonic stem 
celt-derived cardiornyocytes toward pacemaker cells in an 
endothelin receptor- depen dent manner without affecting 
electrophysiologicat properties [96]. This discovery is of 
extreme importance as it enters the level of specialized car- 
diomyocyte targeted differentiation. 
Closing remarks 
Recreation of a pure biochemical microenvironment does 
not guarantee delivery of undifferentiated stem cell popu- 
lations to a desired endpoint, as instructive differentiation 
pathways do not solely rely on growth factor-cell inter- 
action. Cell response is also dependant on dynamic bidi- 
rectional signalling from underlying substrata as well as 
surrounding cell populations. Analysis of specific growth 
factor contribution to the differentiation process is even 
more complicated secondary to their innate characteris- 
tics. Besides redundancy and pleiotropism, growth factors 
may function in a synergistic or even antagonistic manner. 
Investigation of any growth factor must conclude about dose 
dependency, time dependency, and interaction with other 
cytokines. Individual growth factor endpoints in the differ- 
entiation process may resemble a cascade with one cytokine 
commencing action from a previous endpoint. Identification 
of such cascades may prove crucial for improving differen- 
tiation strategies. 
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Figure 1 Phenotypic differentiation of uncommitted cells is 
a mutti-factorial process. The above diagram simply demon- 
strates the difficulty of reproducing in vitro an environment 
promoting directional differentiation. 
Introduction 
Cellular differentiation is a multi-factoriat process with an 
array of parameters involved (Fig. 1). Composition of cell 
culture medium along with growth factors implicated in 
stem cell differentiation towards a cardiornyocyte fate has 
been extensively discussed in the first part of this review. 
A few more parameters have been shown to influence this 
process acting in conjunction with cytokines or even inde- 
pendently. These include various chemicals that have been 
seen to promote targeted differentiation, cues from the 
extraceltular matrix as well as a variety of physical stim- 
uti. Stem cell interaction with differentiated cells in vitro is 
also examined via coculture assays. 
Chemicals 
In the wider attempt to exploit stem cell plasticity a vari- 
ety of synthetic chemicals have been found to induce car- 
diac differentiation cues. DNA demethylating agents have 
attracted the interest of many groups; as DNA methyla- 
tion is associated with a repressed chromatin state and 
subsequent gene silencing [1 ], it is thought that hypomethy- 
lation may play a rote in epigenetic reprogramming dur- 
ing somatic cell cloning and stem cell function [2]. Early 
reports have shown a connection between DNA hypomethy- 
tation and in vitro myobtast differentiation [3]. Compounds 
promoting DNA demethytation, such as 5-azacytidine or 5- 
aza-2'-deoxycytidine, have endorsed transdifferentiation of 
embryonic [4,5], cord blood [6], as well as marrow stro- 
mat cetts into cardiomyocytes in vitro [7-9]. Upregulation 
of expression of cardiornyocyte specific genes/proteins was 
noticed, along with 'beating' on the petri dishes in a few 
cases. More surprisingly cardiomyocyte-like cetts have been 
reported to be obtained from adipose tissue-derived stem 
cells with such pre-treatment [10]. 
A plethora of organic acids have also been described 
to possess differentiation promoting capability. The terato- 
genic effects of retinoic acid (a Vitamin A derivative) in 
human embryos (defects included conotruncat heart defects 
and aortic-arch abnormalities) was documented more than 
2 decades ago [11 ]. Wobus studied further the cardiogenic 
potential of retinoic acid on embryonic cells differenti- 
ating as embryoid bodies [12]. Stimulation of cardiomy- 
ocyte development appeared to correlate with particular 
time and concentration parameters indicating the pres- 
ence of various switch points in the differentiation process. 
This may merely reflect the importance of relative retinoic 
acid receptor expression [13] during the different stages of 
embryonic life. Further work from the same group a few 
years later concluded that besides acceleration of cardiac- 
specific gene expression, retinoic acid promotes certain phe- 
notypic changes compatible with Purkinje and ventricular 
cardiornyocytes [14]. Other groups have also confirmed the 
beneficial effect on cardiac cell differentiation from embry- 
onic stem cells with retinoic acid [15], a novel ester of 
hyaluronan linked to both butyric and retinoic acid [16], or 
even a retinoid X receptor agonist [17]. 
Another vitamin compound that has been associated with 
cardiogenesis is ascorbic acid [18). In an attempt to identify 
substances with the ability to induce cardiac differentiation 
researchers screened 880 compounds utilizing embryonic 
stem cells stably transfected with cardiac -specific a-cardiac 
myosin heavy chain promoter-driven enhanced green flu- 
orescent protein. Ascorbic acid (Vitamin Q was shown to 
induce cardiac differentiation, an effect not explained by 
its antioxidant properties as other antioxidants tested did 
not manifest this effect. At this point some mention should 
be given to the rote of reactive oxygen species, antioxidants 
and free radicals in cardiogenesis. White antioxidants may 
inhibit embryonic stem cell differentiation, H202 or radical- 
generating menadione have been shown to enhance cardio- 
genesis [19]. Reactive oxygen species are well recognized 
intracellular signalling messengers [20] deemed responsible 
for the observed stimulation of a cardiac cell phenotype 
in multiple protocols [21,22]. Once again a dose-dependent 
model applies as high levels of reactive oxygen species act 
as differentiation inhibitors [21,23]. Bloch et at. studied 
the role of nitric oxide during cardiogenesis [24]; both iso- 
forms of nitric oxide synthase (inducible and endothelial) 
followed a specific time-course expression and cardiogenesis 
was promptly arrested when nitric oxide synthase inhibitors 
were added. Finally researchers developing a perfusion fed 
bioreactor for embryonic stem cell-derived cardiomyocyte 
generation discovered that manipulation of oxygen tension, 
by means of hypoxia, can improve cardiomyocyte yield [25]. 
Dimethyt sutfoxide (DMSO) is a free radical scavenger cur- 
rentty used as a cryopreservative for bone marrow cells and 
stem cells. The ability of DMSO to induce cardiornyogenic 
differentiation has been mainly studied in the P19 (includ- 
ing cell tine derivatives) mouse embryonal carcinoma cell 
line [26-29]. Interestingly enough, double stimulation by 5- 
azacytidine and DMSO demonstrated an even higher yield of 
cardiac muscle differentiation in such pluripotent cells [30]. 
Serum-response factor seems to be one of the key mediators 
in this process. Zhang et at. have recently published a list of 
direct serum-response factor target genes inducing cardiac 
cell differentiation [31 ]. Working with the same pluripotent 
P19 cells, Ventura and Maioli reported that dynorphin B, 
a natural K-opioid receptor agonist, could reproduce the 
effects of DMSO; further opioid receptor blocking in con- 
junction with inhibition of opioid gene expression was even 
able to arrest DMSO-induced cardiogenesis [29]. The same 
group reported a connection between endorphin -primed 
cardiogenesis and certain isozymes of protein kinase C [32]. 
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Sachinidis et at. documented comparable results in the expression of cardiac-specific myosin heavy chain alpha and beta in embryoid bodies when stimulated with sphingosine- J-phosphate, a bioactive lipid, as with PDGF [33]. Finally 
a group Of compounds capable of inducing cardiogenesis in embryonic cells consists of icariin -a constituent of Epimedium, a traditional Chinese herbal medicine - and its metabolites icaritin, and desmethylicaritin, with icariin 
being far more efficient in vitro [34,35]. 
Extracellular matrix 
The composition of the extracellular matrix (ECM) is equally 
complex to its multifunctional role within the myocar- 
dial microenvironment. Cardiomyocytes, cardiac fibrob- 
lasts, vascular endothelial and smooth muscle cells - 
all embedded in the ECM - produce in a cell specific 
manner the main components, including structural pro- 
teins (collagen and elastin), adhesive proteins (laminin 
and fibronectin), anti-adhesive proteins (tenascin, throm- 
bospondin and osteopontin) and proteoglycans. Being in 
continuous interaction with locally and remotely produced 
signals, the dynamics of this network are interwoven with 
cell structure development during cardiogenesis [36-41]. 
Impairments between cell and ECM interaction may lead 
to defective heart formation [42]. A family of cell surface 
receptors, the integrins, mediate a large amount of the 
cell-ECM interactions [43]. Bidirectional sensing of mechan- 
ical forces via ECM-integrin-costameric protein complexes 
is capable of inducing growth factor-like signaling [44,45]. 
Fi brob last -derived ECM demonstrates superior growth char- 
acteristics for in vitro cardiomyocyte culture suggesting 
dynamic interaction between cells and matrix [46]. 
ECM provides the architectural scaffold on which myocar- 
dial cellular components are anchored facilitating the trans- 
formation of individual myocyte systolic action into syn- 
chronous ventricular contraction. Other functions of the 
extracettular matrix include causing passive stiffness during 
diastole while preventing undesirable effects such as over- 
stretching and myocardial slippage. Extrace(lular matrix 
also protects the myocardiurn from the development of 
interstitial edema. Besides development, growth and main- 
tenance of the myocardium, ECM is involved in the process 
of ventricular remodeling [47]. Hormonal and growth factor 
production in cardiac hypertrophy/faiture leads to structural 
and compositional ECM changes [48]. The signaling pathways 
vary according to the underlying pathology [49], with dis- 
creet differences noticed between the failing right and left 
ventricutar chambers [50]. Following myocardial injury, cet- 
lutar migration and differentiation has also been attributed 
partly to components of the ECM [51,521. 
Off the shelf availability of biosynthesized ECM patches 
would be of major clinical importance in the restorative 
field of congenital and adult cardiac surgery. Acettutar xeno- 
geneic ECM [53,541 and bioengineered materials [55] have 
both been tested in animal models. Histological examina- 
tion of exptanted patches in the former group was consis- 
tent with native cellular infiltration including cells staining 
positive for sarcomeric actin [54]. As cell seeding in bioengi- 
neered materials has been achieved experimentally (55], 
seeding with muttipotent stem cell populations may also 
provide cellular in addition to plain structural myocardial 
reconstitution. Transplanted cell survival and differentiation 
may also improve in such a mechanically and biochemically 
supportive environment [56]. 
Data supporting directed differentiation towards the 
cardiornyocyte lineage of embryonic stem cells under the 
influence of ECM have recently emerged [57]. Fibroblast- 
derived ECM also supported earlier maturation of embryonic 
stem cell-derived cardiomyocytes [58]. Alperin et at. point 
towards the direction of biodegradable etastomers seeded 
with embryonic stem cell-derived cardiomyocytes based on 
their work with cells cultures on taminin and cottagen IV 
[59]. Finally cells inserted within the ECM may play a mod- 
ulatory rote on the matrix itself; transplantation of mes- 
enchymat stem cells into ischaernic myocardium selectively 
down-regutated the expression of many ECM genes inhibiting 
thus ventricutar remodelling [60]. 
Coculture assays 
A logical approach to overcoming the inability to recreate 
an ideal cellular microenvironment in petri dishes is to hand 
the task over to already differentiated cardiornyocytes. This 
method does not come without theoretical flaws though; not 
necessarily will these cardiornyocytes produce the needed 
differentiation cues as they are terminally differentiated 
and have not been stimulated by ischaemia/injury to gener- 
ate the required homing and differentiation signals expected 
[61 ]. As with in vivo transplantation, the perceived plasticity 
of cultured stem cell populations may be attributed mainly 
to the mechanisms of milieu dependent differentiation and 
fusion. Demonstration of spontaneous fusion between bone 
marrow and embryonic stem cells by Terada et at. provided 
another insight into how stem cells interact in coculture con- 
ditions [62]. Bone marrow-derived mesenchymal stem cells 
and circulating endotheliat progenitor cells have also been 
shown to fuse in vitro with neonatal cardiornyocytes [63]; 
furthermore, cardiornyocytes regain the ability to enter the 
cell cycle after fusion. Fusion obviously remains a rare event 
with many researchers attributing the recorded events prin- 
cipatly to microenvironment signalling and transtineage dif- 
ferentiation [64,65]. Oh et at. have shown fusion to take 
place between cardiornyocytes and donor cells in vivo fot- 
[owing systemic delivery of adult murine cardiac stem cells 
[66]. Finally, an emerging theory is that of transient intercet- 
lutar connection via nanotubutar structures allowing macro- 
molecule exchange [671. 
Coculture of human embryonic stem cells with murine 
visceral endoderm-tike cells initiated differentiation into 
beating cells [68]; although the exact mechanism is 
uncertain, BMPs, FGFs and inhibitors of wnt produced by 
endoderm may play a role in this process. Similarly when 
murine embryonic stem cells were cocuttured with a bitayer 
of avian precardiac endoderm /mesoderm (or cultured in 
cell-free conditioned medium from these cells), the number 
of contractile embryoid bodies increased dramatically com- 
pared to cells cultured atone, or on feeder layers of murine 
embryonic fibroblasts or avian nonprecardiac posterior 
endoderm [69]. Differentiation of human mesenchymal 
stem cells into cardiornyocytes proved more efficient in 
cocutture with human cardiornyocytes compared to sole 
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treatment with celt-free conditioned medium produced by separate cardiOmYocyte cultures [70]. The authors con- cluded that besides soluble mediators, direct cell-to-cell contact is essential to the whole process. Xu et at. sustained this conclusion by observing the clear formation of gap junctions between differentiating myocytes from bone 
marrow stromal cells and native myocytes in coculture [71 ]. 
Lastly, it was reported that rat mesenchymat stem cells differentiate into cardiornyocytes only when cocuttured 
with neonatal and not adult cardiornyocytes suggesting 
possible age-dependency of certain cardiac inducers [72]. 
Endotheiial progenitor cells have also entered the clinical 
realm of regenerative cardiac medicine [73]. Even though 
neoangiogenesis or even paracrine factor production have 
been suspected as underlying mechanisms of action, car- 
diomyocyte transdifferentiation of endotheliat populations 
in coculture with neonatal cardiornyocytes has been docu- 
mented [74]. Cell-to-cell contact-dependant transdifferen- 
tiation was also reported for endothelial progenitor cells 
from healthy adults and coronary artery disease patients 
[75]. Koyanagi et at. have recently reported that E-cadherin 
is a key ceit-to-cell communication mediator implicated in 
the acquirement of a cardiornyogenic phenotype by human 
endothetiat progenitor cells [76]. Encouraging phase I chni- 
cat trial data also exists for skeletal myobtasts, a population 
of precursor cells of established phenotype residing within 
sketetat muscle [77]. Early reports confirmed that a propor- 
tion of these cells have the capability to transdifferenti- 
ate into cardiornyocytes with direct cell-to-cett contact and 
contraction of neighboring cardiornyocytes regulating this 
in cocutture [78]. Similar to endothetiat progenitor cells, 
Formigli et at. demonstrated that intercettutar coupling was 
enhanced by retaxin, upregulating thus the transcettutar 
exchange of regutatory molecules and possibly facilitating 
transdifferentiation (79]. 
Cocutture assays incorporating heterotogous cell poputa- 
tions contraindicates clinical application as mentioned ear- 
tier. This obstacle may be overcome by the production of 
bioreactors that allow cocutture under strict spatial separa- 
tion of cuttured cell populations [80]. It is apparent though 
that direct cett-to-cett contact is far superior to growing 
cetts in pre-conditioned media. Identification of cellular 
membrane targets in cocutture systems initiating transtin- 
eage commitment may eventually render cocutture obso- 
tete. Cocutture remains a useful assay in assessing potential 
for arrhythmogenicity of under examination donor cells [811. 
Physical stimuli 
The efficiency of the heart as a muscular pump is governed 
by a complex electrical circuit that originates from spe- 
ciatized nerve cells within the right atrium and spreads 
throughout the myocardium. Electrical stimulation of adult 
cardiornyocytes in vitro has been shown to enhance both 
mechanical properties and calcium transients compared 
to unstimulated controls [82]. Isolated neonatal rat ven- 
tricutar myocytes subjected to controlled electrical field 
stimulation demonstrate upregulation of cardiac gene 
expression, establishment of gap junctions and a significant 
level of uttrastructural differentiation comparable to native 
myocardiurn [83]; cellular alignment and coupling 
leading 
1. Dimarakis et at. 
to synchronous macroscopic contraction in a way that 
resembles embryonic development was also noted. Embry- 
oid bodies submitted to the test showed an increase in total 
number and size of bodies taking on a 'beating' phenotype 
with activation of certain transcription factors and reactive 
oxygen species being held responsible for the observed 
stimulating effect [21]. Electrically stimulated contraction 
of adult cardiornyocytes is known to act as an anabolic stim- 
utus that produces acceleration of protein synthesis [84]. 
Xia et at. reported that neonatal cardiornyocyte electrical 
stimulation may increase promoter activity of c-fos, p-MHC 
(0-myosin heavy chain) and Cyt, c (cytochrome c) leading 
to cellular maturation and increased mitochondriat activity 
[85]. The same group moved on to associate electrical stim- 
utation with activation of transcription factors mediating 
cardiac gene expression (i. e. GATA-4, MEF2, NFAT) [86]. 
Neonatal cardiornyocytes subjected to repetitive uni- 
directional stretching in vitro demonstrated a variety of 
morphological changes characteristic of in vivo cardiac 
development along with changes at the molecular level 
such as enhanced expression of both myosin heavy chain 
isoforms [87]. From a qualitative point of view mechanical 
stimulation atone is not able to induce the shift between 
the two myosin heavy chain isoforms as hormonal factors 
participate in this process [88]. Another interesting effect 
of cyclic stretch on neonatal cardiornyocytes and cardiac 
fibroblasts is the promotion of growth factor secretion 
in an autocrine/paracrine way from these cells [89]; the 
most prominent growth factor in this process is TGFpl, 
the expression of which may be mediated by the humorat 
response to stretching of cardiornyocytes, fibroblasts and 
endothetiat cells [90]. Finally it should be mentioned that 
cellular stretching enhances the expression of the gap 
junction protein connexin43 [91]. 
A number of other physical stimuli have been investi- 
gated for differentiation -inducing and celtutar-fate chang- 
ing properties. Cardiomyocyte exposure to hyperthermia 
induces an increase in TGFp expression [92], which may 
act as a differentiation stimulus in addition to increas- 
ing post- transplantation survival rates. Exposure of murine 
embryonic stem cells to low field magnetic fields stimulated 
amongst others the expression of the cardiac specific tran- 
scription factors GATA-4 and Nkx-2.5 [93]. Superior three- 
dimensional organization compared to control studies was 
observed when neonatal rat cardiac cells were grown in a 
NASA-designed bioreactor imitating microgravity conditions 
[94]. Mechanical stimuli appear to be involved in differ- 
entiation processes via interaction with an assortment of 
pathways; until clarification of these takes place clinical 
transition should be cautious as similar stimuli have been 
associated even with malignancy in other fields [95]. 
Closing remarks 
Acquisition of a certain phenotype does not solely rely 
on gene interaction as much as on the complex interac- 
tions between the components of the entire developmen- 
tal matrix. The multidirectional communication avenues 
between cells, growth factors, extracellutar matrix and 
physical stimuli form the basis for this conclusion. It appears 
that the differentiation pathways follow an instructive 
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pattern; all stimuli lead to activation of genetic transcripts 
via cascades already present within cells. Evidence is pro- vided by the demonstration of embryonic as well as adult stem cells differentiating into cardiornyocyte lineage phe- notypes in vitro without stimulation. Of utmost significance is cell type definition of starting as well as end populations; 
not only should potent subpopulations be identified in order to increase yield and efficiency, but full characterization of the final cell product should be carried out in order to delin- 
eate targeted differentiation as much as to avoid unwanted 
side-effects (transplantation of pacemaker-type cells in ven- 
tricular tissue leading to arrhythmia generation). As the 
majority of stimuli reviewed herein appear to be time- and dose-dependent, besides being interconnected, the appli- 
cation of a process similar to combinatorial chemistry may 
prove extremely useful in identifying these very fine rela- 
tionships. In conclusion the above information may be seen 
as parts of a puzzle that will lead to identification of com- 
mon terminal pathways of cardiornyocyte differentiation; 
once achieved, cell fate manipulation in the field of cardiac 
regenerative science will have reached another plateau. 
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